uric acid has been researched along with Renal Insufficiency, Chronic in 483 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dapagliflozin (DAPA), a sodium-glucose transporter 2 inhibitor (SGLT2i), attenuates kidney outcomes in patients with not only diabetes mellitus (DM) but also chronic kidney disease (CKD)." | 9.69 | Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus. ( Fukami, K; Kaida, Y; Shibata, R; Taguchi, K, 2023) |
| "The present study compared the efficacy and safety of low-dose febuxostat versus allopurinol in chronic kidney disease (CKD) patients complicated with hyperuricemia (HUA)." | 9.51 | Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study. ( Cao, B; Yang, N, 2022) |
| "Febuxostat had stronger renoprotective and antioxidant effects than topiroxostat in patients with hyperuricemia and CKD." | 9.34 | Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial). ( Osaka, S; Sekino, H; Sezai, A; Tanaka, M; Taoka, M; Unosawa, S, 2020) |
| "To assess the efficacy and safety of febuxostat extended release (XR) and immediate release (IR) in patients with gout and normal or impaired renal function." | 9.30 | Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. ( Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A, 2019) |
| " In the benzbromarone group, kidney stones in one case increased in quantity." | 9.27 | Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study. ( Bao, H; Cheng, J; Liu, X; Peng, A; Qin, L; Song, Y; Wang, L; Yu, H; Zhou, X, 2018) |
| "These data suggest that factors other than uric acid may play a more important role in the regulation of CKD- MBD including vascular calcification and vitamin D metabolism in patients with CKD." | 9.27 | Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial. ( Andrews, ES; Chonchol, M; Jalal, D; Kendrick, J; Nowak, KL; Pasch, A; Perrenoud, L; You, Z, 2018) |
| "There is little evidence guiding selection of nondiuretic, antihypertensive agents with a goal of lowering uric acid (SUA) and minimizing gout risk." | 9.24 | Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension. ( Appel, LJ; Juraschek, SP; Miller, ER, 2017) |
| "Uric acid (UA) is the final product of purine metabolism in the human body, and impaired purine metabolism can increase the uric acid in serum, finally resulting in hyperuricemia (HUA)." | 9.22 | Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights. ( Dong, B; Geng, Z; Mei, Y; Xu, L, 2022) |
| "We assume that decreasing uric acid levels with allopurinol treatment seems to be helpful in restoring endothelial functions, preventing metabolic acidosis and slowing down the progression of CKD." | 9.20 | The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients. ( Altuntaş, A; Bayram, D; İnal, S; Kıdır, V; Orhan, H; Tuğrul Sezer, M, 2015) |
| "The NU-FLASH trial demonstrated that febuxostat was more effective for hyperuricemia than allopurinol." | 9.20 | Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). ( Hata, H; Ishii, Y; Nakata, K; Osaka, S; Sezai, A; Shiono, M; Soma, M; Yaoita, H, 2015) |
| "Treatment of congestive heart failure (CHF) with loop diuretics, such as furosemide, may be associated with complications, including worsening renal function and metabolic or electrolyte disturbances." | 9.20 | Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study. ( Akashi, YJ; Kida, K; Kimura, K; Matsumoto, N; Miyake, F; Shibagaki, Y; Tominaga, N, 2015) |
| "The FEATHER (FEbuxostat versus placebo rAndomized controlled Trial regarding reduced renal function in patients with Hyperuricemia complicated by chRonic kidney disease stage 3) study is a prospective, multicenter, double-blind, randomized, placebo-controlled trial of febuxostat-a novel, nonpurine, selective, xanthine oxidase inhibitor." | 9.19 | The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. ( Hayakawa, H; Hosoya, T; Iimuro, S; Imai, N; Inaba, M; Itoh, S; Kimura, K; Kuwabara, M; Makino, H; Matsuo, S; Ohno, I; Shibagaki, Y; Tomino, Y; Uchida, S; Yamamoto, T, 2014) |
| "Topiroxostat, a selective xanthine oxidase inhibitor, shows effective reduction in the serum urate level in hyperuricemic patients with or without gout." | 9.19 | Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. ( Fujimori, S; Hara, S; Hisatome, I; Hosoya, T; Nomura, S; Ohno, I; Uchida, S; Yamamoto, T, 2014) |
| " In this study, we assessed the additive effects of hydrochlorothiazide (HCTZ) on reducing proteinuria in CKD patients under treatment with losartan (LS)." | 9.19 | Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. ( Fujisaki, K; Higashi, H; Hirakata, H; Kanai, H; Katafuchi, R; Kitazono, T; Nakano, T; Nakayama, M; Taniguchi, M; Tsuruya, K, 2014) |
| " Elevated uric acid levels are risk factors for gout, hypertension, and chronic kidney diseases." | 9.12 | Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis. ( Kimura, Y; Kono, H; Tsukui, D, 2021) |
| "Uric acid, once viewed as an inert metabolic end-product of purine metabolism, has been recently incriminated in a number of chronic disease states, including hypertension, metabolic syndrome, diabetes, non-alcoholic fatty liver disease, and chronic kidney disease." | 8.93 | Uric acid in metabolic syndrome: From an innocent bystander to a central player. ( Jensen, T; Johnson, RJ; Kanbay, M; Lanaspa, MA; Le, M; Nakagawa, T; Rivard, C; Roncal-Jimenez, C; Solak, Y, 2016) |
| "To discuss the evolving data regarding uric acid as a potential cause of hypertension and progressive renal dysfunction and its clinical and research implications." | 8.90 | Serum uric acid and the risk of hypertension and chronic kidney disease. ( Feig, DI, 2014) |
| " Hypertension has been implicated as a factor influencing the association between serum uric acid and CKD." | 8.89 | Serum uric acid and chronic kidney disease: the role of hypertension. ( Dehghan, A; Franco, OH; Hofman, A; Hoorn, EJ; Sedaghat, S; van Rooij, FJ; Witteman, JC, 2013) |
| "Elevated uric acid levels are a common finding in patients with metabolic syndrome and in those with cardiovascular and renal disease, but the meaning of this elevation is still unclear." | 8.88 | Uric acid: a starring role in the intricate scenario of metabolic syndrome with cardio-renal damage? ( Di Giorgio, C; Gesualdo, L; Morrone, LF; Stellato, D, 2012) |
| "The objective of the study was to compare the relative effects of benzbromarone and allopurinol on the risk of developing chronic kidney disease in persons with asymptomatic hyperuricemia." | 8.31 | Comparison of benzbromarone and allopurinol on the risk of chronic kidney disease in people with asymptomatic hyperuricemia. ( Hwang, BF; Kuo, YH; Lai, SW; Liao, KF; Liu, CS, 2023) |
| "To study the associations of non-alcoholic fatty liver disease (NAFLD), chronic kidney disease (CKD), and serum uric acid (SUA) in patients with post-myocardial infarction (MI) patients, and the relationship of SUA with 12-year mortality risk." | 8.31 | Serum uric acid is related to liver and kidney disease and 12-year mortality risk after myocardial infarction. ( Boersma, E; Geleijnse, JM; Heerkens, L; Kardys, I; van Westing, AC; Voortman, T, 2023) |
| " However, a better understanding of the relationship among uric acid (UA) values, glomerular filtration rate (GFR) and albuminuria may shed light on the mechanisms underlying the excess of cardiovascular mortality associated with both chronic kidney disease and hyperuricemia and lead to better risk stratification." | 8.12 | Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. ( Barbagallo, CM; Bombelli, M; Borghi, C; Casiglia, E; Cicero, AFG; Cirillo, M; Cirillo, P; D'Elia, L; Desideri, G; Ferri, C; Galletti, F; Gesualdo, L; Giannattasio, C; Grassi, G; Iaccarino, G; Leoncini, G; Mallamaci, F; Maloberti, A; Masi, S; Mazza, A; Mengozzi, A; Muiesan, ML; Nazzaro, P; Palatini, P; Parati, G; Pontremoli, R; Rattazzi, M; Rivasi, G; Russo, E; Salvetti, M; Tikhonoff, V; Tocci, G; Ungar, A; Verdecchia, P; Viazzi, F; Virdis, A; Volpe, M, 2022) |
| "This cross-sectional study investigates the association between insulin resistance (IR) and serum uric acid (sUA) and relative fat (RFM) and lean mass (RLM) profiles in children with chronic kidney disease (CKD)." | 8.02 | Association between relative fat mass, uric acid, and insulin resistance in children with chronic kidney disease. ( Christoforidis, A; Dotis, J; Karava, V; Kollios, K; Kondou, A; Liakopoulos, V; Papachristou, F; Printza, N; Tsioni, K, 2021) |
| "The level of serum uric acid (SUA) has been reported to be associated with left ventricular hypertrophy (LVH) and left ventricular diastolic dysfunction (LVDD)." | 8.02 | Association between serum uric acid and left ventricular hypertrophy/left ventricular diastolic dysfunction in patients with chronic kidney disease. ( Kim, HJ; Kim, IY; Kim, MJ; Kim, SR; Lee, DW; Lee, SB; Rhee, H; Seong, EY; Song, SH; Ye, BM, 2021) |
| "The results showed that, in patients with CKD and hyperuricemia, febuxostat can be used to reduce the serum uric acid level." | 7.96 | Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases . ( Yang, AY, 2020) |
| "This is a retrospective analysis of 100 CKD patients treated with febuxostat for asymptomatic hyperuricemia in two private Lebanese clinics." | 7.96 | A formula predicting the effective dose of febuxostat in chronic kidney disease patients with asymptomatic hyperuricemia based on a retrospective study and a validation cohort . ( Aoun, M; Chelala, D; Dfouni, A; Salloum, R; Sleilaty, G, 2020) |
| " Serum uric acid levels and estimated glomerular filtration rate (eGFR) of patients with gouty arthritis were collected at baseline and 1 year after febuxostat administration." | 7.96 | Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis. ( Kim, JM; Kim, SH; Lee, SY; Son, CN, 2020) |
| "Gout patients with chronic kidney disease (CKD) accumulate the active allopurinol metabolite oxypurinol, suggesting that allopurinol may promote greater serum urate (sU) lowering in CKD patients." | 7.91 | Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function. ( Crittenden, DB; Fisher, MC; Keenan, RT; Krasnokutsky, S; Modjinou, DV; Oh, C; Pillinger, MH; Toprover, M, 2019) |
| " The associations among metabolic syndrome (MetS), serum uric acid and CKD are also unclear." | 7.88 | Chronic kidney disease associated with decreased bone mineral density, uric acid and metabolic syndrome. ( Loke, SS; Pan, BL, 2018) |
| "The relationship between serum uric acid (SUA) levels and stroke is controversial." | 7.88 | Serum uric acid levels and outcome during admission in acute ischaemic stroke, depending on renal function. ( Arévalo-Lorido, JC; Carretero-Gómez, J; Robles, NR, 2018) |
| "Increasing evidence has shown that albuminuria is related to serum uric acid." | 7.88 | Urinary excretion of uric acid is negatively associated with albuminuria in patients with chronic kidney disease: a cross-sectional study. ( Chen, W; Fu, C; Guo, H; Li, F; Lu, Y; Xiao, J; Ye, Z; Zhang, X; Zou, J, 2018) |
| "Febuxostat is tolerable in chronic kidney disease (CKD) patients with hyperuricemia." | 7.88 | The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia. ( Fujigaki, Y; Goto, D; Kato, A; Ohashi, N; Ohishi, K; Sato, T; Takeda, A; Tsuji, T; Yasuda, H, 2018) |
| "The model consisted of heat stress exposure (1 h, 37°C) plus rhabdomyolysis (R) induced by repetitive IM injections of glycerol (7." | 7.88 | Kidney Injury from Recurrent Heat Stress and Rhabdomyolysis: Protective Role of Allopurinol and Sodium Bicarbonate. ( Blas-Marron, MG; García-Arroyo, FE; Glaser, J; Gonzaga, G; Johnson, RJ; Madero, M; Muñoz-Jimenez, I; Osorio-Alonso, H; Roncal-Jiménez, CA; Sánchez-Lozada, LG; Silverio, O; Tapia, E; Weiss, I, 2018) |
| "The aim of this study was to ascertain the relationships of blood pressure, fasting sugar level, triglyceride (TG) level, uric acid level, and body mass index (BMI) with proteinuria and the estimated glomerular filtration rate (eGFR) in a population from southern Taiwan." | 7.85 | Fasting sugar, blood pressure, and uric acid are factors related to positive proteinuria and an impaired eGFR. ( Chang, NC; Chien, HH; Chuang, WL; Dai, CY; Hsieh, MH; Kuo, MC; Lin, WY; Wang, CL; Yang, JF; Yu, ML, 2017) |
| "Patients with both hypertension and hyperhomocysteinemia, termed H-type hypertension, have a high risk for cardiocerebrovascular diseases." | 7.85 | Prevalence of Homocysteine-Related Hypertension in Patients With Chronic Kidney Disease. ( Li, Y; Lou, T; Ma, X; Peng, H; Wang, C; Ye, Z; Zhang, J; Zhang, Q, 2017) |
| "To evaluate the relationship of vitamin D status and vitamin D replacement therapy with glycemic control, serum uric acid (SUA) levels, and microalbuminuria (MAU) in patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD)." | 7.85 | The Association of Vitamin D Status and Vitamin D Replacement Therapy with Glycemic Control, Serum Uric Acid Levels, and Microalbuminuria in Patients with Type 2 Diabetes and Chronic Kidney Disease. ( Acikgoz, SB; Genc, AB; Sipahi, S; Solak, Y; Tamer, A; Yildirim, M, 2017) |
| "The serum level of uric acid (UA) is a well-known prognostic factor for heart failure (HF) patients." | 7.83 | The prognostic impact of uric acid in patients with severely decompensated acute heart failure. ( Asai, K; Hata, N; Kobayashi, N; Matsushita, M; Nishigoori, S; Okazaki, H; Shibuya, J; Shimizu, W; Shinada, T; Shiomura, R; Shirakabe, A; Yamamoto, Y, 2016) |
| "Gout is a chronic disease characterized by the deposition of urate crystals in the joints and throughout the body, caused by an excess burden of serum uric acid (sUA)." | 7.83 | The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective. ( Gahn, JC; Mitri, G; Shiozawa, A; Smolen, LJ, 2016) |
| " To help understand the pathogenesis and early prevention of progressive CKD, this large-scale study is designed to determine the complex association between serum uric acid (SUA), metabolic syndrome and the prevalence of CKD in hypertensive patients." | 7.83 | Combined Association of Serum Uric Acid and Metabolic Syndrome with Chronic Kidney Disease in Hypertensive Patients. ( Chen, R; Chen, Z; Dai, H; Liu, C; Lu, M; Lu, S; Lu, Y; Tang, X; Yang, P; Yuan, H; Zhou, H, 2016) |
| "Hyperhomocysteinemia (HHcy) is recognized as a risk factor for cardiovascular disease." | 7.83 | High Prevalence of Hyperhomocysteinemia and Its Association with Target Organ Damage in Chinese Patients with Chronic Kidney Disease. ( Li, Y; Lou, T; Ma, X; Peng, H; Wang, C; Ye, Z; Zhang, J; Zhang, Q, 2016) |
| "Several studies have documented an association between serum uric acid (SUA) concentration and cardiac hypertrophy in hypertensive patients; however, the association remains unclear in chronic kidney disease (CKD) patients." | 7.80 | Sex differences in the association between serum uric acid levels and cardiac hypertrophy in patients with chronic kidney disease. ( Fukui, A; Ikeda, H; Kitazono, T; Nakayama, M; Oniki, H; Tsuchihashi, T; Tsuruya, K; Ura, Y; Yoshitomi, R, 2014) |
| "Serum uric acid (SUA) has been suggested as a potentially modifiable mediator associated with the metabolic syndrome." | 7.80 | Serum uric acid, the metabolic syndrome, and the risk of chronic kidney disease in patients with type 2 diabetes. ( Esteghamati, A; Fotouhi, A; Hafezi-Nejad, N; Nakhjavani, M; Sheikhbahaei, S, 2014) |
| "The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients." | 7.80 | Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. ( Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W, 2014) |
| "Hyperhomocysteinemia is one of the important factors of the cardiovascular disease, and gout is well known to be associated with cardiovascular disease." | 7.80 | Elevated serum homocysteine levels were not correlated with serum uric acid levels, but with decreased renal function in gouty patients. ( Choi, ST; Kim, JS; Song, JS, 2014) |
| "The relationship among serum uric acid (SUA), metabolic syndrome, and chronic kidney disease (CKD) is unclear." | 7.75 | Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate. ( Chen, HW; Chen, YM; Chuang, FH; Kuo, CF; Li, HY; See, LC; Yu, KH, 2009) |
| "As oxonic acid diet increased plasma renin activity, plasma aldosterone, and urine K to Na ratio, these changes may play a significant role in the harmful cardiovascular actions of hyperuricemia." | 7.74 | Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. ( Eräranta, A; Kööbi, P; Kurra, V; Lakkisto, P; Mustonen, JT; Niemelä, OJ; Pörsti, IH; Tahvanainen, AM; Tikkanen, I; Vehmas, TI, 2008) |
| "Treatment with febuxostat resulted in a significant decrease in serum UA level and a significant decrease in MDA-LDL compared with baseline, but no significant difference was observed in hsCRP level or blood pressure." | 6.80 | Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: A randomized controlled study. ( Akiba, T; Itabashi, M; Kikuchi, K; Moriyama, T; Nitta, K; Sasaki, Y; Takei, T; Tsuchiya, K; Tsuruta, Y; Uchida, K, 2015) |
| "Although hyperuricemia has been associated with CKD in many studies, it remains controversial whether this is the cause or the result of decreased renal function." | 6.66 | Renal effects of uric acid: hyperuricemia and hypouricemia. ( Jo, YI; Lee, JH; Park, JH, 2020) |
| "Hyperuricemia is seen when kidney function declines." | 6.48 | Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor? ( Fried, LF; Nashar, K, 2012) |
| "Allopurinol is an inhibitor of xanthine oxidoreductase (XOR) and inhibits the generation of uric acid (UA) as the final product of purine catabolism, as well as the resulting generation of superoxide (O2(-)), in humans." | 6.45 | Allopurinol, an inhibitor of uric acid synthesis--can it be used for the treatment of metabolic syndrome and related disorders? ( Nozaki, S; Onuma, M; Suzuki, I; Yamauchi, T, 2009) |
| "Dapagliflozin (DAPA), a sodium-glucose transporter 2 inhibitor (SGLT2i), attenuates kidney outcomes in patients with not only diabetes mellitus (DM) but also chronic kidney disease (CKD)." | 5.69 | Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus. ( Fukami, K; Kaida, Y; Shibata, R; Taguchi, K, 2023) |
| " The aim of this study was to determine whether urate-lowering therapy with an XO inhibitor (febuxostat) and that with a uricosuric drug (benzbromarone) are comparable in slowing renal function decline in patients with CKD complicated with hypertension and hyperuricemia." | 5.69 | Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial. ( Arima, H; Funakoshi, R; Iseki, K; Ishida, A; Kinjyo, K; Kochi, M; Kohagura, K; Nakamura, T; Ohya, Y; Sakima, A; Satoh, A; Tana, T; Yamazato, M; Zamami, R, 2023) |
| "Thus, hyperuricemia is associated with impaired endothelial function." | 5.62 | Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia. ( Bahrudin, U; Hisatome, I; Kuwabara, M; Li, P; Maharani, N; Mahati, E; Miake, J; Ninomiya, H; Taufiq, F; Utami, SB, 2021) |
| "BACKGROUND Depression is the main problem of psycho-nephrology." | 5.56 | Association Between Serum Uric Acid and Depression in Patients with Chronic Kidney Disease not Requiring Kidney Dialysis: Cross-Sectional and Longitudinal Analyses. ( Chang, W; Gao, B; Han, Y; Hao, J; Li, J; Qi, P; Song, X; Sun, N; Uchida, S; Zhang, M, 2020) |
| "The present study compared the efficacy and safety of low-dose febuxostat versus allopurinol in chronic kidney disease (CKD) patients complicated with hyperuricemia (HUA)." | 5.51 | Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study. ( Cao, B; Yang, N, 2022) |
| "Febuxostat was significantly more potent than allopurinol or benzbromarone in lowering SUA levels in the fully adjusted model." | 5.48 | Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. ( Chiu, HT; Chou, HW; Huang, HC; Kuo, CC; Ting, IW; Tsai, CW; Yeh, HC, 2018) |
| "Renal fibrosis is a complication of kidney injury and associated with increased risk of morbidity and mortality." | 5.48 | Ameliorative effect of ursolic acid on renal fibrosis in adenine-induced chronic kidney disease in rats. ( Begum, J; Kumar, D; Kumar, P; Lingaraju, MC; Mathesh, K; Sharma, A; Singh, TU; Thakur, R, 2018) |
| "Early detection diabetic nephropathy (DN) is important." | 5.43 | Serum uric acid and its association with hypertension, early nephropathy and chronic kidney disease in type 2 diabetic patients. ( Fathy, H; Fouad, M; Zidan, A, 2016) |
| "The aim of the present study is to present a historical and unified perspective on the association of serum uric acid (SUA) in the cause of cardiovascular diseases (CVDs)." | 5.41 | Association of hyperuricemia with cardiovascular diseases: current evidence. ( Chrysant, SG, 2023) |
| "Mild hyperuricemia is a strong, independent marker of MS and high cardio-renal risk profile in hypertensive patients under specialist care." | 5.40 | Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: insights from the I-DEMAND study. ( Agabiti Rosei, E; Ambrosioni, E; Costa, FV; Deferrari, G; Garneri, D; Gonnella, A; Leoncini, G; Leonetti, G; Muiesan, ML; Pessina, AC; Pontremoli, R; Trimarco, B; Viazzi, F; Volpe, M, 2014) |
| "Febuxostat is a novel xanthine oxidase inhibitor that is metabolized by many metabolic pathways in the kidney and the liver." | 5.40 | Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease. ( Itabashi, M; Mochizuki, T; Moriyama, T; Nitta, K; Takei, T; Tsuchiya, K; Tsuruta, Y, 2014) |
| "Febuxostat had stronger renoprotective and antioxidant effects than topiroxostat in patients with hyperuricemia and CKD." | 5.34 | Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial). ( Osaka, S; Sekino, H; Sezai, A; Tanaka, M; Taoka, M; Unosawa, S, 2020) |
| "Patients treated with ALA at T1 and T2 showed a significant reduction in serum glucose, insulin, homeostatic model assessment-insulin resistance, and serum uric acid (P = 0." | 5.34 | α-lipoic acid in patients with autosomal dominant polycystic kidney disease. ( Amabile, MI; Ansuini, M; Carta, M; Cianci, R; D'Ambrosio, V; Galani, A; Lai, S; Letizia, C; Mazzaferro, S; Mitterhofer, AP; Molfino, A; Muscaritoli, M; Pasquali, M; Petramala, L; Ramaccini, C, 2020) |
| "To assess the efficacy and safety of febuxostat extended release (XR) and immediate release (IR) in patients with gout and normal or impaired renal function." | 5.30 | Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. ( Becker, MA; Castillo, M; Gunawardhana, L; Hunt, B; Kisfalvi, K; Saag, KG; Whelton, A, 2019) |
| " In the benzbromarone group, kidney stones in one case increased in quantity." | 5.27 | Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study. ( Bao, H; Cheng, J; Liu, X; Peng, A; Qin, L; Song, Y; Wang, L; Yu, H; Zhou, X, 2018) |
| "These data suggest that factors other than uric acid may play a more important role in the regulation of CKD- MBD including vascular calcification and vitamin D metabolism in patients with CKD." | 5.27 | Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial. ( Andrews, ES; Chonchol, M; Jalal, D; Kendrick, J; Nowak, KL; Pasch, A; Perrenoud, L; You, Z, 2018) |
| "Hyperuricemia is common in approximately 50% of patients with kidney failure due to decreased uric acid excretion, and it has been recently known as an independent factor in the progression of renal insufficiency." | 5.24 | Allopurinol Against Progression of Chronic Kidney Disease. ( Almasi, A; Golmohammadi, S; Manouchehri, M; Omrani, HR; Zandkarimi, MR, 2017) |
| "There is little evidence guiding selection of nondiuretic, antihypertensive agents with a goal of lowering uric acid (SUA) and minimizing gout risk." | 5.24 | Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension. ( Appel, LJ; Juraschek, SP; Miller, ER, 2017) |
| "The use of allopurinol in people with chronic kidney disease (CKD) remains one of the most controversial areas in gout management." | 5.24 | The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial. ( Barclay, M; Chapman, PT; Dalbeth, N; Drake, J; Frampton, C; Horne, A; Stamp, LK; Tan, P, 2017) |
| "Hyperuricemia is caused by reduced renal/extrarenal excretion and overproduction of uric acid." | 5.22 | Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease. ( Maeda, N; Nishizawa, H; Shimomura, I, 2022) |
| "Uric acid (UA) is the final product of purine metabolism in the human body, and impaired purine metabolism can increase the uric acid in serum, finally resulting in hyperuricemia (HUA)." | 5.22 | Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights. ( Dong, B; Geng, Z; Mei, Y; Xu, L, 2022) |
| "We assume that decreasing uric acid levels with allopurinol treatment seems to be helpful in restoring endothelial functions, preventing metabolic acidosis and slowing down the progression of CKD." | 5.20 | The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients. ( Altuntaş, A; Bayram, D; İnal, S; Kıdır, V; Orhan, H; Tuğrul Sezer, M, 2015) |
| "Amelioration of both oxidative and inflammation status after cholesterol lowering treatment in CKD might be mediated by restoration of antioxidant taurine concentrations during therapy (from 51." | 5.20 | Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement. ( Carru, C; Mangoni, AA; Sanna, M; Satta, AE; Sotgia, S; Zinellu, A, 2015) |
| "The NU-FLASH trial demonstrated that febuxostat was more effective for hyperuricemia than allopurinol." | 5.20 | Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). ( Hata, H; Ishii, Y; Nakata, K; Osaka, S; Sezai, A; Shiono, M; Soma, M; Yaoita, H, 2015) |
| "Fructose acutely raises serum uric acid in normal subjects, but the effect in subjects with metabolic syndrome or subjects with chronic kidney disease is unknown." | 5.20 | The fructose tolerance test in patients with chronic kidney disease and metabolic syndrome in comparison to healthy controls. ( Donderski, R; Grajewska, M; Johnson, RJ; Junik, R; Kamińska, A; Kretowicz, M; Lanaspa, M; Manitius, J; Miśkowiec-Wiśniewska, I; Odrowąż-Sypniewska, G; Pluta, A; Siódmiak, J; Stefańska, A, 2015) |
| "Treatment of congestive heart failure (CHF) with loop diuretics, such as furosemide, may be associated with complications, including worsening renal function and metabolic or electrolyte disturbances." | 5.20 | Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study. ( Akashi, YJ; Kida, K; Kimura, K; Matsumoto, N; Miyake, F; Shibagaki, Y; Tominaga, N, 2015) |
| "The FEATHER (FEbuxostat versus placebo rAndomized controlled Trial regarding reduced renal function in patients with Hyperuricemia complicated by chRonic kidney disease stage 3) study is a prospective, multicenter, double-blind, randomized, placebo-controlled trial of febuxostat-a novel, nonpurine, selective, xanthine oxidase inhibitor." | 5.19 | The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. ( Hayakawa, H; Hosoya, T; Iimuro, S; Imai, N; Inaba, M; Itoh, S; Kimura, K; Kuwabara, M; Makino, H; Matsuo, S; Ohno, I; Shibagaki, Y; Tomino, Y; Uchida, S; Yamamoto, T, 2014) |
| "Topiroxostat, a selective xanthine oxidase inhibitor, shows effective reduction in the serum urate level in hyperuricemic patients with or without gout." | 5.19 | Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. ( Fujimori, S; Hara, S; Hisatome, I; Hosoya, T; Nomura, S; Ohno, I; Uchida, S; Yamamoto, T, 2014) |
| " In this study, we assessed the additive effects of hydrochlorothiazide (HCTZ) on reducing proteinuria in CKD patients under treatment with losartan (LS)." | 5.19 | Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension. ( Fujisaki, K; Higashi, H; Hirakata, H; Kanai, H; Katafuchi, R; Kitazono, T; Nakano, T; Nakayama, M; Taniguchi, M; Tsuruya, K, 2014) |
| "Lower dosages of allopurinol are recommended to avoid toxicity in gout patients with impaired renal function." | 5.13 | Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. ( Angthararak, S; Panomvana, D; Sripradit, S, 2008) |
| " Elevated uric acid levels are risk factors for gout, hypertension, and chronic kidney diseases." | 5.12 | Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis. ( Kimura, Y; Kono, H; Tsukui, D, 2021) |
| " Results of multiple studies have demonstrated independent associations between increased levels of uric acid and risk of arterial hypertension, cardiovascular diseases, and chronic kidney disease." | 5.12 | [Asymptomatic Hyperuricemia: Treatment Approaches According to the Risk of Cardiovascular and Renal Events]. ( Kobalava, ZD; Troitskaya, EA, 2021) |
| "The Febuxostat versus Placebo Randomized Controlled Trial Regarding Reduced Renal Function in Patients with Hyperuricemia Complicated by Chronic Kidney Disease Stage 3 trial evaluated the effect of febuxostat in 443 patients with stage 3 CKD (mean estimated glomerular filtration rate [eGFR] 45 mL/min/1." | 5.12 | Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease. ( Badve, SV; Johnson, DW; Tiku, A, 2021) |
| "Hyperuricemia is a state in which the serum levels of uric acid are elevated." | 5.05 | Hyperuricemia, the heart, and the kidneys - to treat or not to treat? ( Bevc, S; Ekart, R; Hojs, R; Petreski, T, 2020) |
| "This review brings together concepts of uric acid metabolism affecting renal parenchyma and its function and the current therapies to reduce hyperuricemia (HyU) and avoid renal disease progression." | 4.98 | Uric Acid: The Unknown Uremic Toxin. ( Treviño-Becerra, A, 2018) |
| "Several epidemiological studies have demonstrated the existence of a correlation between high serum uric acid (SUA) levels, hypertension, and chronic kidney disease (CKD)." | 4.95 | The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function. ( Borghi, C; Bove, M; Cicero, AFG, 2017) |
| "Uric acid, once viewed as an inert metabolic end-product of purine metabolism, has been recently incriminated in a number of chronic disease states, including hypertension, metabolic syndrome, diabetes, non-alcoholic fatty liver disease, and chronic kidney disease." | 4.93 | Uric acid in metabolic syndrome: From an innocent bystander to a central player. ( Jensen, T; Johnson, RJ; Kanbay, M; Lanaspa, MA; Le, M; Nakagawa, T; Rivard, C; Roncal-Jimenez, C; Solak, Y, 2016) |
| "To discuss the evolving data regarding uric acid as a potential cause of hypertension and progressive renal dysfunction and its clinical and research implications." | 4.90 | Serum uric acid and the risk of hypertension and chronic kidney disease. ( Feig, DI, 2014) |
| "Enalapril has similar effects to losartan on systemic blood pressure, renal function and serum UA in patients with CKD, but carries a higher risk of dry cough." | 4.89 | Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis. ( Feng, L; He, YM; Huo, DM; Liao, YH; Yang, ZH, 2013) |
| " Hypertension has been implicated as a factor influencing the association between serum uric acid and CKD." | 4.89 | Serum uric acid and chronic kidney disease: the role of hypertension. ( Dehghan, A; Franco, OH; Hofman, A; Hoorn, EJ; Sedaghat, S; van Rooij, FJ; Witteman, JC, 2013) |
| "Elevated uric acid levels are a common finding in patients with metabolic syndrome and in those with cardiovascular and renal disease, but the meaning of this elevation is still unclear." | 4.88 | Uric acid: a starring role in the intricate scenario of metabolic syndrome with cardio-renal damage? ( Di Giorgio, C; Gesualdo, L; Morrone, LF; Stellato, D, 2012) |
| "The objective of the study was to compare the relative effects of benzbromarone and allopurinol on the risk of developing chronic kidney disease in persons with asymptomatic hyperuricemia." | 4.31 | Comparison of benzbromarone and allopurinol on the risk of chronic kidney disease in people with asymptomatic hyperuricemia. ( Hwang, BF; Kuo, YH; Lai, SW; Liao, KF; Liu, CS, 2023) |
| " Uric acid (UA), a major risk factor for gout, has also been suggested to be a risk factor for CKD, but the efficacy of existing urate-lowering therapies for CKD is controversial." | 4.31 | GLUT9 as a potential drug target for chronic kidney disease: Drug target validation by a Mendelian randomization study. ( Fukui, K; Kamatani, N; Kamitsuji, S; Matsuo, A; Matsushita, M; Nishiu, J; Sasase, T; Ueda, M, 2023) |
| "To study the associations of non-alcoholic fatty liver disease (NAFLD), chronic kidney disease (CKD), and serum uric acid (SUA) in patients with post-myocardial infarction (MI) patients, and the relationship of SUA with 12-year mortality risk." | 4.31 | Serum uric acid is related to liver and kidney disease and 12-year mortality risk after myocardial infarction. ( Boersma, E; Geleijnse, JM; Heerkens, L; Kardys, I; van Westing, AC; Voortman, T, 2023) |
| "Febuxostat is recommended for lowering serum uric acid (sUA) concentration in chronic kidney disease (CKD) patients with hyperuricemia." | 4.12 | Effects of Renal Function on Urinary Excretion and Serum Concentration of Uric Acid in Patients Treated with Febuxostat for Chronic Kidney Disease. ( Kashiwagi, T; Sakai, Y; Yamada, T, 2022) |
| " Patients were aged ≥19 years; had CKD G3-G4; and used drugs including colchicine, allopurinol and febuxostat for hyperuricaemia or chronic gout during the period from April 2000 to October 2020." | 4.12 | Colchicine use and the risk of CKD progression: a multicentre nested case-control study. ( Chang, TI; Han, SH; Jhee, JH; Joo, YS; Kang, SW; Kim, HW; Kim, JY; Park, JT; Roh, YH; Yoo, TH; Yun, HR, 2022) |
| " Whether hyperuricemia is an independent risk factor for renal progression and whether there are sex differences in the relationships between serum uric acid (UA) and a decline in renal function are unclear." | 4.12 | Sex Difference in the Associations among Hyperuricemia with New-Onset Chronic Kidney Disease in a Large Taiwanese Population Follow-Up Study. ( Chen, JH; Chen, SC; Chung, TL; Huang, JC; Liu, YH; Su, HM; Tsai, CC; Wu, PY, 2022) |
| " Finally, we used multivariate linear regression to evaluate the relationship between serum leptin and eGFR levels with adjustment for age, sex, smoking status, drinking status, body mass index (BMI), uric acid levels, hypertension (HTN), diabetes mellitus (DM), and dyslipidemia." | 4.12 | Elevated serum leptin levels are associated with lower renal function among middle-aged and elderly adults in Taiwan, a community-based, cross-sectional study. ( Chen, JY; Chen, SY; Shih, CC; Shih, YL, 2022) |
| " However, a better understanding of the relationship among uric acid (UA) values, glomerular filtration rate (GFR) and albuminuria may shed light on the mechanisms underlying the excess of cardiovascular mortality associated with both chronic kidney disease and hyperuricemia and lead to better risk stratification." | 4.12 | Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. ( Barbagallo, CM; Bombelli, M; Borghi, C; Casiglia, E; Cicero, AFG; Cirillo, M; Cirillo, P; D'Elia, L; Desideri, G; Ferri, C; Galletti, F; Gesualdo, L; Giannattasio, C; Grassi, G; Iaccarino, G; Leoncini, G; Mallamaci, F; Maloberti, A; Masi, S; Mazza, A; Mengozzi, A; Muiesan, ML; Nazzaro, P; Palatini, P; Parati, G; Pontremoli, R; Rattazzi, M; Rivasi, G; Russo, E; Salvetti, M; Tikhonoff, V; Tocci, G; Ungar, A; Verdecchia, P; Viazzi, F; Virdis, A; Volpe, M, 2022) |
| "Treatment with STAT3 inhibitor S3I-201 improved renal dysfunction, reduced serum uric acid level, and delayed the progression of kidney fibrosis." | 4.02 | Pharmacologic inhibiting STAT3 delays the progression of kidney fibrosis in hyperuricemia-induced chronic kidney disease. ( Fu, P; Guo, F; Ma, L; Pan, J; Shi, M, 2021) |
| "We aimed to investigate the association between serum uric acid (SUA) level and development of hypertension as well as the interaction effect of chronic kidney disease (CKD) on this relationship in the general Japanese population." | 4.02 | Effect of chronic kidney disease on the association between hyperuricemia and new-onset hypertension in the general Japanese population: ISSA-CKD study. ( Arima, H; Fujii, H; Funakoshi, S; Ishida, S; Ito, K; Kawanami, D; Kawazoe, M; Kondo, S; Maeda, T; Masutani, K; Mukobara, S; Nabeshima, S; Okutsu, S; Satoh, A; Tada, K; Takahashi, K; Tsuji, M; Yasuno, T; Yokota, S; Yoshimura, C, 2021) |
| "This cross-sectional study investigates the association between insulin resistance (IR) and serum uric acid (sUA) and relative fat (RFM) and lean mass (RLM) profiles in children with chronic kidney disease (CKD)." | 4.02 | Association between relative fat mass, uric acid, and insulin resistance in children with chronic kidney disease. ( Christoforidis, A; Dotis, J; Karava, V; Kollios, K; Kondou, A; Liakopoulos, V; Papachristou, F; Printza, N; Tsioni, K, 2021) |
| "While hyperuricemia is recognized as a risk factor for chronic kidney disease (CKD), the risk of CKD in subjects with a low level of serum uric acid (UA) remains controversial." | 4.02 | U-shaped relationship between serum uric acid level and decline in renal function during a 10-year period in female subjects: BOREAS-CKD2. ( Furuhashi, M; Hanawa, N; Higashiura, Y; Hisasue, T; Inyaku, M; Koyama, M; Matsumoto, M; Miura, T; Moniwa, N; Mori, K; Numata, K; Ohnishi, H; Osanami, A; Tanaka, M, 2021) |
| " We observed an improvement of renal function biomarkers (estimated-glomerular filtration rate, albuminuria, azotemia, uric acid), lipid profile, oxidative stress, inflammatory parameters (erythrocyte sedimentation rate, C-reactive protein) and in body composition at T1." | 4.02 | Usefulness of Extra Virgin Olive Oil Minor Polar Compounds in the Management of Chronic Kidney Disease Patients. ( Di Daniele, F; Di Daniele, N; Di Lauro, M; Marrone, G; Noce, A; Pietroboni Zaitseva, A; Romani, A; Urciuoli, S, 2021) |
| "Hyperuricemia is highly prevalent in chronic kidney disease (CKD) patients, but the evidence for a relationship between uric acid (UA) and clinical outcomes in CKD patients is limited and inconsistent." | 4.02 | Different clinical impact of hyperuricemia according to etiologies of chronic kidney disease: Gonryo Study. ( Ito, S; Miyazaki, M; Nakayama, M; Sato, H; Watanabe, K; Yamada, G; Yamamoto, T, 2021) |
| "The level of serum uric acid (SUA) has been reported to be associated with left ventricular hypertrophy (LVH) and left ventricular diastolic dysfunction (LVDD)." | 4.02 | Association between serum uric acid and left ventricular hypertrophy/left ventricular diastolic dysfunction in patients with chronic kidney disease. ( Kim, HJ; Kim, IY; Kim, MJ; Kim, SR; Lee, DW; Lee, SB; Rhee, H; Seong, EY; Song, SH; Ye, BM, 2021) |
| "To explore whether dyslipidemia, hyperglycemia or hypertension has mediating effect on the association between serum uric acid (SUA) and the development of chronic kidney disease (CKD)." | 4.02 | The Effects of Cardiometabolic Factors on the Association Between Serum Uric Acid and Chronic Kidney Disease in Chinese Middle-Aged and Older Population: A Mediation Analysis. ( Liu, L; Lv, X; Song, Y; Sun, H; Wang, S; Xu, L; Zhan, S, 2021) |
| "The results showed that, in patients with CKD and hyperuricemia, febuxostat can be used to reduce the serum uric acid level." | 3.96 | Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases . ( Yang, AY, 2020) |
| "This is a retrospective analysis of 100 CKD patients treated with febuxostat for asymptomatic hyperuricemia in two private Lebanese clinics." | 3.96 | A formula predicting the effective dose of febuxostat in chronic kidney disease patients with asymptomatic hyperuricemia based on a retrospective study and a validation cohort . ( Aoun, M; Chelala, D; Dfouni, A; Salloum, R; Sleilaty, G, 2020) |
| "A significant relationship exists between elevated uric acid concentration and both prevalent and incident hypertension; however, data regarding the influence of higher uric acid concentration at baseline on blood pressure control by antihypertensive drugs is scarce." | 3.96 | Higher baseline uric acid concentration is associated with non-attainment of optimal blood pressure. ( Asahi, K; Fujimoto, S; Iseki, K; Kasahara, M; Kondo, M; Konta, T; Moriyama, T; Narita, I; Sato, Y; Shibagaki, Y; Tsuruya, K; Watanabe, T; Yamagata, K, 2020) |
| " Here, we report the use of whole genome sequencing (WGS) to establish a diagnosis in a family in which individuals were affected with gout, hyperuricemia associated with reduced fractional excretion of uric acid, chronic kidney disease (CKD), and secondary hyperparathyroidism, that are consistent with familial juvenile hyperuricemic nephropathy (FJHN)." | 3.96 | Whole genome sequence analysis identifies a PAX2 mutation to establish a correct diagnosis for a syndromic form of hyperuricemia. ( Gorvin, CM; Lhotta, K; Lines, KE; Pagnamenta, AT; Philpott, C; Reichart, S; Stevenson, M; Taylor, JC; Thakker, RV, 2020) |
| " Serum uric acid levels and estimated glomerular filtration rate (eGFR) of patients with gouty arthritis were collected at baseline and 1 year after febuxostat administration." | 3.96 | Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis. ( Kim, JM; Kim, SH; Lee, SY; Son, CN, 2020) |
| "Gout patients with chronic kidney disease (CKD) accumulate the active allopurinol metabolite oxypurinol, suggesting that allopurinol may promote greater serum urate (sU) lowering in CKD patients." | 3.91 | Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function. ( Crittenden, DB; Fisher, MC; Keenan, RT; Krasnokutsky, S; Modjinou, DV; Oh, C; Pillinger, MH; Toprover, M, 2019) |
| "Because the serum uric acid level increases as the glomerular filtration rate (GFR) decreases, hyperuricemia is associated with chronic kidney disease (CKD)." | 3.91 | Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function. ( Jeon, HJ; Oh, J; Shin, DH, 2019) |
| " laboratory evidence of kidney function decline (reference indicator), uric acid, and hypertension in different patient groups, separated according to their baseline uProt levels and baseline eGFR." | 3.88 | Effects of topiroxostat in hyperuricemic patients with chronic kidney disease. ( Hatakeyama, Y; Horino, T; Ichii, O; Inoue, K; Matsumoto, T; Okuhara, Y; Shimamura, Y; Terada, Y, 2018) |
| " The associations among metabolic syndrome (MetS), serum uric acid and CKD are also unclear." | 3.88 | Chronic kidney disease associated with decreased bone mineral density, uric acid and metabolic syndrome. ( Loke, SS; Pan, BL, 2018) |
| " Serum uric acid (SUA) has been associated with cardiovascular diseases (CVD), but no conclusive findings are available nowadays in patients suffering from hypoglycaemia." | 3.88 | Levels of serum uric acid at admission for hypoglycaemia predict 1-year mortality. ( Bonaventura, A; Carbone, F; Cordera, R; Dallegri, F; Gallo, F; Liberale, L; Maggi, D; Montecucco, F; Sacchi, G, 2018) |
| "Although the clinical implication of hyperuricemia in chronic kidney disease has been an issue of active debate, recent data suggested a causative role of uric acid (UA) in the development of renal disease." | 3.88 | Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells. ( Kang, DH, 2018) |
| " Disturbance in purine metabolism pathway and a higher level of serum uric acid, called hyperuricemia, is a risk factor of CKD, and it has been linked to increased prevalence and progression of the disease." | 3.88 | Disturbed purine nucleotide metabolism in chronic kidney disease is a risk factor for cognitive impairment. ( Bhattacharjee, A; Borah, A; Mazumder, MK; Phukan, BC, 2018) |
| "The relationship between serum uric acid (SUA) levels and stroke is controversial." | 3.88 | Serum uric acid levels and outcome during admission in acute ischaemic stroke, depending on renal function. ( Arévalo-Lorido, JC; Carretero-Gómez, J; Robles, NR, 2018) |
| "Uric acid has been known since long ago for its implication in gout and in certain kinds of nephrolithiasis." | 3.88 | [Acid uric : key player in a recently recognized devastating nephropathy and in the development of chronic kidney disease.] ( Humbert, A; Stucker, F, 2018) |
| "Increasing evidence has shown that albuminuria is related to serum uric acid." | 3.88 | Urinary excretion of uric acid is negatively associated with albuminuria in patients with chronic kidney disease: a cross-sectional study. ( Chen, W; Fu, C; Guo, H; Li, F; Lu, Y; Xiao, J; Ye, Z; Zhang, X; Zou, J, 2018) |
| "Febuxostat is tolerable in chronic kidney disease (CKD) patients with hyperuricemia." | 3.88 | The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia. ( Fujigaki, Y; Goto, D; Kato, A; Ohashi, N; Ohishi, K; Sato, T; Takeda, A; Tsuji, T; Yasuda, H, 2018) |
| "As uncontrolled hyperuricemia has been associated with an increased risk of cardiovascular disease and the progression of chronic kidney disease (CKD), management of serum uric acid levels is important." | 3.88 | Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease . ( Cho, YS; Han, N; Kim, YS; Kwak, CH; Oh, JM; Sohn, M, 2018) |
| "According to multiple linear regression analysis, in hypertension group, fractional excretion of sodium (FEna) was negatively correlated with 24 hour urinary uric acid (24-hUur) and uric acid clearance rate (Cur) (beta coefficients [B]=-0." | 3.88 | The Association of Urinary Sodium and Potassium with Renal Uric Acid Excretion in Patients with Chronic Kidney Disease. ( Chen, W; Fu, C; Guo, H; Li, F; Lu, Y; Xiao, J; Ye, Z; Zhang, X; Zou, J, 2018) |
| "Subjects included 633 Japanese subjects not receiving medication for hyperuricemia, diabetes mellitus, dyslipidemia, or chronic renal disease who underwent an annual health examination that included determination of small, dense low-density lipoprotein cholesterol (sdLDL-C) and malondialdehyde-modified low-density lipoprotein (MDA-LDL) levels." | 3.88 | Low-density Lipoprotein Subclasses are Associated with Serum Uric Acid Levels. ( Moriyama, K, 2018) |
| "The model consisted of heat stress exposure (1 h, 37°C) plus rhabdomyolysis (R) induced by repetitive IM injections of glycerol (7." | 3.88 | Kidney Injury from Recurrent Heat Stress and Rhabdomyolysis: Protective Role of Allopurinol and Sodium Bicarbonate. ( Blas-Marron, MG; García-Arroyo, FE; Glaser, J; Gonzaga, G; Johnson, RJ; Madero, M; Muñoz-Jimenez, I; Osorio-Alonso, H; Roncal-Jiménez, CA; Sánchez-Lozada, LG; Silverio, O; Tapia, E; Weiss, I, 2018) |
| "The mean eGFR was statistically significantly lower in patients with hyperuricemia than in those with normal uric acid levels (143 vs." | 3.85 | Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia. ( Cutter, GR; Feig, DI; Howard, TH; Lebensburger, JD; Muntner, P, 2017) |
| " One-hundred and seventy-eight CKD patients with hyperuricemia who received febuxostat therapy were included in this study." | 3.85 | Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study. ( Harada, M; Hashimoto, K; Kamijo, Y; Yamada, Y; Yamaguchi, A, 2017) |
| "An elevated level of serum uric acid-hyperuricemia, is strongly associated with the development of gout and chronic kidney disease (CKD) which is often accompanied by a significantly reduced glomerular filtration rate (GFR)." | 3.85 | Oral uricase eliminates blood uric acid in the hyperuricemic pig model. ( Goncharova, K; Grujic, D; Lozinska, L; Mosiichuk, N; Pierzynowski, SG; Pieszka, M; Święch, E; Szczurek, P; Woliński, J; Yatsenko, T, 2017) |
| "The aim of this study was to ascertain the relationships of blood pressure, fasting sugar level, triglyceride (TG) level, uric acid level, and body mass index (BMI) with proteinuria and the estimated glomerular filtration rate (eGFR) in a population from southern Taiwan." | 3.85 | Fasting sugar, blood pressure, and uric acid are factors related to positive proteinuria and an impaired eGFR. ( Chang, NC; Chien, HH; Chuang, WL; Dai, CY; Hsieh, MH; Kuo, MC; Lin, WY; Wang, CL; Yang, JF; Yu, ML, 2017) |
| " Multivariable analysis using eGFRcreat as an independent variable identified age, smoking status, body mass index, haemoglobin, serum uric acid, serum albumin, albuminuria, and C reactive protein as non-GFR determinants of eGFRcys." | 3.85 | The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: A primary care cohort study. ( Fluck, RJ; Fraser, SDS; McIntyre, CW; McIntyre, NJ; Raftery, J; Roderick, P; Shardlow, A; Taal, MW, 2017) |
| "Patients with both hypertension and hyperhomocysteinemia, termed H-type hypertension, have a high risk for cardiocerebrovascular diseases." | 3.85 | Prevalence of Homocysteine-Related Hypertension in Patients With Chronic Kidney Disease. ( Li, Y; Lou, T; Ma, X; Peng, H; Wang, C; Ye, Z; Zhang, J; Zhang, Q, 2017) |
| "The influence of serum urate on kidney disease is attracting attention, but the effects of uric acid (UA) on nephrosclerosis have not been elucidated." | 3.85 | Hyperuricemia as a Predictive Marker for Progression of Nephrosclerosis: Clinical Assessment of Prognostic Factors in Biopsy-Proven Arterial/Arteriolar Nephrosclerosis. ( Kataoka, H; Mochizuki, T; Momoki, K; Moriyama, T; Nitta, K, 2017) |
| "To evaluate the relationship of vitamin D status and vitamin D replacement therapy with glycemic control, serum uric acid (SUA) levels, and microalbuminuria (MAU) in patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD)." | 3.85 | The Association of Vitamin D Status and Vitamin D Replacement Therapy with Glycemic Control, Serum Uric Acid Levels, and Microalbuminuria in Patients with Type 2 Diabetes and Chronic Kidney Disease. ( Acikgoz, SB; Genc, AB; Sipahi, S; Solak, Y; Tamer, A; Yildirim, M, 2017) |
| " Fifty patients with hyperuricemia defined as a serum uric acid greater than 7 mg/dL (average of ~9 mg/dL), newly started on allopurinol for any reason, with evidence of treatment compliance, were matched by age, race, sex, and estimated glomerular filtration rate (EGFR) to 50 hyperuricemic control subjects." | 3.85 | The Effect of Allopurinol on Renal Function. ( Blumenthal, D; Gerber, D; Krishnamurthy, A; Lazaro, D; Patel, S; Stefanov, DG, 2017) |
| "To compare total and disease-specific health care expenditures by line of therapy in allopurinol and febuxostat initiators after diagnosis with gout and moderate-to-severe CKD." | 3.83 | Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease. ( Mitri, G; Schulman, KL; Tidwell, BA; Turpin, RS; Wittbrodt, ET, 2016) |
| "The role of systemic vascular involvement in mediating the association between serum uric acid (SUA) and renal function in hypertension has not been explored." | 3.83 | Association between uric acid and renal function in hypertensive patients: which role for systemic vascular involvement? ( Castiglia, A; Cottone, S; Cusumano, C; D'Ignoto, F; Geraci, C; Geraci, G; Gervasi, F; Mogavero, M; Morreale, M; Mulè, G, 2016) |
| "Whether renal dysfunction influences the hypouricemic effect of febuxostat, a xanthine oxidase (XO) inhibitor, in patients with hyperuricemia due to overproduction or underexcretion of uric acid (UA) remains unclear." | 3.83 | Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid. ( Echizen, H; Hirai, T; Kimura, T, 2016) |
| "The serum level of uric acid (UA) is a well-known prognostic factor for heart failure (HF) patients." | 3.83 | The prognostic impact of uric acid in patients with severely decompensated acute heart failure. ( Asai, K; Hata, N; Kobayashi, N; Matsushita, M; Nishigoori, S; Okazaki, H; Shibuya, J; Shimizu, W; Shinada, T; Shiomura, R; Shirakabe, A; Yamamoto, Y, 2016) |
| "Gout is a chronic disease characterized by the deposition of urate crystals in the joints and throughout the body, caused by an excess burden of serum uric acid (sUA)." | 3.83 | The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective. ( Gahn, JC; Mitri, G; Shiozawa, A; Smolen, LJ, 2016) |
| " To help understand the pathogenesis and early prevention of progressive CKD, this large-scale study is designed to determine the complex association between serum uric acid (SUA), metabolic syndrome and the prevalence of CKD in hypertensive patients." | 3.83 | Combined Association of Serum Uric Acid and Metabolic Syndrome with Chronic Kidney Disease in Hypertensive Patients. ( Chen, R; Chen, Z; Dai, H; Liu, C; Lu, M; Lu, S; Lu, Y; Tang, X; Yang, P; Yuan, H; Zhou, H, 2016) |
| " Plasma MED concentrations, inflammation and oxidative stress indices [Kynurenine/Tryptophan (Kyn/Trp) ratio, malondialdehyde (MDA) and allantoin/uric acid (All/UA) ratio] were measured in 30 CKD patients randomized to three cholesterol lowering regimens for 12 months (simvastatin 40mg/day, ezetimibe/simvastatin 10/20mg/day, or ezetimibe/simvastatin 10/40mg/day)." | 3.83 | Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease. ( Carru, C; Ena, S; Mangoni, AA; Satta, AE; Sotgia, S; Sotgiu, E; Zinellu, A, 2016) |
| "Hyperhomocysteinemia (HHcy) is recognized as a risk factor for cardiovascular disease." | 3.83 | High Prevalence of Hyperhomocysteinemia and Its Association with Target Organ Damage in Chinese Patients with Chronic Kidney Disease. ( Li, Y; Lou, T; Ma, X; Peng, H; Wang, C; Ye, Z; Zhang, J; Zhang, Q, 2016) |
| "Recent studies have revealed an association between elevated levels of uric acid and conditions correlated to chronic kidney diseases such as hypertension, cardiovascular and cerebral disease, insulin resistance." | 3.81 | [Hyperuricemia and renal risk]. ( Bonino, B; Desideri, G; Pontremoli, R; Ratto, E; Viazzi, F, 2015) |
| "Several studies have documented an association between serum uric acid (SUA) concentration and cardiac hypertrophy in hypertensive patients; however, the association remains unclear in chronic kidney disease (CKD) patients." | 3.80 | Sex differences in the association between serum uric acid levels and cardiac hypertrophy in patients with chronic kidney disease. ( Fukui, A; Ikeda, H; Kitazono, T; Nakayama, M; Oniki, H; Tsuchihashi, T; Tsuruya, K; Ura, Y; Yoshitomi, R, 2014) |
| "Serum uric acid (SUA) has been suggested as a potentially modifiable mediator associated with the metabolic syndrome." | 3.80 | Serum uric acid, the metabolic syndrome, and the risk of chronic kidney disease in patients with type 2 diabetes. ( Esteghamati, A; Fotouhi, A; Hafezi-Nejad, N; Nakhjavani, M; Sheikhbahaei, S, 2014) |
| "The object of this study was to evaluate the effect of uric acid lowering therapy in reducing the new development of comorbidities and the frequency of acute attacks in gout patients." | 3.80 | Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. ( Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W, 2014) |
| "Hyperhomocysteinemia is one of the important factors of the cardiovascular disease, and gout is well known to be associated with cardiovascular disease." | 3.80 | Elevated serum homocysteine levels were not correlated with serum uric acid levels, but with decreased renal function in gouty patients. ( Choi, ST; Kim, JS; Song, JS, 2014) |
| " The relationship between albuminuria and circulating biomarkers for both oxidative damage, that is carbonyl and malondialdehyde, as well as antioxidant defense, that is reduced glutathione, thiol groups, uric acid, bilirubin, or catalase, and superoxide scavenging activity, was assessed." | 3.80 | Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression. ( Aranguez, I; Arribas, S; Cerezo, C; Condezo-Hoyos, L; Del Carmen Gónzalez, M; Fernández-Alfonso, MS; Praga, M; Pulido-Olmo, H; Ruilope, LM; Ruiz-Hurtado, G; Segura, J, 2014) |
| "To study the effects of uric acid on cardiac lesions and its possible mechanism by establishing an early-stage CKD animal model with hyperuricemia." | 3.80 | Effects of uric acid on hearts of rats with chronic kidney disease. ( Bao, X; Wang, Y; Wei, C; Zhang, Q, 2014) |
| " Lower measured GFR associated with lower 24-hour urine creatinine, albuminuria, hypertension, diabetes, higher triglycerides, and higher uric acid." | 3.79 | Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease. ( Bailey, KR; Lieske, JC; Peyser, PA; Rule, AD; Turner, ST, 2013) |
| "Hyperuricemia and left ventricular (LV) hypertrophy are prevalent in chronic kidney disease (CKD), but the association of uric acid (UA) and left ventricular mass index (LVMI) with renal outcomes in patients with CKD is unclear." | 3.79 | Association of uric acid and left ventricular mass index with renal outcomes in chronic kidney disease. ( Chang, JM; Chen, HC; Chen, SC; Su, HM; Yeh, SM, 2013) |
| " But quercetin was only partially effective in restoring glomerular filtration rate, albuminuria, serum cholesterol, triglyceride, blood urea nitrogen (BUN), uric acid, malondialdehyde, superoxide dismutase; urinary BUN and urinary creatinine." | 3.78 | Selected nutraceutic screening by therapeutic effects on doxorubicin-induced chronic kidney disease. ( Chen, KC; Hsieh, CL; Ker, YB; Peng, CC; Peng, RY; Wang, HY, 2012) |
| "As elevated serum uric acid (SUA) is an independent risk factor for hypertension, we examined whether baseline SUA may influence the blood pressure (BP) response to antihypertensive medications." | 3.78 | Effect of hyperuricemia on the blood pressure response to antihypertensive agents in hospitalized elderly patients. ( Chen, H; Hong, D; Lin, C; Lin, F; Lin, K; Zhu, P, 2012) |
| " Univariate logistic regression analysis revealed a significant association between the onset of CKD and age, male gender, body mass index, blood pressure, fasting plasma glucose, dyslipidemia and uric acid." | 3.77 | Uric acid levels predict future development of chronic kidney disease. ( Dohi, Y; Kimura, G; Sonoda, H; Takase, H, 2011) |
| " Hyperuricemia (serum uric acid >7 mg/dL) was found in 15." | 3.77 | Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider. ( Dukes, J; Hinyard, LJ; Lentine, KL; Neri, L; Pinsky, B; Rocca Rey, LA; Schnitzler, MA; Xiao, H, 2011) |
| "Participants with hyperuricemia tended to have higher systolic blood pressure, sugar levels, body mass index, and cholesterol and triglyceride levels but lower estimated glomerular filtration rate (eGFR) levels; eGFR negatively correlated with serum uric acid level." | 3.76 | Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. ( Chang, HH; Chang, HY; Chao, YS; Chen, CY; Fang, KY; Hsu, YC; Jong, MC; Lee, PH; Lei, CC; Lin, CL; Lu, LC; Shih, YH; Tung, CW; Yang, HF, 2010) |
| "The relationship among serum uric acid (SUA), metabolic syndrome, and chronic kidney disease (CKD) is unclear." | 3.75 | Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate. ( Chen, HW; Chen, YM; Chuang, FH; Kuo, CF; Li, HY; See, LC; Yu, KH, 2009) |
| "As oxonic acid diet increased plasma renin activity, plasma aldosterone, and urine K to Na ratio, these changes may play a significant role in the harmful cardiovascular actions of hyperuricemia." | 3.74 | Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. ( Eräranta, A; Kööbi, P; Kurra, V; Lakkisto, P; Mustonen, JT; Niemelä, OJ; Pörsti, IH; Tahvanainen, AM; Tikkanen, I; Vehmas, TI, 2008) |
| "In CKD patients with dyslipidemia, hyperuricemia was an independent risk factor for CKD progression." | 2.94 | The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial. ( Kasahara, M; Kuwabara, Y; Nakao, K; Ueshima, K; Yasuno, S, 2020) |
| "Hyperuricemia is an independent risk factor in chronic kidney disease (CKD)." | 2.94 | A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjec ( Koilagundla, N; Nutalapati, C; Pingali, U; Taduri, G, 2020) |
| "Allopurinol treatment resulted in a decrease in SUA, a decrease in systolic and diastolic BP, a decrease in hsCRP, and an increase in eGFR compared with the baseline values (p < 0." | 2.87 | Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease. ( Assadi, F; Ghane Sharbaf, F, 2018) |
| " Dose-response analysis suggested a nonlinear association between SUA and all-cause mortality risk (Pnonlinearity = 0." | 2.82 | Serum uric acid level and all-cause and cardiovascular mortality in peritoneal dialysis patients: A systematic review and dose-response meta-analysis of cohort studies. ( Amoah, AN; Hu, Y; Huang, X; Kang, T; Lyu, Q, 2022) |
| "Hyperuricemia is an independent risk factor for the progression of chronic kidney disease." | 2.82 | Research progress on related mechanisms of uric acid activating NLRP3 inflammasome in chronic kidney disease. ( Lin, X; Wang, M; Yang, X; Yang, Y, 2022) |
| "Febuxostat was the most effective treatment in lowering urate levels according to the rank probability." | 2.82 | Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials. ( Gu, M; Kong, W; Yu, X; Zhang, L; Zhu, Y; Zou, Y, 2022) |
| "Hypertension is common in CKD patients and many mechanisms inducing it (upregulation of renin-angiotensin-aldosterone system, endothelial dysfunction and atherosclerosis) may be influenced by XOR products." | 2.82 | Chronic kidney disease: Which role for xanthine oxidoreductase activity and products? ( Battelli, MG; Bolognesi, A; Bortolotti, M; Polito, L, 2022) |
| "Long-term flexible dosing with colestilan reduces serum phosphorus and demonstrates an acceptable safety and tolerability profile." | 2.82 | Long-Term Evaluation of Colestilan in Chronic Kidney Disease Stage 5 Dialysis Patients with Hyperphosphataemia. ( Dimkovic, N; Locatelli, F; Spasovski, G; Wanner, C, 2016) |
| "Hyperuricemia is associated with the onset of chronic kidney disease (CKD) and renal disease progression." | 2.80 | Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. ( Asahi, K; Hayashi, Y; Kanno, M; Kimura, H; Nakayama, M; Tanaka, K; Tani, Y; Terawaki, H; Watanabe, K; Watanabe, T, 2015) |
| "Treatment with febuxostat resulted in a significant decrease in serum UA level and a significant decrease in MDA-LDL compared with baseline, but no significant difference was observed in hsCRP level or blood pressure." | 2.80 | Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: A randomized controlled study. ( Akiba, T; Itabashi, M; Kikuchi, K; Moriyama, T; Nitta, K; Sasaki, Y; Takei, T; Tsuchiya, K; Tsuruta, Y; Uchida, K, 2015) |
| "Allopurinol is a potent xanthine oxidase inhibitor used in hyperuricemic patients." | 2.80 | Benefits of Allopurinol Treatment on Blood Pressure and Renal Function in Patients with Early Stage of Chronic Kidney Disease. ( Burata, A; Ruangkanchanasetr, P; Satirapoj, B; Supasyndh, O; Wirajit, O, 2015) |
| "Mean eGFR in both pegloticase dosing cohorts remained constant over the randomized treatment phase and long-term open-label extension study." | 2.79 | Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials. ( Irish, W; Ottery, FD; Wolfson, M; Yood, RA, 2014) |
| "Hyperuricemia is defined as an abnormally high level of uric acid (UA; i." | 2.72 | Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease. ( Sun, D; Waheed, Y; Yang, F, 2021) |
| "Hyperuricemia is present in 20-35% of patients with chronic kidney disease." | 2.66 | The role of uric acid in inflammasome-mediated kidney injury. ( Braga, TT; Camara, NOS; Foresto-Neto, O, 2020) |
| "Although hyperuricemia has been associated with CKD in many studies, it remains controversial whether this is the cause or the result of decreased renal function." | 2.66 | Renal effects of uric acid: hyperuricemia and hypouricemia. ( Jo, YI; Lee, JH; Park, JH, 2020) |
| "This has been ascribed, in part, to haemodynamic changes, body weight reduction and several possible effects on myocardial, endothelial and tubulo-glomerular functions, as well as to reduced glucotoxicity." | 2.61 | Uric acid and the cardio-renal effects of SGLT2 inhibitors. ( Bailey, CJ, 2019) |
| "Although gout is one of the most common forms of inflammatory arthritis, it has been relatively neglected until recently." | 2.55 | Major unanswered questions in the clinical gout field. ( Stamp, LK, 2017) |
| "Hyperuricemia is associated with a number of effects on the vascular endothelium and vascular smooth muscle cells, including an increase in oxidative stress, production of vasoconstrictors, and changes on the structural properties of the large artery wall." | 2.55 | Uric Acid, Vascular Stiffness, and Chronic Kidney Disease: Is There a Link? ( Madero, M; Ramirez-Sandoval, JC; Sanchez-Lozada, LG, 2017) |
| " For dose-response analysis, a linear relationship (8 studies; Pfor non-linearity=0." | 2.53 | Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis. ( Huang, F; Li, B; Lin, Z; Luo, Q; Xia, X; Yu, X, 2016) |
| "Uric acid is a product of purine metabolism and has been linked to gout and kidney calculi." | 2.53 | Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association. ( Al Kattar, S; Jurjus, A; Mallat, SG; Tanios, BY, 2016) |
| "Hyperuricemia is one of the many metabolic changes that occur during the course of chronic kidney disease (CKD)." | 2.52 | [Uric acid, the kidney and cardiovascular mortality]. ( Mandreoli, M; Santoro, A, 2015) |
| "Hyperphosphatemia is a major problem in these patients especially at advanced stages of CKD, and it is associated with cardiovascular and mineral complications in these patients." | 2.50 | [Pleiotropic effects of sevelamer: a model of intestinal tract chelating agent]. ( Maizel, J; Massy, ZA, 2014) |
| "However, all patients with lupus nephritis have by definition chronic kidney disease (CKD) as they will have proteinuria with varying degrees of renal impairment." | 2.49 | Renoprotective strategies in lupus nephritis: beyond immunosuppression. ( Griffin, B; Lightstone, L, 2013) |
| "In addition, hyperuricemia is largely prevalent in patients with CKD." | 2.49 | Uric acid as a target of therapy in CKD. ( Chen, W; Chonchol, M; Jalal, DI; Targher, G, 2013) |
| "Hyperuricemia is seen when kidney function declines." | 2.48 | Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor? ( Fried, LF; Nashar, K, 2012) |
| "The definition of hyperuricemia is currently arbitrary." | 2.47 | Allopurinol, uric acid, and oxidative stress in cardiorenal disease. ( Covic, A; Goldsmith, D; Riegersperger, M, 2011) |
| "Allopurinol is an inhibitor of xanthine oxidoreductase (XOR) and inhibits the generation of uric acid (UA) as the final product of purine catabolism, as well as the resulting generation of superoxide (O2(-)), in humans." | 2.45 | Allopurinol, an inhibitor of uric acid synthesis--can it be used for the treatment of metabolic syndrome and related disorders? ( Nozaki, S; Onuma, M; Suzuki, I; Yamauchi, T, 2009) |
| "The current childhood obesity pandemic is likely to result in an increased risk of chronic kidney disease (CKD) later in life." | 1.91 | Relation between obesity-related comorbidities and kidney function estimation in children. ( Pottel, H; van Dam, MJCM; Vreugdenhil, ACE, 2023) |
| "Pulmonary hypertension (PH) is common in obstructive sleep apnea syndrome (OSAS)." | 1.91 | Impact of Pulmonary Hypertension on Renal Functions in Obstructive Sleep Apnea Syndrome. ( Uyar, M, 2023) |
| "Gout is considered uncommon among Black Africans." | 1.91 | Pattern of gout and its association with chronic kidney disease in Maiduguri, northeastern Nigeria. ( Adamu, AA; Sulaiman, MM; Yerima, A, 2023) |
| "Adenine was found to elevate the levels of serum creatinine, urea, uric acid, sodium, potassium, chloride, magnesium, and phosphorus and reduce the level of serum calcium." | 1.91 | Roflumilast alleviates adenine-induced chronic kidney disease by regulating inflammatory biomarkers. ( Chudasama, P; Patel, P; Patel, S; Raval, M; Soni, S, 2023) |
| "Hyperuricemia is an independent predictor of incident CKD." | 1.91 | Serum uric acid is associated with chronic kidney disease in elderly Chinese patients with diabetes. ( Guo, Y; Ke, S; Liu, Q; Yan, Y; Zhou, Q, 2023) |
| "Chronic inflammation is an important factor for CKD progression." | 1.91 | Increased risk of chronic kidney disease in uric acid stone formers with high neutrophil-to-lymphocyte ratio. ( Huang, HS; Liu, CJ; Liu, CM; Lu, ZH; Tung, HT, 2023) |
| "Incidence rate for ESRD among patients with no episodes of AKI and one, two, and three or more episodes of AKI was 7." | 1.72 | Clinical Predictors and Long-term Impact of Acute Kidney Injury on Progression of Diabetic Kidney Disease in Chinese Patients With Type 2 Diabetes. ( Chan, JCN; Cheng, YL; Chow, CC; Chow, EYK; Fan, B; Fung, S; Hiu, G; Huang, Y; Jiang, G; Kam, G; Kong, APS; Lan, HY; Lau, E; Lau, ES; Lau, IT; Lau, KP; Lee, KF; Leung, JY; Li, JK; Lim, CKP; Lo, S; Luk, AO; Ma, RCW; Oram, RA; Ozaki, R; Siu, SC; So, WY; Szeto, CC; Tam, CHT; Tang, NLS; Tsang, CC; Tsang, MW; Yeung, VT, 2022) |
| "Hyperuricemia is common among patients with chronic kidney disease (CKD)." | 1.72 | Hyperuricemia is associated with secondary hyperparathyroidism in patients with chronic kidney disease. ( Coelho, VA; Costa, TEM; Elias, RM; Innecchi, MLR; Lauar, JC; Moysés, RMA, 2022) |
| "Chronic kidney disease and left ventricular hypertrophy are potent modifiers of the prognostic value of the circadian BP changes." | 1.72 | Chronic Kidney Disease and Left Ventricular Hypertrophy. Potent Modifiers of the Prognostic Impact of Circadian Blood Pressure Changes. ( Angeli, F; Reboldi, G; Verdecchia, P, 2022) |
| "Recent studies showed that treatment of hyperuricemia did not affect the progression in chronic kidney disease (CKD) patients." | 1.72 | [Management of hyperuricemia in chronic kidney disease]. ( Auberson, M; Bonny, O; Livio, F; Schwotzer, N; So, A, 2022) |
| "Nonalcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD) share common pathogenic mechanisms and risk factors." | 1.72 | The Negative Association Between NAFLD Severity and CKD in a Non-Diabetic Gouty Population. ( Chen, Y; Chi, J; Huang, Y; Lv, W; Wang, Y; Zhou, Y, 2022) |
| "Uric acid is a waste metabolite produced from the breakdown of purines, and elevated serum uric acid levels are associated with higher risk of hypertension, cardiovascular disease, and mortality and progression of chronic kidney disease (CKD)." | 1.72 | Association of Uric Acid-Lowering Therapy With Incident Chronic Kidney Disease. ( Hassan, W; Kalantar-Zadeh, K; Kovesdy, CP; Potukuchi, PK; Rhee, CM; Shrestha, P; Streja, E; Sumida, K; Sweeney, PL; Thomas, F, 2022) |
| "Geniposide (GEN) is a typical natural iridoid glucoside compound with a series of biological activities, but the poor bioavailability of GEN limits its clinical application." | 1.72 | A geniposide-phospholipid complex ameliorates posthyperuricemia chronic kidney disease induced by inflammatory reactions and oxidative stress. ( Chen, JS; Guo, X; Liao, ZX; Liu, C; Liu, JS; Sun, JY; Wang, MM; Wang, MX; Zhang, J; Zhang, MQ, 2022) |
| "Carnitine plays a pivotal role in energy synthesis through β-oxidation in mitochondria." | 1.62 | Kinetics of Serum Carnitine Fractions in Patients with Chronic Kidney Disease Not on Dialysis. ( Fukami, K; Ito, S; Kaida, Y; Kinoshita, Y; Kodama, G; Nakayama, Y; Tashiro, K; Yano, J; Yokota, Y, 2021) |
| "Thus, hyperuricemia is associated with impaired endothelial function." | 1.62 | Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia. ( Bahrudin, U; Hisatome, I; Kuwabara, M; Li, P; Maharani, N; Mahati, E; Miake, J; Ninomiya, H; Taufiq, F; Utami, SB, 2021) |
| "Patients with type 2 diabetes mellitus (T2DM) are susceptible to coexisted with chronic kidney disease (CKD), which may increase cardiovascular mortality in these patients." | 1.62 | The additive effects of kidney dysfunction on left ventricular function and strain in type 2 diabetes mellitus patients verified by cardiac magnetic resonance imaging. ( Jiang, L; Li, Y; Ren, Y; Wang, J; Yan, WF; Yang, ZG; Zhang, Y, 2021) |
| "Urolithiasis is considered a vital public health issue with a substantial burden on kidney function." | 1.62 | A retrospective study on sex difference in patients with urolithiasis: who is more vulnerable to chronic kidney disease? ( Chang, HW; Chien, TM; Chou, YH; Li, CC; Lu, YM; Wu, WJ, 2021) |
| "Gout has significant impact on the quality of life with over-utilisation of health resources." | 1.56 | Burden and management of gout in a multi-ethnic Asian cohort. ( Cheung, PP; Chua, CKT; Lim, AYN; Santosa, A; Teng, GG, 2020) |
| "Febuxostat was associated with greater reduction in SUA level than allopurinol in patients with CKD." | 1.56 | Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease. ( Hsu, CN; Huang, YB; Lee, CT; Peng, YL; Tain, YL; Wen, YH; Yang, YH, 2020) |
| "Hyperuricemia is a common laboratory finding in different types of patients." | 1.56 | Hyperuricemia in renal disease patients. ( Bandúr, Š, 2020) |
| "BACKGROUND Depression is the main problem of psycho-nephrology." | 1.56 | Association Between Serum Uric Acid and Depression in Patients with Chronic Kidney Disease not Requiring Kidney Dialysis: Cross-Sectional and Longitudinal Analyses. ( Chang, W; Gao, B; Han, Y; Hao, J; Li, J; Qi, P; Song, X; Sun, N; Uchida, S; Zhang, M, 2020) |
| "Hyperuricemia has been associated with high blood pressure (BP) values, diabetes mellitus, metabolic syndrome and chronic kidney disease (CKD)." | 1.51 | Gender-related differences in serum uric acid in treated hypertensive patients from central and east European countries: findings from the Blood Pressure control rate and CArdiovascular Risk profilE study. ( Bombelli, M; Facchetti, R; Grassi, G; Lurbe, E; Maloberti, A; Mancia, G; Redon, J; Redon, P, 2019) |
| "We recruited 98 Taiwanese patients with type 2 diabetes and 10 patients with early chronic kidney disease (CKD) into this study." | 1.51 | Serum and urinary SOD3 in patients with type 2 diabetes: comparison with early chronic kidney disease patients and association with development of diabetic nephropathy. ( Chen, CM; Chen, HL; Kuo, CW; Tu, MY, 2019) |
| "Gout is a common inflammatory arthritis associated with adverse clinical outcomes." | 1.51 | Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: A national study. ( Adeeb, F; Browne, LD; Fraser, AD; Kumar A U, A; Mohammed, E; Stack, AG, 2019) |
| "Gout is a disease driven solely by IL-1β secretion in response to monosodium urate (MSU) crystals which form during periods of hyperuricemia and thus presents an opportunity to study factors contributing to IL-1β secretion." | 1.51 | Secretion of IL-1β From Monocytes in Gout Is Redox Independent. ( Alberts, BM; Basnayake, K; Bruce, C; Davies, KA; Ghezzi, P; Mullen, LM, 2019) |
| "Elderly obese patients with NAFLD are at a higher risk of CKD." | 1.51 | Association of obesity with chronic kidney disease in elderly patients with nonalcoholic fatty liver disease. ( Bian, J; Chen, F; Jin, D; Li, H; Luo, K; Wang, J; Wang, Q, 2019) |
| "Early markers of disease progression could facilitate and improve patient management." | 1.51 | Novel plasma peptide markers involved in the pathology of CKD identified using mass spectrometric approach. ( Bruck, H; Ceccarelli, F; Gajjala, PR; Heinze, G; Jankowski, J; Jankowski, V; Kribben, A; Marx, N; Noels, H; Saez-Rodriguez, J; Zidek, W, 2019) |
| " Compared with those with a low SUA trajectory, the adjusted hazard ratio of patients for incident ESRD was in a dose-response manner as follows: moderate, 1." | 1.48 | Uric acid predicts adverse outcomes in chronic kidney disease: a novel insight from trajectory analyses. ( Chiu, HT; Huang, HC; Kuo, CC; Ting, IW; Tsai, CW; Yeh, HC, 2018) |
| "Febuxostat was significantly more potent than allopurinol or benzbromarone in lowering SUA levels in the fully adjusted model." | 1.48 | Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study. ( Chiu, HT; Chou, HW; Huang, HC; Kuo, CC; Ting, IW; Tsai, CW; Yeh, HC, 2018) |
| "His uric acid was 11 mg/dL despite maximal dosing of febuxostat." | 1.48 | Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease. ( Case, R; Jester, G; Wentworth, B, 2018) |
| "Hyperuricemia is associated with metabolic syndrome, diabetes, hypertension, and kidney and cardiovascular diseases." | 1.48 | Renal Effects of Hyperuricemia. ( Méndez Landa, CE, 2018) |
| "Renal fibrosis is a complication of kidney injury and associated with increased risk of morbidity and mortality." | 1.48 | Ameliorative effect of ursolic acid on renal fibrosis in adenine-induced chronic kidney disease in rats. ( Begum, J; Kumar, D; Kumar, P; Lingaraju, MC; Mathesh, K; Sharma, A; Singh, TU; Thakur, R, 2018) |
| "Quercetin-treated model rats had reduced serum levels of parathyroid hormone (PTH), inorganic phosphate, increased urine protein-to-creatinine ratio, increased urine antioxidants, serum lactate dehydrogenase (LDH), and interleukin (IL)-8 when compared with the untreated model group and the control group." | 1.48 | Quercetin Treatment Improves Renal Function and Protects the Kidney in a Rat Model of Adenine-Induced Chronic Kidney Disease. ( Li, R; Liang, YN; Song, Y; Yang, H, 2018) |
| "Hyperuricemia is an independent risk factor for progression of kidney disease." | 1.48 | Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease. ( Cheetham, TC; Levy, G; Rashid, N; Shi, JM, 2018) |
| "Gout was associated with an increased risk of incident CKD (adjusted HR 1." | 1.48 | Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study. ( Belcher, J; Clarson, L; Mallen, CD; Muller, S; Roddy, E; Roughley, M; Sultan, AA; Whittle, R, 2018) |
| "Uric acid (UA) is a risk marker of CKD and SUA level in CKD 3-4 patients closely correlates with hyperuricemic nephropathy (HN) morbidity." | 1.48 | Risk factors analysis for hyperuricemic nephropathy among CKD stages 3-4 patients: an epidemiological study of hyperuricemia in CKD stages 3-4 patients in Ningbo, China. ( Gao, C; Qiu, XH; Wu, F; Wu, YY; Xia, G; Ye, Y, 2018) |
| "Although hyperuricemia is common after orthotopic liver transplantation (OLT), its relationship to mortality, progressive kidney disease, or the development of end stage renal disease (ESRD) is not well-described." | 1.46 | Hyperuricemia after orthotopic liver transplantation: divergent associations with progression of renal disease, incident end-stage renal disease, and mortality. ( Atta, MG; Bandak, G; Gelber, AC; Longenecker, JC; McMahon, BA; Murakami, CA; Waheed, S, 2017) |
| "Hyperuricemia is associated with the progression of chronic kidney disease (CKD), but it is not known whether the relationship is causal." | 1.46 | Impact of Uric Acid Levels on Kidney Disease Progression. ( Arrigain, S; Jolly, SE; Konig, V; Nakhoul, G; Nally, JV; Navaneethan, SD; Rincon-Choles, H; Rothberg, MB; Schold, JD, 2017) |
| "Though efficacious and affordable treatments for gout are widely available, gout is still not well controlled in many countries of the world including China." | 1.46 | Adherence to gout management recommendations of Chinese patients. ( Fang, W; Sha, Y; Sheng, F; Zeng, X; Zhang, B, 2017) |
| "Recently hyperuricemia has been identified as a risk factor for progression of chronic kidney disease (CKD)." | 1.43 | Revisiting medullary tophi: a link between uric acid and progressive chronic kidney disease? ( Almaani, S; Ayoub, I; Brodsky, S; Hebert, L; Nadasdy, T; Prosek, J; Rovin, B, 2016) |
| "Hyperuricemia is a common symptom in adult population." | 1.43 | Familial juvenile hyperuricemic nephropathy as rare cause of dialysis-dependent chronic kidney disease-a series of cases in two families. ( Adamczyk, P; Beck, B; Dyga, K; Kaminska-Pajak, KA; Szczepańska, M; Tkaczyk, M; Zaniew, M, 2016) |
| "Uric acid (UA) is a potential risk factor of the progression of chronic kidney disease (CKD)." | 1.43 | Uric acid metabolism of kidney and intestine in a rat model of chronic kidney disease. ( Hosoyamada, M; Kumagai, T; Nagura, M; Tamura, Y; Uchida, S, 2016) |
| "Early detection diabetic nephropathy (DN) is important." | 1.43 | Serum uric acid and its association with hypertension, early nephropathy and chronic kidney disease in type 2 diabetic patients. ( Fathy, H; Fouad, M; Zidan, A, 2016) |
| "Glycosuria is associated with increased fractional excretion of electrolytes and is related to favorable renal outcomes in nondiabetic patients with stage 5 CKD." | 1.43 | Glycosuria and Renal Outcomes in Patients with Nondiabetic Advanced Chronic Kidney Disease. ( Chen, HC; Chiang, HP; Chiu, YW; Hung, CC; Hwang, SJ; Lee, JJ; Lim, LM; Lin, HY, 2016) |
| "High uric acid level is a known risk factor for deterioration of renal function in chronic kidney disease (CKD), but its influence on the progression of IgA nephropathy (IgAN) remains unclear." | 1.42 | High uric acid level is a risk factor for progression of IgA nephropathy with chronic kidney disease stage G3a. ( Itabashi, M; Iwabuchi, Y; Kataoka, H; Moriyama, T; Nishida, M; Nitta, K; Sato, M; Shimizu, A; Takei, T; Uchida, K, 2015) |
| " Since disturbed NO bioavailability is a major pathway whereby high uric may cause renal damage, we tested the interaction between the major endogenous inhibitor of NO synthase, asymmetric-dimethylargine (ADMA), and the rs734553 polymorphism for CKD progression in the same cohort." | 1.42 | Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression. ( Leonardis, D; Mallamaci, F; Pisano, A; Sanguedolce, MC; Spoto, B; Testa, A; Tripepi, G; Zoccali, C, 2015) |
| "Hyperuricemia is associated with essential hypertension in children." | 1.42 | Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study. ( Furth, SL; Mitsnefes, MM; Moxey-Mims, MM; Rodenbach, KE; Schneider, MF; Schwartz, GJ; Warady, BA; Weaver, DJ, 2015) |
| "Uric acid was not predictive of events." | 1.42 | Plasma Xanthine Oxidase Activity Is Predictive of Cardiovascular Disease in Patients with Chronic Kidney Disease, Independently of Uric Acid Levels. ( Berland, Y; Brunet, P; Burtey, S; Cerini, C; Dou, L; Dussol, B; Gondouin, B; Guieu, R; Jourde-Chiche, N; Loundou, A; Morange, S; Sallee, M, 2015) |
| "Reduced nitric oxide bioavailability contributes to increased cardiovascular disease risk in patients with chronic kidney disease (CKD)." | 1.40 | Impaired L-arginine uptake but not arginase contributes to endothelial dysfunction in rats with chronic kidney disease. ( Edwards, DG; Kuczmarski, JM; Lennon-Edwards, S; Martens, CR, 2014) |
| "Here we tested whether recurrent dehydration may cause renal injury by activation of the polyol pathway, resulting in the generation of endogenous fructose in the kidney that might subsequently induce renal injury via metabolism by fructokinase." | 1.40 | Fructokinase activity mediates dehydration-induced renal injury. ( Aragón, A; Cicerchi, C; Correa-Rotter, R; Ejaz, AA; Glaser, J; González, MA; Inaba, S; Ishimoto, T; Johnson, RJ; Lanaspa, MA; Le, M; Miyazaki, M; Nakagawa, T; Rivard, CJ; Roncal Jimenez, CA; Sánchez-Lozada, LG; Wesseling, C, 2014) |
| "We found that hyperuricemia is an independent risk factor for the development of CKD." | 1.40 | Hyperuricemia is a significant risk factor for the onset of chronic kidney disease. ( Ishizaka, Y; Tani, M; Toda, A; Yamakado, M, 2014) |
| "In the drug treatment of hyperuricemia and hyperlipidemia complications, Atorvastatin (ATV), which inhibits urinary protein, increases glomerular filtration rate (GFR) and has renal protective effects, and Rosuvastatin (ROS) were found be suitable because they promote serum uric acid (SUA) excretion." | 1.40 | Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients. ( An, T; Hayashi, H; Kikkawa, A; Kose, E; Matsumoto, Y, 2014) |
| "Mild hyperuricemia is a strong, independent marker of MS and high cardio-renal risk profile in hypertensive patients under specialist care." | 1.40 | Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: insights from the I-DEMAND study. ( Agabiti Rosei, E; Ambrosioni, E; Costa, FV; Deferrari, G; Garneri, D; Gonnella, A; Leoncini, G; Leonetti, G; Muiesan, ML; Pessina, AC; Pontremoli, R; Trimarco, B; Viazzi, F; Volpe, M, 2014) |
| "Hyperuricemia is an independent risk factor for renal function decline." | 1.40 | Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. ( Cheetham, TC; Levy, GD; Niu, F; Rashid, N, 2014) |
| "Uric acid levels were correlated with eGFR(cr-cys) (r = -0." | 1.40 | Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. ( Amadu, AR; Lo, L; Odden, MC; Peralta, CA; Smit, E, 2014) |
| "Febuxostat was safe and efficacious in the treatment of CKD stages 3b-5." | 1.40 | Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. ( Hosoya, T; Kimura, K; Ohno, I; Shibagaki, Y, 2014) |
| "Febuxostat is a novel xanthine oxidase inhibitor that is metabolized by many metabolic pathways in the kidney and the liver." | 1.40 | Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease. ( Itabashi, M; Mochizuki, T; Moriyama, T; Nitta, K; Takei, T; Tsuchiya, K; Tsuruta, Y, 2014) |
| "Hyperuricemia is a risk factor for adverse renal outcomes in patients with chronic kidney disease." | 1.40 | A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. ( Asahi, K; Fujimoto, S; Hirayama, A; Ichikawa, K; Iseki, K; Kamei, K; Kimura, K; Kondo, M; Konta, T; Moriyama, T; Narita, I; Suzuki, K; Tsuruya, K; Watanabe, T; Yamagata, K, 2014) |
| "Uric acid was measured preoperatively." | 1.39 | Uric acid levels correlate with baseline renal function and high levels are a potent risk factor for postoperative chronic kidney disease in patients with renal cell carcinoma. ( Choi, HY; Choo, SH; Jeon, HG; Jeon, SS; Jeong, BC; Lee, HM; Seo, SI, 2013) |
| "Hyperuricemia is a risk factor for CKD in Taiwan, future studies are still necessary to determine whether hypouricemia increases the risk of CKD." | 1.37 | Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan. ( Li, L; Shu, Z; Tao, Q; Wang, S; Yu, C; Zhan, S, 2011) |
| "Hyperuricemia is a common feature in patients with chronic kidney disease (CKD)." | 1.33 | J-shaped mortality relationship for uric acid in CKD. ( Axelsson, J; Bárány, P; Carrero, JJ; García-López, E; Heimbürger, O; Johnson, RJ; Lindholm, B; Molinaei, H; Qureshi, AR; Stenvinkel, P; Suliman, ME, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (1.86) | 29.6817 |
| 2010's | 310 (64.18) | 24.3611 |
| 2020's | 164 (33.95) | 2.80 |
| Authors | Studies |
|---|---|
| Pan, J | 1 |
| Shi, M | 1 |
| Guo, F | 1 |
| Ma, L | 3 |
| Fu, P | 3 |
| Silva, NR | 1 |
| Gonçalves, CET | 1 |
| Gonçalves, DLN | 2 |
| Cotta, RMM | 1 |
| da Silva, LS | 2 |
| Shibata, Y | 1 |
| Yamazaki, M | 1 |
| Kitahara, J | 1 |
| Okubo, Y | 1 |
| Oiwa, A | 1 |
| Sato, A | 1 |
| Komatsu, M | 1 |
| Tsukamoto, S | 1 |
| Okami, N | 1 |
| Yamada, T | 3 |
| Azushima, K | 1 |
| Yamaji, T | 1 |
| Kinguchi, S | 1 |
| Uneda, K | 1 |
| Kanaoka, T | 1 |
| Wakui, H | 1 |
| Tamura, K | 2 |
| Kawazoe, M | 2 |
| Funakoshi, S | 2 |
| Ishida, S | 1 |
| Yoshimura, C | 2 |
| Satoh, A | 3 |
| Maeda, T | 2 |
| Tsuji, M | 1 |
| Yokota, S | 1 |
| Tada, K | 2 |
| Takahashi, K | 2 |
| Ito, K | 2 |
| Yasuno, T | 2 |
| Fujii, H | 1 |
| Okutsu, S | 1 |
| Mukobara, S | 1 |
| Kawanami, D | 1 |
| Nabeshima, S | 1 |
| Kondo, S | 1 |
| Masutani, K | 2 |
| Arima, H | 3 |
| Kimura, Y | 1 |
| Tsukui, D | 1 |
| Kono, H | 1 |
| Kashiwagi, T | 1 |
| Sakai, Y | 2 |
| Chen, T | 4 |
| Ma, DL | 1 |
| Jiang, G | 1 |
| Luk, AO | 1 |
| Tam, CHT | 1 |
| Ozaki, R | 1 |
| Lim, CKP | 1 |
| Chow, EYK | 1 |
| Lau, ES | 1 |
| Kong, APS | 1 |
| Fan, B | 1 |
| Lee, KF | 1 |
| Siu, SC | 1 |
| Hiu, G | 1 |
| Tsang, CC | 1 |
| Lau, KP | 1 |
| Leung, JY | 1 |
| Tsang, MW | 1 |
| Kam, G | 1 |
| Lau, IT | 1 |
| Li, JK | 1 |
| Yeung, VT | 1 |
| Lau, E | 1 |
| Lo, S | 1 |
| Fung, S | 1 |
| Cheng, YL | 1 |
| Chow, CC | 1 |
| Tang, NLS | 1 |
| Huang, Y | 2 |
| Lan, HY | 1 |
| Oram, RA | 1 |
| Szeto, CC | 1 |
| So, WY | 1 |
| Chan, JCN | 1 |
| Ma, RCW | 1 |
| Nishizawa, H | 1 |
| Maeda, N | 1 |
| Shimomura, I | 1 |
| Costa, TEM | 1 |
| Lauar, JC | 1 |
| Innecchi, MLR | 1 |
| Coelho, VA | 1 |
| Moysés, RMA | 1 |
| Elias, RM | 1 |
| Kuma, A | 1 |
| Mafune, K | 1 |
| Uchino, B | 1 |
| Ochiai, Y | 1 |
| Enta, K | 1 |
| Kato, A | 2 |
| Kim, HW | 1 |
| Joo, YS | 1 |
| Yun, HR | 1 |
| Kim, JY | 1 |
| Jhee, JH | 1 |
| Roh, YH | 1 |
| Park, JT | 1 |
| Chang, TI | 1 |
| Yoo, TH | 1 |
| Kang, SW | 1 |
| Han, SH | 1 |
| Singhal, R | 1 |
| Hechanova, LA | 1 |
| Verdecchia, P | 2 |
| Angeli, F | 1 |
| Reboldi, G | 1 |
| Kang, T | 1 |
| Hu, Y | 1 |
| Huang, X | 2 |
| Amoah, AN | 1 |
| Lyu, Q | 1 |
| Schwotzer, N | 1 |
| Auberson, M | 1 |
| Livio, F | 1 |
| So, A | 1 |
| Bonny, O | 1 |
| Kataoka, H | 4 |
| Mochizuki, T | 3 |
| Ohara, M | 1 |
| Tsuruta, Y | 4 |
| Iwasa, N | 1 |
| Yoshida, R | 1 |
| Tsuchiya, K | 3 |
| Nitta, K | 5 |
| Kimura, K | 5 |
| Hosoya, T | 6 |
| Gherghina, ME | 1 |
| Peride, I | 1 |
| Tiglis, M | 1 |
| Neagu, TP | 1 |
| Niculae, A | 1 |
| Checherita, IA | 1 |
| Gurung, RL | 1 |
| Yiamunaa, M | 1 |
| Liu, JJ | 2 |
| Dorajoo, R | 1 |
| Wang, J | 7 |
| Wang, L | 3 |
| Liu, S | 1 |
| Chan, C | 1 |
| Ang, K | 1 |
| Shao, YM | 1 |
| Subramaniam, T | 1 |
| Tang, WE | 1 |
| Fang Sum, C | 1 |
| Lim, SC | 2 |
| Zhou, Y | 1 |
| Wang, Y | 12 |
| Chi, J | 1 |
| Lv, W | 1 |
| Chen, Y | 5 |
| Wang, M | 1 |
| Lin, X | 1 |
| Yang, X | 1 |
| Yang, Y | 4 |
| Ramos, GK | 1 |
| Goldfarb, DS | 2 |
| Moreira, TR | 1 |
| Chung, MC | 1 |
| Hsu, HT | 1 |
| Mao, YC | 1 |
| Wu, CC | 2 |
| Ho, CT | 1 |
| Liu, CS | 2 |
| Chung, CJ | 1 |
| Bragina, АЕ | 1 |
| Osadchiy, KK | 1 |
| Rodionova, JN | 1 |
| Bayutina, DА | 1 |
| Cherepanov, АG | 1 |
| Podzolkov, VI | 1 |
| Yu, X | 2 |
| Gu, M | 1 |
| Zhu, Y | 1 |
| Zhang, L | 2 |
| Kong, W | 1 |
| Zou, Y | 1 |
| Zhu, KJ | 1 |
| Deng, GS | 1 |
| Zhang, LY | 1 |
| Yang, YC | 1 |
| Xu, Q | 1 |
| Zhang, MY | 1 |
| Zhang, M | 4 |
| Lei, N | 1 |
| Zhang, XL | 1 |
| Xu, Y | 2 |
| Chen, HF | 1 |
| Fu, LZ | 1 |
| Tang, F | 1 |
| Liu, X | 3 |
| Wu, Y | 2 |
| He, L | 1 |
| Li, Z | 1 |
| Zhang, Q | 5 |
| Gao, Y | 1 |
| Wang, N | 1 |
| Jiang, L | 2 |
| Fan, Y | 1 |
| Fujita, K | 1 |
| Nonaka, T | 1 |
| Kutsuno, R | 1 |
| Ichida, K | 1 |
| Schwartz, GJ | 2 |
| Roem, JL | 1 |
| Hooper, SR | 1 |
| Furth, SL | 2 |
| Weaver, DJ | 3 |
| Warady, BA | 3 |
| Schneider, MF | 2 |
| Hassan, W | 1 |
| Shrestha, P | 1 |
| Sumida, K | 1 |
| Thomas, F | 1 |
| Sweeney, PL | 1 |
| Potukuchi, PK | 1 |
| Rhee, CM | 1 |
| Streja, E | 1 |
| Kalantar-Zadeh, K | 1 |
| Kovesdy, CP | 1 |
| Khimion, LV | 1 |
| Burianov, OA | 1 |
| Nayshtetik, IM | 1 |
| Rotova, SO | 1 |
| Smiyan, SI | 1 |
| Danyliuk, SV | 1 |
| Trofanchuk, VV | 1 |
| Oku, F | 1 |
| Hara, A | 2 |
| Tsujiguchi, H | 1 |
| Suzuki, K | 2 |
| Pham, KO | 1 |
| Suzuki, F | 1 |
| Miyagi, S | 1 |
| Nakamura, M | 1 |
| Takazawa, C | 1 |
| Sato, K | 1 |
| Yanagisawa, T | 1 |
| Kannon, T | 1 |
| Tajima, A | 1 |
| Nakamura, H | 1 |
| Wang, MX | 1 |
| Wang, MM | 1 |
| Liu, C | 2 |
| Chen, JS | 2 |
| Liu, JS | 1 |
| Guo, X | 1 |
| Zhang, MQ | 1 |
| Zhang, J | 6 |
| Sun, JY | 1 |
| Liao, ZX | 1 |
| Lupi, AS | 1 |
| Sumpter, NA | 2 |
| Leask, MP | 1 |
| O'Sullivan, J | 1 |
| Fadason, T | 1 |
| de Los Campos, G | 1 |
| Merriman, TR | 4 |
| Reynolds, RJ | 2 |
| Vazquez, AI | 1 |
| Lee, CL | 1 |
| Chen, CH | 3 |
| Wu, MJ | 1 |
| Tsai, SF | 1 |
| Mei, Y | 1 |
| Dong, B | 1 |
| Geng, Z | 1 |
| Xu, L | 3 |
| Zhou, X | 3 |
| Zhang, B | 3 |
| Zhao, X | 1 |
| Lin, Y | 1 |
| Zhuang, Y | 1 |
| Guo, J | 1 |
| Wang, S | 6 |
| Sarker, MHR | 1 |
| Moriyama, M | 1 |
| Rashid, HU | 1 |
| Rahman, MM | 1 |
| Chisti, MJ | 1 |
| Das, SK | 1 |
| Saha, SK | 1 |
| Arifeen, SE | 1 |
| Ahmed, T | 1 |
| Faruque, ASG | 1 |
| Polito, L | 1 |
| Bortolotti, M | 1 |
| Battelli, MG | 1 |
| Bolognesi, A | 1 |
| Shibata, R | 1 |
| Taguchi, K | 1 |
| Kaida, Y | 2 |
| Fukami, K | 2 |
| Xiong, J | 1 |
| Zheng, X | 1 |
| Luo, J | 1 |
| Luo, X | 1 |
| Zhang, Y | 5 |
| Meremo, A | 1 |
| Paget, G | 1 |
| Duarte, R | 1 |
| Dickens, C | 1 |
| Dix-Peek, T | 1 |
| Bintabara, D | 1 |
| Naicker, S | 1 |
| Chen, JH | 2 |
| Tsai, CC | 2 |
| Liu, YH | 2 |
| Wu, PY | 2 |
| Huang, JC | 2 |
| Chung, TL | 1 |
| Su, HM | 3 |
| Chen, SC | 3 |
| Johnson, RJ | 23 |
| Shui, G | 1 |
| Cai, Z | 1 |
| Wang, F | 1 |
| Cai, Y | 1 |
| Mi, X | 1 |
| Taguchi, S | 1 |
| Nasu, T | 1 |
| Satoh, M | 2 |
| Kotozaki, Y | 1 |
| Tanno, K | 1 |
| Tanaka, F | 1 |
| Asahi, K | 4 |
| Ohmomo, H | 1 |
| Kikuchi, H | 1 |
| Kobayashi, T | 1 |
| Morino, Y | 1 |
| Shimizu, A | 2 |
| Sobue, K | 1 |
| Sasaki, M | 1 |
| Yang, N | 3 |
| Cao, B | 3 |
| van Dam, MJCM | 3 |
| Pottel, H | 3 |
| Vreugdenhil, ACE | 3 |
| Jin, H | 3 |
| He, M | 4 |
| Yang, G | 3 |
| Xie, W | 3 |
| Yu, D | 3 |
| Li, H | 5 |
| Xiao, W | 3 |
| Li, Y | 8 |
| Wang, H | 4 |
| Liu, D | 2 |
| Choi, Y | 1 |
| Jacobs, DR | 1 |
| Kramer, HJ | 1 |
| Shroff, GR | 1 |
| Chang, AR | 1 |
| Duprez, DA | 1 |
| Uyar, M | 1 |
| Cheng, Y | 2 |
| Zhang, H | 2 |
| Zheng, H | 1 |
| Yin, H | 1 |
| Gu, L | 2 |
| Yin, D | 1 |
| Shih, YL | 1 |
| Shih, CC | 1 |
| Chen, SY | 1 |
| Chen, JY | 2 |
| Pan, ZY | 1 |
| Liu, HQ | 1 |
| Zhuang, YP | 1 |
| Tan, HB | 1 |
| Yang, XY | 1 |
| Zhong, HJ | 1 |
| He, XX | 1 |
| Chen, YC | 3 |
| Chang, JM | 2 |
| Chrysant, SG | 1 |
| Song, R | 1 |
| Hua, Y | 1 |
| Su, X | 1 |
| Ma, Z | 1 |
| Wang, X | 2 |
| Yang, C | 1 |
| Du, H | 1 |
| Dou, F | 1 |
| Li, J | 3 |
| Zhao, Y | 3 |
| Quan, P | 1 |
| Hu, X | 1 |
| Ueda, H | 1 |
| Inoue, K | 2 |
| Seki, R | 1 |
| Nemoto, Y | 1 |
| Terawaki, H | 2 |
| Zhong, Y | 2 |
| Hui, R | 1 |
| Zhang, W | 2 |
| Tsao, HM | 1 |
| Lai, TS | 1 |
| Chang, YC | 1 |
| Hsiung, CN | 1 |
| Chou, YH | 5 |
| Wu, VC | 1 |
| Lin, SL | 1 |
| Chen, YM | 2 |
| Prezelin-Reydit, M | 1 |
| Combe, C | 1 |
| Fouque, D | 1 |
| Frimat, L | 1 |
| Jacquelinet, C | 1 |
| Laville, M | 1 |
| Massy, ZA | 3 |
| Lange, C | 1 |
| Ayav, C | 1 |
| Pecoits-Filho, R | 1 |
| Liabeuf, S | 2 |
| Stengel, B | 1 |
| Harambat, J | 1 |
| Leffondré, K | 1 |
| Yerima, A | 1 |
| Sulaiman, MM | 1 |
| Adamu, AA | 1 |
| Xue, C | 1 |
| Yang, B | 1 |
| Xu, J | 1 |
| Mao, Z | 1 |
| Iwata, Y | 2 |
| Notsu, S | 1 |
| Kawamura, Y | 1 |
| Mitani, W | 1 |
| Tamai, S | 1 |
| Morimoto, M | 2 |
| Yamato, M | 1 |
| Bao, D | 1 |
| Lv, N | 1 |
| Duan, X | 1 |
| Zhang, X | 3 |
| Zhao, MH | 1 |
| Patel, P | 1 |
| Patel, S | 2 |
| Chudasama, P | 1 |
| Soni, S | 1 |
| Raval, M | 1 |
| Haruyama, N | 1 |
| Nakayama, M | 6 |
| Fukui, A | 3 |
| Yoshitomi, R | 3 |
| Tsuruya, K | 8 |
| Nakano, T | 2 |
| Kitazono, T | 5 |
| Lai, SW | 1 |
| Liao, KF | 1 |
| Kuo, YH | 1 |
| Hwang, BF | 1 |
| Liu, P | 1 |
| Liang, Y | 1 |
| Cui, S | 1 |
| Hu, K | 2 |
| Lin, L | 1 |
| Shao, X | 1 |
| Lei, M | 1 |
| Mironova, OI | 1 |
| Ueda, M | 1 |
| Fukui, K | 1 |
| Kamatani, N | 2 |
| Kamitsuji, S | 1 |
| Matsuo, A | 1 |
| Sasase, T | 1 |
| Nishiu, J | 1 |
| Matsushita, M | 2 |
| Kohagura, K | 3 |
| Kochi, M | 3 |
| Nakamura, T | 1 |
| Zamami, R | 2 |
| Tana, T | 1 |
| Kinjyo, K | 1 |
| Funakoshi, R | 1 |
| Yamazato, M | 1 |
| Ishida, A | 1 |
| Sakima, A | 2 |
| Iseki, K | 5 |
| Ohya, Y | 3 |
| Paul, R | 1 |
| Sarkar, R | 1 |
| Imasuen, UJ | 1 |
| Swanson, KJ | 1 |
| Parajuli, S | 1 |
| Sun, L | 2 |
| Liu, Q | 2 |
| Xue, M | 1 |
| Yan, H | 1 |
| Qiu, X | 1 |
| Tian, Y | 1 |
| Liang, H | 1 |
| Zhou, Q | 2 |
| Ke, S | 1 |
| Yan, Y | 3 |
| Guo, Y | 1 |
| Kannuthurai, V | 1 |
| Gaffo, A | 1 |
| Nata, N | 1 |
| Ninwisut, N | 1 |
| Inkong, P | 1 |
| Supasyndh, O | 2 |
| Satirapoj, B | 2 |
| Tung, HT | 1 |
| Liu, CM | 1 |
| Huang, HS | 1 |
| Lu, ZH | 1 |
| Liu, CJ | 1 |
| Heerkens, L | 1 |
| van Westing, AC | 1 |
| Voortman, T | 1 |
| Kardys, I | 1 |
| Boersma, E | 1 |
| Geleijnse, JM | 1 |
| Ermakov, VS | 1 |
| Granados, JC | 1 |
| Nigam, SK | 1 |
| Oni, OO | 1 |
| Akinwusi, PO | 1 |
| Owolabi, JI | 1 |
| Odeyemi, AO | 1 |
| Israel, GM | 1 |
| Ala, O | 1 |
| Akande, JO | 1 |
| Durodola, A | 1 |
| Israel, OK | 1 |
| Ajibola, I | 1 |
| Aremu, AO | 1 |
| Yin, W | 1 |
| Zhou, QL | 1 |
| OuYang, SX | 1 |
| Gong, YT | 1 |
| Liang, YM | 1 |
| Suijk, DL | 1 |
| Smits, MM | 1 |
| Muskiet, MH | 1 |
| Tonneijck, L | 1 |
| Kramer, MH | 1 |
| Joles, JA | 1 |
| van Raalte, DH | 1 |
| Roumeliotis, S | 1 |
| Roumeliotis, A | 1 |
| Dounousi, E | 2 |
| Eleftheriadis, T | 1 |
| Liakopoulos, V | 2 |
| Stamp, LK | 3 |
| Chapman, P | 1 |
| Hudson, B | 1 |
| Frampton, C | 2 |
| Hamilton, G | 1 |
| Judd, A | 1 |
| Kaewput, W | 1 |
| Thongprayoon, C | 1 |
| Rangsin, R | 2 |
| Ruangkanchanasetr, P | 2 |
| Bathini, T | 1 |
| Mao, MA | 1 |
| Cheungpasitporn, W | 1 |
| Chung, TT | 1 |
| Yu, KH | 2 |
| Kuo, CF | 2 |
| Luo, SF | 1 |
| Chiou, MJ | 1 |
| Lan, WC | 1 |
| Tseng, WY | 1 |
| Hsieh, AH | 1 |
| Wang, LC | 1 |
| Hu, G | 1 |
| Bai, Y | 2 |
| Tang, S | 1 |
| Hu, L | 1 |
| Yang, AY | 1 |
| Ge, JY | 1 |
| Ji, Y | 1 |
| Zhu, ZY | 1 |
| Li, X | 5 |
| Chen, C | 3 |
| Yuan, Y | 2 |
| Wang, KK | 2 |
| Chu, C | 2 |
| Hu, JW | 2 |
| Ma, Q | 4 |
| Liao, YY | 2 |
| Fu, BW | 2 |
| Gao, K | 3 |
| Sun, Y | 2 |
| Lv, YB | 1 |
| Zhu, WJ | 1 |
| Yang, L | 1 |
| Yang, RH | 1 |
| Yang, J | 1 |
| Mu, JJ | 2 |
| Sezai, A | 2 |
| Unosawa, S | 1 |
| Taoka, M | 1 |
| Osaka, S | 2 |
| Sekino, H | 1 |
| Tanaka, M | 4 |
| Chua, CKT | 1 |
| Cheung, PP | 1 |
| Santosa, A | 1 |
| Lim, AYN | 1 |
| Teng, GG | 1 |
| Lai, S | 2 |
| Petramala, L | 1 |
| Muscaritoli, M | 1 |
| Cianci, R | 2 |
| Mazzaferro, S | 1 |
| Mitterhofer, AP | 1 |
| Pasquali, M | 1 |
| D'Ambrosio, V | 1 |
| Carta, M | 1 |
| Ansuini, M | 1 |
| Ramaccini, C | 1 |
| Galani, A | 1 |
| Amabile, MI | 1 |
| Molfino, A | 2 |
| Letizia, C | 1 |
| Testorio, M | 1 |
| Perrotta, AM | 1 |
| Currado, A | 1 |
| Pintus, G | 1 |
| Pietrucci, D | 1 |
| Unida, V | 1 |
| La Rocca, D | 1 |
| Biocca, S | 1 |
| Desideri, A | 1 |
| Kuwabara, Y | 1 |
| Yasuno, S | 1 |
| Kasahara, M | 3 |
| Ueshima, K | 1 |
| Nakao, K | 1 |
| Saag, KG | 3 |
| Kawamoto, R | 4 |
| Ninomiya, D | 4 |
| Akase, T | 2 |
| Kikuchi, A | 2 |
| Kumagi, T | 4 |
| Kobayashi, Y | 1 |
| Omote, K | 1 |
| Nagai, T | 1 |
| Kamiya, K | 1 |
| Konishi, T | 1 |
| Sato, T | 2 |
| Kato, Y | 1 |
| Komoriyama, H | 1 |
| Tsujinaga, S | 1 |
| Iwano, H | 1 |
| Yamamoto, K | 2 |
| Yoshikawa, T | 1 |
| Saito, Y | 1 |
| Anzai, T | 1 |
| Bonino, B | 2 |
| Leoncini, G | 3 |
| Russo, E | 2 |
| Pontremoli, R | 6 |
| Viazzi, F | 6 |
| Törmänen, S | 1 |
| Lakkisto, P | 2 |
| Eräranta, A | 3 |
| Kööbi, P | 2 |
| Tikkanen, I | 2 |
| Niemelä, O | 2 |
| Mustonen, J | 2 |
| Pörsti, I | 2 |
| Sessa, C | 1 |
| Granata, A | 1 |
| Gaudio, A | 1 |
| Xourafa, A | 1 |
| Malatino, L | 1 |
| Lentini, P | 1 |
| Fatuzzo, P | 1 |
| Rapisarda, F | 1 |
| Castellino, P | 1 |
| Zanoli, L | 1 |
| Yamakage, H | 1 |
| Inoue, T | 1 |
| Odori, S | 1 |
| Kusakabe, T | 1 |
| Shimatsu, A | 1 |
| Satoh-Asahara, N | 1 |
| Zheng, Y | 1 |
| Guan, H | 1 |
| Fu, C | 3 |
| Xiao, J | 3 |
| Ye, Z | 5 |
| Kanbay, M | 4 |
| Girerd, N | 1 |
| Machu, JL | 1 |
| Bozec, E | 1 |
| Duarte, K | 1 |
| Boivin, JM | 1 |
| Wagner, S | 1 |
| Ferreira, JP | 1 |
| Zannad, F | 1 |
| Rossignol, P | 1 |
| Patel, PM | 1 |
| Kandabarow, AM | 1 |
| Druck, A | 1 |
| Hart, S | 1 |
| Blackwell, RH | 1 |
| Kadlec, A | 1 |
| Farooq, A | 1 |
| Turk, TMT | 1 |
| Baldea, KG | 1 |
| Steiger, S | 1 |
| Anders, HJ | 1 |
| Sato, Y | 4 |
| Feig, DI | 6 |
| Stack, AG | 3 |
| Kang, DH | 6 |
| Lanaspa, MA | 8 |
| Ejaz, AA | 3 |
| Sánchez-Lozada, LG | 10 |
| Kuwabara, M | 6 |
| Borghi, C | 6 |
| Hu, AM | 1 |
| Brown, JN | 1 |
| Braga, TT | 1 |
| Foresto-Neto, O | 1 |
| Camara, NOS | 1 |
| Badve, SV | 5 |
| Pascoe, EM | 2 |
| Tiku, A | 3 |
| Boudville, N | 2 |
| Brown, FG | 2 |
| Cass, A | 2 |
| Clarke, P | 1 |
| Dalbeth, N | 3 |
| Day, RO | 2 |
| de Zoysa, JR | 2 |
| Douglas, B | 1 |
| Faull, R | 2 |
| Harris, DC | 2 |
| Hawley, CM | 2 |
| Jones, GRD | 1 |
| Kanellis, J | 2 |
| Palmer, SC | 2 |
| Perkovic, V | 3 |
| Rangan, GK | 2 |
| Reidlinger, D | 1 |
| Robison, L | 1 |
| Walker, RJ | 2 |
| Walters, G | 2 |
| Johnson, DW | 4 |
| Aoun, M | 1 |
| Salloum, R | 1 |
| Dfouni, A | 1 |
| Sleilaty, G | 1 |
| Chelala, D | 1 |
| Peng, YL | 1 |
| Tain, YL | 1 |
| Lee, CT | 1 |
| Yang, YH | 1 |
| Huang, YB | 1 |
| Wen, YH | 1 |
| Hsu, CN | 1 |
| Ponticelli, C | 2 |
| Podestà, MA | 2 |
| Moroni, G | 1 |
| Mauer, M | 1 |
| Doria, A | 1 |
| Fujimoto, S | 2 |
| Konta, T | 2 |
| Moriyama, T | 6 |
| Yamagata, K | 3 |
| Narita, I | 3 |
| Kondo, M | 2 |
| Shibagaki, Y | 4 |
| Watanabe, T | 3 |
| Karava, V | 1 |
| Dotis, J | 1 |
| Kondou, A | 1 |
| Christoforidis, A | 1 |
| Tsioni, K | 1 |
| Kollios, K | 1 |
| Papachristou, F | 1 |
| Printza, N | 1 |
| Stevenson, M | 1 |
| Pagnamenta, AT | 1 |
| Reichart, S | 1 |
| Philpott, C | 1 |
| Lines, KE | 1 |
| Gorvin, CM | 1 |
| Lhotta, K | 1 |
| Taylor, JC | 1 |
| Thakker, RV | 1 |
| Mori, K | 1 |
| Furuhashi, M | 1 |
| Numata, K | 1 |
| Hisasue, T | 1 |
| Hanawa, N | 1 |
| Koyama, M | 1 |
| Osanami, A | 1 |
| Higashiura, Y | 1 |
| Inyaku, M | 1 |
| Matsumoto, M | 1 |
| Moniwa, N | 1 |
| Ohnishi, H | 1 |
| Miura, T | 1 |
| Yano, J | 1 |
| Ito, S | 2 |
| Kodama, G | 1 |
| Nakayama, Y | 1 |
| Yokota, Y | 1 |
| Kinoshita, Y | 1 |
| Tashiro, K | 1 |
| Park, JH | 1 |
| Jo, YI | 1 |
| Lee, JH | 2 |
| Pingali, U | 1 |
| Nutalapati, C | 1 |
| Koilagundla, N | 1 |
| Taduri, G | 1 |
| Pooni, RS | 1 |
| Corbett, R | 1 |
| Al Za'abi, M | 1 |
| Al Salam, S | 1 |
| Al Suleimani, Y | 1 |
| Ashique, M | 1 |
| Manoj, P | 1 |
| Nemmar, A | 1 |
| Ali, BH | 1 |
| Bandúr, Š | 1 |
| Petreski, T | 1 |
| Ekart, R | 1 |
| Hojs, R | 1 |
| Bevc, S | 1 |
| Gao, B | 1 |
| Song, X | 1 |
| Hao, J | 1 |
| Han, Y | 1 |
| Sun, N | 1 |
| Qi, P | 1 |
| Uchida, S | 8 |
| Chang, W | 1 |
| Du, MF | 1 |
| Gao, WH | 1 |
| Li, M | 2 |
| Chen, X | 1 |
| Wang, D | 1 |
| Zhang, XY | 1 |
| Li, CH | 1 |
| Zhou, HW | 1 |
| Lu, WH | 1 |
| Yuan, ZY | 1 |
| Chang, J | 1 |
| Waheed, Y | 1 |
| Yang, F | 1 |
| Sun, D | 1 |
| Oluwo, O | 1 |
| Scialla, JJ | 1 |
| Chen, Q | 1 |
| Wang, Z | 2 |
| Zhou, J | 2 |
| Chen, Z | 2 |
| Li, S | 1 |
| Zhao, H | 1 |
| Lv, J | 1 |
| Sofue, T | 1 |
| Nakagawa, N | 1 |
| Kanda, E | 2 |
| Nagasu, H | 1 |
| Matsushita, K | 2 |
| Nangaku, M | 1 |
| Maruyama, S | 1 |
| Wada, T | 3 |
| Terada, Y | 2 |
| Yanagita, M | 1 |
| Sugiyama, H | 1 |
| Shigematsu, T | 2 |
| Ito, T | 1 |
| Isaka, Y | 1 |
| Okada, H | 1 |
| Yokoyama, H | 1 |
| Nakashima, N | 1 |
| Ohe, K | 1 |
| Okada, M | 1 |
| Kashihara, N | 1 |
| Conway, R | 1 |
| McCormick, N | 1 |
| Choi, HK | 2 |
| Fernandez-Prado, R | 1 |
| Ortiz, A | 1 |
| Perez-Gomez, MV | 1 |
| Tedeschi, A | 1 |
| Agostoni, P | 1 |
| Pezzuto, B | 1 |
| Corra', U | 1 |
| Scrutinio, D | 1 |
| La Gioia, R | 1 |
| Raimondo, R | 1 |
| Passantino, A | 1 |
| Piepoli, MF | 1 |
| Obi, EC | 1 |
| Chukwuonye, II | 1 |
| Anyabolu, EN | 1 |
| Okpara, C | 1 |
| Ohagwu, KA | 1 |
| Oladele, CO | 1 |
| Oviasu, E | 1 |
| Uwa, O | 1 |
| Agaba, EI | 1 |
| Ojogwu, LI | 1 |
| Sandoval-Plata, G | 1 |
| Nakafero, G | 1 |
| Chakravorty, M | 1 |
| Morgan, K | 1 |
| Abhishek, A | 1 |
| Hisatome, I | 3 |
| Li, P | 2 |
| Miake, J | 1 |
| Taufiq, F | 1 |
| Mahati, E | 1 |
| Maharani, N | 1 |
| Utami, SB | 1 |
| Bahrudin, U | 1 |
| Ninomiya, H | 1 |
| Floege, J | 1 |
| Premachandra, KH | 1 |
| Roberts, DM | 1 |
| Ren, Y | 1 |
| Yan, WF | 1 |
| Yang, ZG | 1 |
| Wang, CP | 1 |
| Lu, YC | 1 |
| Hung, WC | 1 |
| Tsai, IT | 1 |
| Chang, YH | 2 |
| Hu, DW | 1 |
| Hsu, CC | 2 |
| Wei, CT | 1 |
| Chung, FM | 1 |
| Lee, YJ | 2 |
| Son, YB | 1 |
| Yang, JH | 1 |
| Kim, MG | 2 |
| Jo, SK | 1 |
| Cho, WY | 1 |
| Oh, SW | 1 |
| Kobalava, ZD | 1 |
| Troitskaya, EA | 1 |
| Jalal, DI | 2 |
| Chertow, GM | 1 |
| Noce, A | 1 |
| Marrone, G | 1 |
| Urciuoli, S | 1 |
| Di Daniele, F | 1 |
| Di Lauro, M | 1 |
| Pietroboni Zaitseva, A | 1 |
| Di Daniele, N | 1 |
| Romani, A | 1 |
| Mukoubara, S | 1 |
| Nakashima, H | 1 |
| Weisman, A | 1 |
| Tomlinson, GA | 1 |
| Lipscombe, LL | 1 |
| Garg, AX | 1 |
| Perkins, BA | 1 |
| Cherney, DZI | 1 |
| Hawker, GA | 1 |
| Lu, X | 1 |
| Barbagallo, CM | 1 |
| Bombelli, M | 2 |
| Casiglia, E | 1 |
| Cicero, AFG | 3 |
| Cirillo, M | 2 |
| Cirillo, P | 2 |
| Desideri, G | 2 |
| D'Elia, L | 1 |
| Ferri, C | 2 |
| Galletti, F | 1 |
| Gesualdo, L | 3 |
| Giannattasio, C | 1 |
| Iaccarino, G | 1 |
| Mallamaci, F | 4 |
| Maloberti, A | 2 |
| Masi, S | 1 |
| Mengozzi, A | 1 |
| Mazza, A | 1 |
| Muiesan, ML | 2 |
| Nazzaro, P | 1 |
| Palatini, P | 1 |
| Parati, G | 1 |
| Rattazzi, M | 1 |
| Rivasi, G | 1 |
| Salvetti, M | 1 |
| Tikhonoff, V | 1 |
| Tocci, G | 1 |
| Ungar, A | 1 |
| Virdis, A | 1 |
| Volpe, M | 2 |
| Grassi, G | 2 |
| Watanabe, K | 2 |
| Yamamoto, T | 3 |
| Yamada, G | 1 |
| Sato, H | 1 |
| Miyazaki, M | 2 |
| Gaffo, AL | 1 |
| Calhoun, DA | 1 |
| Rahn, EJ | 1 |
| Oparil, S | 1 |
| Dudenbostel, T | 1 |
| Redden, DT | 1 |
| Muntner, P | 2 |
| Foster, PJ | 1 |
| Biggers-Clark, SR | 1 |
| Mudano, A | 1 |
| Sattui, SE | 1 |
| Saddekni, MB | 1 |
| Bridges, SL | 1 |
| Correa, S | 1 |
| Curtis, KA | 1 |
| Waikar, SS | 1 |
| Mc Causland, FR | 1 |
| Kim, IY | 2 |
| Ye, BM | 1 |
| Kim, MJ | 2 |
| Kim, SR | 1 |
| Lee, DW | 2 |
| Kim, HJ | 1 |
| Rhee, H | 1 |
| Song, SH | 1 |
| Seong, EY | 1 |
| Lee, SB | 2 |
| Tokumoto, Y | 1 |
| Chien, TM | 2 |
| Lu, YM | 1 |
| Li, CC | 2 |
| Wu, WJ | 3 |
| Chang, HW | 1 |
| Zhu, C | 1 |
| Sun, B | 1 |
| Zhou, Z | 3 |
| Sun, H | 1 |
| Liu, L | 2 |
| Zhan, S | 2 |
| Lv, X | 1 |
| Song, Y | 5 |
| Nakagawa, T | 5 |
| Andres-Hernando, A | 2 |
| Kojima, H | 1 |
| Rodriguez-Iturbe, B | 1 |
| Bjornstad, P | 2 |
| Nakayama, S | 1 |
| Tatsumi, Y | 1 |
| Murakami, T | 1 |
| Muroya, T | 1 |
| Hirose, T | 1 |
| Ohkubo, T | 1 |
| Mori, T | 2 |
| Hozawa, A | 1 |
| Metoki, H | 1 |
| Longenecker, JC | 1 |
| Waheed, S | 1 |
| Bandak, G | 1 |
| Murakami, CA | 1 |
| McMahon, BA | 1 |
| Gelber, AC | 1 |
| Atta, MG | 1 |
| Lebensburger, JD | 1 |
| Cutter, GR | 1 |
| Howard, TH | 1 |
| Yamada, Y | 2 |
| Sakuma, J | 1 |
| Takeuchi, I | 1 |
| Yasukochi, Y | 1 |
| Kato, K | 1 |
| Oguri, M | 1 |
| Fujimaki, T | 1 |
| Horibe, H | 1 |
| Muramatsu, M | 1 |
| Sawabe, M | 1 |
| Fujiwara, Y | 1 |
| Taniguchi, Y | 1 |
| Obuchi, S | 1 |
| Kawai, H | 1 |
| Shinkai, S | 1 |
| Mori, S | 1 |
| Arai, T | 1 |
| Ceriello, A | 2 |
| De Cosmo, S | 2 |
| Rossi, MC | 2 |
| Lucisano, G | 1 |
| Genovese, S | 1 |
| Fioretto, P | 1 |
| Giorda, C | 2 |
| Pacilli, A | 2 |
| Russo, G | 2 |
| Nicolucci, A | 2 |
| Vargas-Santos, AB | 1 |
| Neogi, T | 1 |
| Yamaguchi, A | 1 |
| Harada, M | 1 |
| Hashimoto, K | 1 |
| Kamijo, Y | 1 |
| Senzaki, K | 1 |
| Kasai, Y | 2 |
| Kusunoki, T | 2 |
| Ohtsuka, N | 2 |
| Szczurek, P | 1 |
| Mosiichuk, N | 1 |
| Woliński, J | 1 |
| Yatsenko, T | 1 |
| Grujic, D | 1 |
| Lozinska, L | 1 |
| Pieszka, M | 1 |
| Święch, E | 1 |
| Pierzynowski, SG | 1 |
| Goncharova, K | 1 |
| Horino, T | 1 |
| Hatakeyama, Y | 1 |
| Ichii, O | 1 |
| Matsumoto, T | 1 |
| Shimamura, Y | 1 |
| Okuhara, Y | 1 |
| Zinellu, A | 4 |
| Sotgia, S | 4 |
| Sotgiu, E | 2 |
| Assaretti, S | 1 |
| Baralla, A | 1 |
| Mangoni, AA | 3 |
| Satta, AE | 4 |
| Carru, C | 4 |
| Chini, LSN | 1 |
| Assis, LIS | 1 |
| Lugon, JR | 1 |
| Golmohammadi, S | 1 |
| Almasi, A | 1 |
| Manouchehri, M | 1 |
| Omrani, HR | 1 |
| Zandkarimi, MR | 1 |
| Tayebi Khosroshahi, H | 2 |
| Abedi, B | 1 |
| Daneshvar, S | 1 |
| Alizadeh, E | 1 |
| Khalilzadeh, M | 1 |
| Abedi, Y | 1 |
| Juraschek, SP | 1 |
| Appel, LJ | 2 |
| Miller, ER | 1 |
| Miyagi, T | 2 |
| Nagahama, K | 2 |
| Yonemoto, K | 1 |
| Snauwaert, E | 1 |
| Van Biesen, W | 2 |
| Raes, A | 1 |
| Holvoet, E | 1 |
| Glorieux, G | 3 |
| Van Hoeck, K | 1 |
| Van Dyck, M | 1 |
| Godefroid, N | 1 |
| Vanholder, R | 3 |
| Roels, S | 2 |
| Walle, JV | 1 |
| Eloot, S | 3 |
| Hsieh, MH | 1 |
| Yang, JF | 1 |
| Lin, WY | 1 |
| Chien, HH | 1 |
| Kuo, MC | 1 |
| Chang, NC | 1 |
| Wang, CL | 1 |
| Chuang, WL | 1 |
| Yu, ML | 1 |
| Dai, CY | 1 |
| Shardlow, A | 1 |
| McIntyre, NJ | 1 |
| Fraser, SDS | 1 |
| Roderick, P | 1 |
| Raftery, J | 1 |
| Fluck, RJ | 1 |
| McIntyre, CW | 1 |
| Taal, MW | 1 |
| Delrue, W | 1 |
| Schepers, E | 1 |
| Dhondt, A | 1 |
| Peng, Z | 1 |
| Yuan, Q | 1 |
| Xiao, X | 1 |
| Xu, H | 1 |
| Xie, Y | 1 |
| Wang, W | 2 |
| Huang, L | 2 |
| Ao, X | 1 |
| Zhao, M | 1 |
| Tao, L | 1 |
| Rincon-Choles, H | 1 |
| Jolly, SE | 2 |
| Arrigain, S | 1 |
| Konig, V | 1 |
| Schold, JD | 1 |
| Nakhoul, G | 1 |
| Navaneethan, SD | 2 |
| Nally, JV | 1 |
| Rothberg, MB | 1 |
| Bove, M | 2 |
| Sampson, AL | 1 |
| Singer, RF | 1 |
| Walters, GD | 1 |
| Butković, M | 1 |
| Sheng, F | 1 |
| Fang, W | 1 |
| Sha, Y | 1 |
| Zeng, X | 1 |
| Tsai, CW | 2 |
| Chiu, HT | 2 |
| Huang, HC | 2 |
| Ting, IW | 2 |
| Yeh, HC | 2 |
| Kuo, CC | 2 |
| Chou, HW | 1 |
| Chapman, PT | 1 |
| Barclay, M | 1 |
| Horne, A | 1 |
| Tan, P | 1 |
| Drake, J | 1 |
| Yang, R | 2 |
| Richette, P | 1 |
| Latourte, A | 1 |
| Bardin, T | 2 |
| Zoccali, C | 3 |
| Pan, BL | 1 |
| Loke, SS | 1 |
| Bonaventura, A | 1 |
| Gallo, F | 1 |
| Carbone, F | 1 |
| Liberale, L | 1 |
| Maggi, D | 1 |
| Sacchi, G | 1 |
| Dallegri, F | 1 |
| Montecucco, F | 1 |
| Cordera, R | 1 |
| Chang, WX | 3 |
| Xu, N | 1 |
| Kumagai, T | 4 |
| Iijima, R | 1 |
| Waki, K | 1 |
| Yamanaka, M | 1 |
| Nagura, M | 2 |
| Arai, S | 1 |
| Tamura, Y | 5 |
| Shibata, S | 3 |
| Fujigaki, Y | 2 |
| Case, R | 1 |
| Wentworth, B | 1 |
| Jester, G | 1 |
| Treviño-Becerra, A | 1 |
| Méndez Landa, CE | 1 |
| Mazumder, MK | 1 |
| Phukan, BC | 1 |
| Bhattacharjee, A | 1 |
| Borah, A | 1 |
| Arévalo-Lorido, JC | 1 |
| Carretero-Gómez, J | 1 |
| Robles, NR | 1 |
| Mwasongwe, SE | 1 |
| Fülöp, T | 1 |
| Katz, R | 2 |
| Musani, SK | 1 |
| Sims, M | 1 |
| Correa, A | 1 |
| Flessner, MF | 1 |
| Young, BA | 1 |
| Humbert, A | 1 |
| Stucker, F | 1 |
| Huang, CN | 2 |
| Gul, A | 1 |
| Zager, P | 1 |
| Ghane Sharbaf, F | 1 |
| Assadi, F | 1 |
| Lee, J | 1 |
| Lee, Y | 1 |
| Park, B | 1 |
| Won, S | 1 |
| Han, JS | 1 |
| Heo, NJ | 1 |
| Johnson, R | 1 |
| Fogacci, F | 1 |
| Rosticci, M | 1 |
| Giovannini, M | 1 |
| D'Addato, S | 1 |
| Fayed, A | 2 |
| El Nokeety, MM | 2 |
| Heikal, AA | 2 |
| Abdulazim, DO | 2 |
| Naguib, MM | 1 |
| Sharaf El Din, UAA | 1 |
| Thakur, R | 1 |
| Sharma, A | 1 |
| Lingaraju, MC | 1 |
| Begum, J | 1 |
| Kumar, D | 2 |
| Mathesh, K | 1 |
| Kumar, P | 1 |
| Singh, TU | 1 |
| Xun, C | 1 |
| Li, F | 2 |
| Guo, H | 2 |
| Zou, J | 2 |
| Chen, W | 3 |
| Lu, Y | 4 |
| Tsuji, T | 1 |
| Ohishi, K | 1 |
| Takeda, A | 1 |
| Goto, D | 1 |
| Ohashi, N | 1 |
| Yasuda, H | 1 |
| Kwak, CH | 1 |
| Sohn, M | 1 |
| Han, N | 1 |
| Cho, YS | 2 |
| Kim, YS | 2 |
| Oh, JM | 1 |
| Yu, H | 1 |
| Cheng, J | 1 |
| Bao, H | 1 |
| Qin, L | 2 |
| Peng, A | 2 |
| Hanai, K | 1 |
| Tauchi, E | 1 |
| Nishiwaki, Y | 1 |
| Yokoyama, Y | 1 |
| Uchigata, Y | 1 |
| Babazono, T | 1 |
| Mancusi, C | 1 |
| Izzo, R | 1 |
| Ferrara, LA | 1 |
| Rozza, F | 1 |
| Losi, MA | 1 |
| Canciello, G | 1 |
| Pepe, M | 1 |
| de Luca, N | 1 |
| Trimarco, B | 2 |
| de Simone, G | 1 |
| Yang, H | 2 |
| Liang, YN | 1 |
| Li, R | 2 |
| Yu, Y | 1 |
| Li, D | 1 |
| Xu, C | 1 |
| Yuan, J | 1 |
| Wei, S | 1 |
| Yang, K | 1 |
| Zheng, D | 1 |
| Tang, Y | 1 |
| Wu, T | 2 |
| Ye, M | 1 |
| Jin, J | 1 |
| Wu, D | 1 |
| Hu, P | 1 |
| He, Q | 1 |
| Becker, MA | 1 |
| Whelton, A | 1 |
| Hunt, B | 1 |
| Castillo, M | 1 |
| Kisfalvi, K | 1 |
| Gunawardhana, L | 1 |
| Redon, P | 1 |
| Facchetti, R | 1 |
| Redon, J | 1 |
| Lurbe, E | 1 |
| Mancia, G | 2 |
| Yaribeygi, H | 1 |
| Butler, AE | 1 |
| Atkin, SL | 1 |
| Katsiki, N | 2 |
| Sahebkar, A | 1 |
| Liu, Y | 2 |
| Zhao, J | 2 |
| Mohan, C | 1 |
| Dias, RSC | 1 |
| Calado, IL | 1 |
| Alencar, JD | 1 |
| Hortegal, EV | 1 |
| Santos, EJF | 1 |
| Brito, DJA | 1 |
| Lages, JS | 1 |
| Santos, AMD | 1 |
| Salgado Filho, N | 1 |
| Moriyama, K | 1 |
| Jing, J | 1 |
| Ekici, AB | 1 |
| Sitter, T | 1 |
| Eckardt, KU | 1 |
| Schaeffner, E | 1 |
| Kronenberg, F | 1 |
| Köttgen, A | 3 |
| Schultheiss, UT | 1 |
| Levy, G | 1 |
| Shi, JM | 1 |
| Cheetham, TC | 2 |
| Rashid, N | 2 |
| Qin, S | 1 |
| Mun, KH | 1 |
| Yu, GI | 1 |
| Choi, BY | 1 |
| Kim, MK | 1 |
| Shin, MH | 1 |
| Shin, DH | 2 |
| Kuo, CW | 1 |
| Chen, HL | 1 |
| Tu, MY | 1 |
| Chen, CM | 1 |
| Imamura, Y | 1 |
| Takahashi, Y | 2 |
| Hayashi, T | 2 |
| Iwamoto, M | 1 |
| Nakamura, R | 1 |
| Goto, M | 1 |
| Takeba, K | 1 |
| Shinohara, M | 1 |
| Kubo, S | 1 |
| Joki, N | 1 |
| Andrews, ES | 1 |
| Perrenoud, L | 1 |
| Nowak, KL | 1 |
| You, Z | 1 |
| Pasch, A | 1 |
| Chonchol, M | 3 |
| Kendrick, J | 1 |
| Jalal, D | 2 |
| Olofsson, C | 1 |
| Anderstam, B | 1 |
| Bragfors-Helin, AC | 1 |
| Eriksson, M | 1 |
| Qureshi, AR | 4 |
| Lindholm, B | 3 |
| Hilding, A | 1 |
| Wiczkowski, W | 1 |
| Orsini, N | 1 |
| Stenvinkel, P | 2 |
| Rajamand Ekberg, N | 1 |
| Mazidi, M | 1 |
| Mikhailidis, DP | 1 |
| Banach, M | 1 |
| Roughley, M | 1 |
| Sultan, AA | 1 |
| Clarson, L | 1 |
| Muller, S | 1 |
| Whittle, R | 1 |
| Belcher, J | 1 |
| Mallen, CD | 1 |
| Roddy, E | 1 |
| García-Arroyo, FE | 1 |
| Gonzaga, G | 1 |
| Silverio, O | 1 |
| Blas-Marron, MG | 1 |
| Muñoz-Jimenez, I | 1 |
| Tapia, E | 1 |
| Osorio-Alonso, H | 1 |
| Madero, M | 3 |
| Roncal-Jiménez, CA | 3 |
| Weiss, I | 2 |
| Glaser, J | 3 |
| Wu, YY | 1 |
| Qiu, XH | 1 |
| Ye, Y | 1 |
| Gao, C | 1 |
| Wu, F | 1 |
| Xia, G | 1 |
| Tao, S | 2 |
| Liu, J | 3 |
| Freyne, B | 1 |
| Lee, JW | 1 |
| Lee, KH | 1 |
| Jordan, DM | 1 |
| Verbanck, M | 1 |
| Topless, R | 1 |
| Won, HH | 1 |
| Nadkarni, G | 1 |
| Do, R | 1 |
| Mohammed, E | 1 |
| Browne, LD | 1 |
| Kumar A U, A | 1 |
| Adeeb, F | 1 |
| Fraser, AD | 1 |
| Han, QX | 1 |
| Zhang, D | 1 |
| Zhao, YL | 1 |
| Zhang, F | 1 |
| Luan, FX | 1 |
| Duan, JY | 1 |
| Liu, ZS | 1 |
| Cai, GY | 1 |
| Chen, XM | 1 |
| Zhu, HY | 1 |
| Alberts, BM | 1 |
| Bruce, C | 1 |
| Basnayake, K | 1 |
| Ghezzi, P | 1 |
| Davies, KA | 1 |
| Mullen, LM | 1 |
| Bailey, CJ | 1 |
| Sethna, CB | 1 |
| Ng, DK | 1 |
| Jiang, S | 1 |
| Saland, J | 1 |
| Furth, S | 1 |
| Meyers, KE | 1 |
| Chen, MY | 1 |
| Wang, AP | 2 |
| Wang, JW | 2 |
| Ke, JF | 1 |
| Yu, TP | 1 |
| Li, LX | 2 |
| Jia, WP | 2 |
| Kim, SH | 1 |
| Lee, SY | 1 |
| Kim, JM | 1 |
| Son, CN | 1 |
| Zhou, W | 1 |
| Zhou, R | 1 |
| Oh, TR | 1 |
| Choi, HS | 2 |
| Kim, CS | 1 |
| Bae, EH | 1 |
| Ma, SK | 1 |
| Sung, SA | 1 |
| Oh, KH | 1 |
| Ahn, C | 1 |
| Kim, SW | 1 |
| Chunlei, Y | 1 |
| Liubao, G | 1 |
| Tao, W | 1 |
| Changying, X | 1 |
| Lenglet, A | 1 |
| Fabresse, N | 1 |
| Taupin, M | 1 |
| Gomila, C | 1 |
| Kamel, S | 1 |
| Alvarez, JC | 1 |
| Drueke, TB | 1 |
| Zang, L | 1 |
| Wang, SQ | 1 |
| Mao, N | 1 |
| Fu, XJ | 1 |
| Lin, XJ | 1 |
| Meng, DJ | 1 |
| Li, G | 1 |
| Toprover, M | 1 |
| Crittenden, DB | 1 |
| Modjinou, DV | 1 |
| Oh, C | 1 |
| Krasnokutsky, S | 1 |
| Fisher, MC | 1 |
| Keenan, RT | 1 |
| Pillinger, MH | 1 |
| Okada, Y | 2 |
| Uehara, S | 1 |
| Shibata, M | 1 |
| Koh, H | 1 |
| Oue, K | 1 |
| Kambe, H | 1 |
| Sato, KK | 1 |
| Jeon, HJ | 1 |
| Oh, J | 1 |
| Sadek, KM | 1 |
| Hammad, H | 1 |
| Salem, MM | 1 |
| Sharaf El Din, UA | 1 |
| Shchelochkov, OA | 1 |
| Manoli, I | 1 |
| Sloan, JL | 1 |
| Ferry, S | 1 |
| Pass, A | 1 |
| Van Ryzin, C | 1 |
| Myles, J | 1 |
| Schoenfeld, M | 1 |
| McGuire, P | 1 |
| Rosing, DR | 1 |
| Levin, MD | 1 |
| Kopp, JB | 1 |
| Venditti, CP | 1 |
| Bilancio, G | 2 |
| Cavallo, P | 1 |
| Lombardi, C | 2 |
| Guarino, E | 1 |
| Cozza, V | 1 |
| Giordano, F | 1 |
| Palladino, G | 1 |
| Luo, K | 1 |
| Bian, J | 1 |
| Wang, Q | 1 |
| Chen, F | 1 |
| Jin, D | 1 |
| Lin, TC | 1 |
| Hung, LY | 1 |
| Lo, WC | 1 |
| Lin, CH | 1 |
| Tam, KW | 1 |
| Wu, MY | 1 |
| Gajjala, PR | 1 |
| Bruck, H | 1 |
| Noels, H | 1 |
| Heinze, G | 1 |
| Ceccarelli, F | 1 |
| Kribben, A | 1 |
| Saez-Rodriguez, J | 1 |
| Marx, N | 1 |
| Zidek, W | 1 |
| Jankowski, J | 1 |
| Jankowski, V | 1 |
| Shroff, RC | 1 |
| Price, KL | 1 |
| Kolatsi-Joannou, M | 1 |
| Todd, AF | 1 |
| Wells, D | 1 |
| Deanfield, J | 1 |
| Rees, L | 1 |
| Woolf, AS | 1 |
| Long, DA | 1 |
| Rule, AD | 1 |
| Bailey, KR | 1 |
| Lieske, JC | 1 |
| Peyser, PA | 1 |
| Turner, ST | 1 |
| Yee, J | 1 |
| Iseki, C | 1 |
| Kinjo, K | 1 |
| Nishimura, H | 1 |
| Shintani, M | 1 |
| Maeda, K | 1 |
| Otoshi, K | 1 |
| Fukuda, M | 1 |
| Okuda, J | 1 |
| Nishi, S | 1 |
| Ohashi, S | 1 |
| Kato, S | 1 |
| Baba, Y | 1 |
| Ritz, E | 1 |
| Yano, H | 1 |
| Kobayashi, K | 1 |
| Tanemoto, M | 1 |
| Diallo, D | 1 |
| Dubourg, L | 1 |
| Ranchin, B | 1 |
| Cochat, P | 2 |
| Bacchetta, J | 2 |
| Lee, SS | 1 |
| Chen, MC | 1 |
| Lin, SD | 1 |
| Lai, CS | 1 |
| Ryoo, JH | 1 |
| Choi, JM | 1 |
| Oh, CM | 1 |
| Ohno, I | 4 |
| Kaya, MG | 1 |
| Yin, Z | 1 |
| Fang, Z | 1 |
| Yang, M | 1 |
| Du, X | 1 |
| Nie, B | 1 |
| Cabrera, SE | 1 |
| Edwards, NC | 1 |
| Steeds, RP | 1 |
| Townend, JN | 1 |
| Ferro, CJ | 1 |
| Zawiasa, A | 1 |
| Nowicki, M | 1 |
| He, YM | 1 |
| Feng, L | 1 |
| Huo, DM | 1 |
| Yang, ZH | 1 |
| Liao, YH | 1 |
| Shcherbak, AV | 1 |
| Kozlovskaia, LV | 1 |
| Bobkova, IN | 1 |
| Balkarov, IM | 1 |
| Lebedeva, MV | 1 |
| Stakhova, TIu | 1 |
| Bao, X | 2 |
| Rivara, CM | 1 |
| Johnson, CR | 1 |
| Lulich, JP | 1 |
| Osborne, CA | 1 |
| Murtaugh, M | 1 |
| Bose, B | 1 |
| Hiremath, SS | 1 |
| Fassett, RG | 1 |
| Hughes, K | 1 |
| Flynn, T | 1 |
| de Zoysa, J | 1 |
| Shafiu, M | 1 |
| Sundaram, S | 1 |
| Le, M | 3 |
| Ishimoto, T | 2 |
| Sautin, YY | 2 |
| Martens, CR | 1 |
| Kuczmarski, JM | 1 |
| Lennon-Edwards, S | 1 |
| Edwards, DG | 1 |
| Ura, Y | 1 |
| Ikeda, H | 1 |
| Oniki, H | 1 |
| Tsuchihashi, T | 2 |
| Griffin, B | 1 |
| Lightstone, L | 1 |
| Otsuka, T | 1 |
| Ohno, D | 1 |
| Murasawa, T | 1 |
| Sato, N | 1 |
| Tsuruoka, S | 1 |
| Balta, S | 1 |
| Demir, M | 1 |
| Demirkol, S | 1 |
| Kucuk, U | 1 |
| Unlu, M | 1 |
| Arslan, Z | 1 |
| Erayman, A | 1 |
| Gude, D | 1 |
| Chennamsetty, S | 1 |
| Jha, R | 1 |
| Gilbert, RE | 1 |
| Sedaghat, S | 1 |
| Hoorn, EJ | 1 |
| van Rooij, FJ | 1 |
| Hofman, A | 1 |
| Franco, OH | 1 |
| Witteman, JC | 1 |
| Dehghan, A | 1 |
| Roncal Jimenez, CA | 1 |
| Rivard, CJ | 1 |
| Cicerchi, C | 1 |
| Inaba, S | 1 |
| Correa-Rotter, R | 1 |
| González, MA | 2 |
| Aragón, A | 2 |
| Wesseling, C | 3 |
| Cheng, P | 2 |
| Xia, Y | 2 |
| Peng, C | 2 |
| Puddu, PE | 2 |
| Terradura Vagnarelli, O | 1 |
| Mancini, M | 1 |
| Zanchetti, A | 1 |
| Menotti, A | 2 |
| Itoh, S | 1 |
| Inaba, M | 1 |
| Tomino, Y | 1 |
| Makino, H | 1 |
| Matsuo, S | 1 |
| Iimuro, S | 1 |
| Imai, N | 1 |
| Hayakawa, H | 1 |
| Toda, A | 1 |
| Ishizaka, Y | 1 |
| Tani, M | 1 |
| Yamakado, M | 1 |
| Sheikhbahaei, S | 1 |
| Fotouhi, A | 1 |
| Hafezi-Nejad, N | 1 |
| Nakhjavani, M | 1 |
| Esteghamati, A | 1 |
| Yood, RA | 1 |
| Ottery, FD | 1 |
| Irish, W | 1 |
| Wolfson, M | 1 |
| Nomura, S | 1 |
| Fujimori, S | 1 |
| Hara, S | 1 |
| Stępniewska, J | 1 |
| Dołęgowska, B | 1 |
| Popińska, M | 1 |
| Sałata, D | 1 |
| Budkowska, M | 1 |
| Gołembiewska, E | 1 |
| Myślak, M | 1 |
| Domański, M | 1 |
| Marchelek-Myśliwiec, M | 1 |
| Ciechanowski, K | 1 |
| Kose, E | 1 |
| An, T | 1 |
| Kikkawa, A | 1 |
| Matsumoto, Y | 1 |
| Hayashi, H | 1 |
| Hsu, YC | 2 |
| Lee, PH | 2 |
| Lei, CC | 3 |
| Shih, YH | 2 |
| Lin, CL | 2 |
| Song, HL | 1 |
| Yang, FJ | 1 |
| Huang, HJ | 1 |
| Li, SQ | 1 |
| Garneri, D | 1 |
| Gonnella, A | 1 |
| Ambrosioni, E | 1 |
| Costa, FV | 1 |
| Leonetti, G | 1 |
| Pessina, AC | 1 |
| Agabiti Rosei, E | 1 |
| Deferrari, G | 1 |
| Levy, GD | 1 |
| Niu, F | 1 |
| Kawada, T | 1 |
| Testa, A | 2 |
| Spoto, B | 2 |
| Pisano, A | 2 |
| Sanguedolce, MC | 2 |
| Tripepi, G | 2 |
| Leonardis, D | 2 |
| Wang, CJ | 1 |
| Bao, XR | 1 |
| Du, GW | 1 |
| Chen, K | 1 |
| Shen, ML | 1 |
| Wang, LZ | 1 |
| Joo, K | 1 |
| Kwon, SR | 1 |
| Lim, MJ | 1 |
| Jung, KH | 1 |
| Joo, H | 1 |
| Park, W | 1 |
| Ohya, M | 1 |
| Kwak, IS | 1 |
| Elsurer, R | 2 |
| Afsar, B | 2 |
| Odden, MC | 1 |
| Amadu, AR | 1 |
| Smit, E | 1 |
| Lo, L | 1 |
| Peralta, CA | 1 |
| Choi, ST | 1 |
| Kim, JS | 1 |
| Song, JS | 1 |
| Nacak, H | 2 |
| van Diepen, M | 2 |
| de Goeij, MC | 1 |
| Rotmans, JI | 1 |
| Dekker, FW | 2 |
| Zhu, P | 2 |
| Han, L | 1 |
| Xu, G | 1 |
| Ran, JM | 1 |
| Fujisaki, K | 1 |
| Taniguchi, M | 1 |
| Higashi, H | 1 |
| Katafuchi, R | 1 |
| Kanai, H | 2 |
| Hirakata, H | 1 |
| Ruiz-Hurtado, G | 1 |
| Condezo-Hoyos, L | 1 |
| Pulido-Olmo, H | 1 |
| Aranguez, I | 1 |
| Del Carmen Gónzalez, M | 1 |
| Arribas, S | 1 |
| Cerezo, C | 1 |
| Segura, J | 1 |
| Praga, M | 1 |
| Fernández-Alfonso, MS | 1 |
| Ruilope, LM | 1 |
| Itabashi, M | 3 |
| Takei, T | 3 |
| Wen, CP | 1 |
| Wu, SB | 1 |
| Lan, JL | 1 |
| Tsai, MK | 1 |
| Tai, YP | 1 |
| Tsao, CK | 1 |
| Wai, JP | 1 |
| Chiang, PH | 1 |
| Pan, WH | 1 |
| Hsiung, CA | 1 |
| Kamei, K | 1 |
| Hirayama, A | 1 |
| Ichikawa, K | 1 |
| Maizel, J | 1 |
| Bayram, D | 1 |
| Tuğrul Sezer, M | 1 |
| İnal, S | 1 |
| Altuntaş, A | 1 |
| Kıdır, V | 1 |
| Orhan, H | 1 |
| Dousdampanis, P | 1 |
| Trigka, K | 1 |
| Musso, CG | 3 |
| Fourtounas, C | 1 |
| Zhang, YF | 1 |
| He, F | 1 |
| Ding, HH | 1 |
| Dai, W | 1 |
| Luan, H | 1 |
| Lv, YM | 1 |
| Zeng, HB | 1 |
| Jeon, JS | 1 |
| Chung, SH | 1 |
| Han, DC | 1 |
| Noh, H | 1 |
| Kwon, SH | 1 |
| Lee, HB | 1 |
| Solomenchuk, TN | 1 |
| Semegen-Bodak, KV | 1 |
| Slaba, NA | 1 |
| Chngrian, GV | 1 |
| Mysyshin, MB | 1 |
| Habibzadeh, A | 1 |
| Khoshbaten, M | 1 |
| Rahbari, B | 1 |
| Chaichi, P | 1 |
| Badiee, AH | 1 |
| Robinson-Cohen, C | 1 |
| Hall, YN | 1 |
| Rivara, MB | 1 |
| de Boer, IH | 1 |
| Kestenbaum, BR | 1 |
| Himmelfarb, J | 1 |
| Wei, C | 1 |
| Sato, M | 1 |
| Iwabuchi, Y | 1 |
| Nishida, M | 1 |
| Uchida, K | 2 |
| Ohno, M | 2 |
| Deguchi, F | 1 |
| Izumi, K | 1 |
| Ishigaki, H | 1 |
| Sarui, H | 1 |
| Sasaki, A | 1 |
| Segawa, T | 1 |
| Yamaki, T | 1 |
| Kojima, T | 1 |
| Ohashi, H | 1 |
| Chou, YC | 1 |
| Kuan, JC | 1 |
| Yang, T | 1 |
| Chou, WY | 1 |
| Hsieh, PC | 1 |
| Bai, CH | 1 |
| You, SL | 1 |
| Wei, CY | 1 |
| Sun, CA | 1 |
| Hasegawa, Y | 1 |
| Nakanishi, T | 1 |
| Hosomi, A | 1 |
| Komori, H | 1 |
| Tamai, I | 1 |
| Sanna, M | 1 |
| Kolomiets, MV | 1 |
| Bil'chenko, AV | 1 |
| Mulè, G | 3 |
| Nardi, E | 2 |
| Guarino, L | 1 |
| Cacciatore, V | 1 |
| Geraci, G | 3 |
| Calcaterra, I | 1 |
| Oddo, B | 1 |
| Vaccaro, F | 1 |
| Cottone, S | 3 |
| Goicoechea, M | 1 |
| Garcia de Vinuesa, S | 1 |
| Verdalles, U | 1 |
| Verde, E | 1 |
| Macias, N | 1 |
| Santos, A | 1 |
| Pérez de Jose, A | 1 |
| Cedeño, S | 1 |
| Linares, T | 1 |
| Luño, J | 1 |
| Vieira, FO | 1 |
| Leal, Vde O | 1 |
| Stockler-Pinto, MB | 1 |
| Barros, Ade F | 1 |
| Borges, NA | 1 |
| Lobo, JC | 1 |
| Mafra, D | 1 |
| Soma, M | 1 |
| Nakata, K | 1 |
| Ishii, Y | 1 |
| Yaoita, H | 1 |
| Hata, H | 1 |
| Shiono, M | 1 |
| Muneyuki, T | 1 |
| Kanno, Y | 1 |
| Suwa, K | 1 |
| Nakajima, K | 1 |
| Tanaka, K | 1 |
| Kanno, M | 1 |
| Kimura, H | 1 |
| Tani, Y | 1 |
| Hayashi, Y | 1 |
| Greenberg, KI | 1 |
| McAdams-DeMarco, MA | 1 |
| Coresh, J | 2 |
| Grams, ME | 1 |
| Assis, RP | 1 |
| Castro, JF | 1 |
| Gutierres, VO | 1 |
| Arcaro, CA | 1 |
| Brotto, RS | 1 |
| Oliveira, OM | 1 |
| Baviera, AM | 1 |
| Brunetti, IL | 1 |
| Kurra, V | 2 |
| Vehmas, T | 1 |
| Jokihaara, J | 1 |
| Pirttiniemi, P | 1 |
| Ruskoaho, H | 1 |
| Tokola, H | 1 |
| Zhang, R | 1 |
| Li, TT | 1 |
| Bao, YQ | 1 |
| Kanji, T | 1 |
| Gandhi, M | 1 |
| Clase, CM | 1 |
| Donderski, R | 1 |
| Miśkowiec-Wiśniewska, I | 1 |
| Kretowicz, M | 1 |
| Grajewska, M | 1 |
| Manitius, J | 2 |
| Kamińska, A | 1 |
| Junik, R | 1 |
| Siódmiak, J | 1 |
| Stefańska, A | 2 |
| Odrowąż-Sypniewska, G | 1 |
| Pluta, A | 1 |
| Lanaspa, M | 1 |
| Kuriyama, S | 1 |
| Maruyama, Y | 1 |
| Nishio, S | 1 |
| Kidoguchi, S | 1 |
| Kobayashi, C | 1 |
| Takahashi, D | 1 |
| Sugano, N | 1 |
| Yokoo, T | 1 |
| Tominaga, N | 1 |
| Kida, K | 1 |
| Matsumoto, N | 1 |
| Akashi, YJ | 1 |
| Miyake, F | 1 |
| Kikuchi, K | 1 |
| Sasaki, Y | 1 |
| Akiba, T | 1 |
| Santoro, A | 1 |
| Mandreoli, M | 1 |
| Ratto, E | 1 |
| Rosei, EA | 1 |
| Dawson, J | 1 |
| Dominiczak, A | 1 |
| Kielstein, JT | 1 |
| Manolis, AJ | 1 |
| Perez-Ruiz, F | 1 |
| Donadio, C | 1 |
| Calia, D | 1 |
| Ghimenti, S | 1 |
| Onor, M | 1 |
| Colombini, E | 1 |
| Fuoco, R | 1 |
| Di Francesco, F | 1 |
| Carrero, JJ | 3 |
| Stijnen, T | 1 |
| Evans, M | 1 |
| Oshima, N | 1 |
| Onimaru, H | 1 |
| Matsubara, H | 1 |
| Uchida, T | 1 |
| Watanabe, A | 1 |
| Takechi, H | 1 |
| Nishida, Y | 1 |
| Kumagai, H | 1 |
| Rodenbach, KE | 1 |
| Moxey-Mims, MM | 1 |
| Mitsnefes, MM | 1 |
| Gentile, S | 1 |
| Guida, P | 1 |
| Feig, D | 1 |
| Kummer, AE | 1 |
| Grams, M | 1 |
| Lutsey, P | 1 |
| Folsom, AR | 1 |
| Toyama, T | 1 |
| Furuichi, K | 1 |
| Shimizu, M | 1 |
| Sakai, N | 1 |
| Kobayashi, M | 1 |
| Mano, T | 1 |
| Kaneko, S | 1 |
| Gondouin, B | 1 |
| Jourde-Chiche, N | 1 |
| Sallee, M | 1 |
| Dou, L | 1 |
| Cerini, C | 1 |
| Loundou, A | 1 |
| Morange, S | 1 |
| Berland, Y | 1 |
| Burtey, S | 1 |
| Brunet, P | 1 |
| Guieu, R | 1 |
| Dussol, B | 1 |
| Roncal-Jimenez, C | 2 |
| García-Trabanino, R | 2 |
| Barregard, L | 1 |
| Harra, T | 1 |
| Grases, F | 1 |
| Jarquin, ER | 1 |
| Zhang, MM | 1 |
| Zhu, YL | 1 |
| Lin, KC | 1 |
| Chang, DM | 1 |
| Hsieh, CH | 1 |
| Hsieh, YP | 1 |
| Chang, CC | 1 |
| Wen, YK | 1 |
| Chiu, PF | 1 |
| Lin, CC | 1 |
| Deedwania, PC | 1 |
| Stone, PH | 1 |
| Fayyad, RS | 1 |
| Laskey, RE | 1 |
| Wilson, DJ | 1 |
| Mende, C | 1 |
| Locatelli, F | 1 |
| Spasovski, G | 1 |
| Dimkovic, N | 1 |
| Wanner, C | 1 |
| Jensen, T | 2 |
| Solak, Y | 4 |
| Rivard, C | 1 |
| Ayoub, I | 1 |
| Almaani, S | 1 |
| Brodsky, S | 1 |
| Nadasdy, T | 1 |
| Prosek, J | 1 |
| Hebert, L | 1 |
| Rovin, B | 1 |
| Gigante, A | 1 |
| Barbano, B | 1 |
| Barilaro, G | 1 |
| Quarta, S | 1 |
| Gasperini, ML | 1 |
| Di Mario, F | 1 |
| Romaniello, A | 1 |
| Amoroso, A | 1 |
| Rosato, E | 1 |
| Wirajit, O | 1 |
| Burata, A | 1 |
| Krittayaphong, R | 1 |
| Thinkhamrop, B | 1 |
| Hurst, C | 1 |
| Rattanamongkolgul, S | 1 |
| Sripaiboonkij, N | 1 |
| Yindeengam, A | 1 |
| Mogavero, M | 2 |
| Geraci, C | 2 |
| Mitri, G | 2 |
| Wittbrodt, ET | 1 |
| Turpin, RS | 1 |
| Tidwell, BA | 1 |
| Schulman, KL | 1 |
| Mome, R | 1 |
| Bakinde, N | 1 |
| Filiopoulos, V | 1 |
| Hadjiyannakos, D | 1 |
| Vlassopoulos, D | 1 |
| Sircar, D | 1 |
| Liu, CW | 1 |
| Moolchandani, K | 1 |
| Priyadarssini, M | 1 |
| Rajappa, M | 1 |
| Parameswaran, S | 1 |
| Revathy, G | 1 |
| Morreale, M | 1 |
| Cusumano, C | 1 |
| Castiglia, A | 1 |
| Gervasi, F | 1 |
| D'Ignoto, F | 1 |
| Hirai, T | 1 |
| Kimura, T | 1 |
| Echizen, H | 1 |
| Okazaki, H | 1 |
| Shirakabe, A | 1 |
| Kobayashi, N | 1 |
| Hata, N | 1 |
| Shinada, T | 1 |
| Yamamoto, Y | 1 |
| Shibuya, J | 1 |
| Shiomura, R | 1 |
| Nishigoori, S | 1 |
| Asai, K | 1 |
| Shimizu, W | 1 |
| Smolen, LJ | 1 |
| Gahn, JC | 1 |
| Shiozawa, A | 1 |
| Quilis, N | 1 |
| Andrés, M | 1 |
| Gil, S | 1 |
| Ranieri, L | 1 |
| Vela, P | 1 |
| Pascual, E | 1 |
| Takae, K | 1 |
| Nagata, M | 1 |
| Hata, J | 1 |
| Mukai, N | 1 |
| Hirakawa, Y | 1 |
| Yoshida, D | 1 |
| Kishimoto, H | 1 |
| Kiyohara, Y | 1 |
| Ninomiya, T | 1 |
| Song, YM | 1 |
| Sung, J | 1 |
| Lee, K | 1 |
| Ota, T | 1 |
| Dai, H | 1 |
| Lu, S | 1 |
| Tang, X | 1 |
| Lu, M | 1 |
| Chen, R | 1 |
| Yang, P | 1 |
| Zhou, H | 1 |
| Yuan, H | 1 |
| Wang, C | 2 |
| Ma, X | 2 |
| Peng, H | 2 |
| Lou, T | 2 |
| Ena, S | 1 |
| Xia, X | 1 |
| Luo, Q | 1 |
| Li, B | 1 |
| Lin, Z | 1 |
| Huang, F | 1 |
| Sakoh, T | 1 |
| Tanaka, S | 1 |
| Katafuchi, E | 1 |
| Shikuwa, Y | 1 |
| Anzai, N | 1 |
| Mallat, SG | 1 |
| Al Kattar, S | 1 |
| Tanios, BY | 1 |
| Jurjus, A | 1 |
| Kaminska-Pajak, KA | 1 |
| Dyga, K | 1 |
| Adamczyk, P | 1 |
| Szczepańska, M | 1 |
| Zaniew, M | 1 |
| Beck, B | 1 |
| Tkaczyk, M | 1 |
| Momoki, K | 1 |
| Dehghani, H | 1 |
| Heidari, F | 1 |
| Mozaffari-Khosravi, H | 1 |
| Nouri-Majelan, N | 1 |
| Dehghani, A | 1 |
| Hosoyamada, M | 1 |
| Sipahi, S | 1 |
| Acikgoz, SB | 1 |
| Genc, AB | 1 |
| Yildirim, M | 1 |
| Tamer, A | 1 |
| Fouad, M | 1 |
| Fathy, H | 1 |
| Zidan, A | 1 |
| Krishnamurthy, A | 1 |
| Lazaro, D | 1 |
| Stefanov, DG | 1 |
| Blumenthal, D | 1 |
| Gerber, D | 1 |
| Hung, CC | 1 |
| Lin, HY | 1 |
| Lee, JJ | 1 |
| Lim, LM | 1 |
| Chiu, YW | 1 |
| Chiang, HP | 1 |
| Hwang, SJ | 1 |
| Chen, HC | 2 |
| Ramirez-Sandoval, JC | 1 |
| Wu, H | 1 |
| Lou, Q | 1 |
| Bian, R | 1 |
| Niwa, K | 1 |
| Milagres, T | 1 |
| Garcia, G | 1 |
| Tahvanainen, AM | 1 |
| Vehmas, TI | 1 |
| Niemelä, OJ | 1 |
| Mustonen, JT | 1 |
| Pörsti, IH | 1 |
| Beddhu, S | 1 |
| Gersch, MS | 1 |
| Mu, W | 1 |
| Scherer, PM | 1 |
| Kim, KM | 1 |
| Henderson, GN | 1 |
| See, LC | 1 |
| Chuang, FH | 1 |
| Li, HY | 1 |
| Chen, HW | 1 |
| Suzuki, I | 1 |
| Yamauchi, T | 1 |
| Onuma, M | 1 |
| Nozaki, S | 1 |
| Moe, OW | 1 |
| Yilmaz, MI | 2 |
| Saglam, M | 2 |
| Suliman, ME | 2 |
| Caglar, K | 2 |
| Eyileten, T | 1 |
| Sonmez, A | 2 |
| Oguz, Y | 2 |
| Vural, A | 1 |
| Yenicesu, M | 1 |
| Axelsson, J | 2 |
| Bellomo, G | 1 |
| Venanzi, S | 1 |
| Verdura, C | 1 |
| Saronio, P | 1 |
| Esposito, A | 1 |
| Timio, M | 1 |
| Chang, HY | 1 |
| Tung, CW | 1 |
| Chang, HH | 1 |
| Yang, HF | 1 |
| Lu, LC | 1 |
| Jong, MC | 1 |
| Chen, CY | 1 |
| Fang, KY | 1 |
| Chao, YS | 1 |
| Endo, M | 1 |
| Kumakura, H | 1 |
| Araki, Y | 1 |
| Kasama, S | 1 |
| Sumino, H | 1 |
| Ichikawa, S | 1 |
| Kurabayashi, M | 1 |
| Tangri, N | 1 |
| Weiner, DE | 2 |
| Gudbjartsson, DF | 1 |
| Holm, H | 1 |
| Indridason, OS | 1 |
| Thorleifsson, G | 1 |
| Edvardsson, V | 1 |
| Sulem, P | 1 |
| de Vegt, F | 1 |
| d'Ancona, FC | 1 |
| den Heijer, M | 1 |
| Wetzels, JF | 1 |
| Franzson, L | 1 |
| Rafnar, T | 1 |
| Kristjansson, K | 1 |
| Bjornsdottir, US | 1 |
| Eyjolfsson, GI | 1 |
| Kiemeney, LA | 1 |
| Kong, A | 1 |
| Palsson, R | 1 |
| Thorsteinsdottir, U | 1 |
| Stefansson, K | 1 |
| Ranganathan, N | 1 |
| Ranganathan, P | 1 |
| Friedman, EA | 1 |
| Joseph, A | 1 |
| Delano, B | 1 |
| Tam, P | 1 |
| Rao, AV | 1 |
| Anteyi, E | 1 |
| Li, SY | 1 |
| Yang, WC | 1 |
| Chuang, CL | 1 |
| Mekki, K | 1 |
| Remaoun, M | 1 |
| Belleville, J | 1 |
| Bouchenak, M | 1 |
| Sonoda, H | 1 |
| Takase, H | 1 |
| Dohi, Y | 1 |
| Kimura, G | 1 |
| Riegersperger, M | 1 |
| Covic, A | 2 |
| Goldsmith, D | 1 |
| Brymora, A | 1 |
| Flisiński, M | 1 |
| Goszka, G | 1 |
| Fukatsu, M | 1 |
| Suzuki, S | 1 |
| Joh, T | 1 |
| Neri, L | 1 |
| Rocca Rey, LA | 1 |
| Lentine, KL | 1 |
| Hinyard, LJ | 1 |
| Pinsky, B | 1 |
| Xiao, H | 1 |
| Dukes, J | 1 |
| Schnitzler, MA | 1 |
| Stellato, D | 1 |
| Morrone, LF | 1 |
| Di Giorgio, C | 1 |
| Shu, Z | 1 |
| Tao, Q | 1 |
| Yu, C | 1 |
| Li, L | 1 |
| Zoppini, G | 1 |
| Targher, G | 2 |
| Ortalda, V | 1 |
| Abaterusso, C | 1 |
| Pichiri, I | 1 |
| Negri, C | 1 |
| Bonora, E | 1 |
| Mete, M | 1 |
| Zhu, J | 1 |
| Ebbesson, SOE | 1 |
| Voruganti, VS | 1 |
| Comuzzie, AG | 1 |
| Howard, BV | 1 |
| Umans, JG | 1 |
| Salusky, IB | 1 |
| Wesseling-Perry, K | 1 |
| Li, WM | 1 |
| Huang, SP | 1 |
| Chang, AW | 1 |
| Chen, SM | 1 |
| Lin, YL | 1 |
| Lin, YP | 1 |
| Pisanu, E | 1 |
| Loriga, G | 1 |
| Deiana, L | 1 |
| Sim, X | 1 |
| Go, MJ | 1 |
| Wu, JY | 1 |
| Gu, D | 1 |
| Takeuchi, F | 1 |
| Takahashi, A | 1 |
| Maeda, S | 1 |
| Tsunoda, T | 1 |
| Chen, P | 1 |
| Wong, TY | 1 |
| Young, TL | 1 |
| Aung, T | 1 |
| Seielstad, M | 1 |
| Teo, YY | 1 |
| Kim, YJ | 1 |
| Lee, JY | 1 |
| Han, BG | 1 |
| Kang, D | 1 |
| Tsai, FJ | 1 |
| Chang, LC | 1 |
| Fann, SJ | 1 |
| Mei, H | 1 |
| Rao, DC | 1 |
| Hixson, JE | 1 |
| Chen, S | 1 |
| Katsuya, T | 1 |
| Isono, M | 1 |
| Ogihara, T | 1 |
| Chambers, JC | 1 |
| Kooner, JS | 1 |
| Albrecht, E | 1 |
| Kubo, M | 1 |
| Nakamura, Y | 1 |
| Kato, N | 1 |
| He, J | 1 |
| Chen, YT | 1 |
| Tai, ES | 1 |
| Tanaka, T | 1 |
| Juarez, R | 1 |
| Vilas, M | 1 |
| Navarro, M | 1 |
| Rivera, H | 1 |
| Jauregui, R | 1 |
| Peng, CC | 1 |
| Hsieh, CL | 1 |
| Ker, YB | 1 |
| Wang, HY | 1 |
| Chen, KC | 1 |
| Peng, RY | 1 |
| Kinjyo, T | 1 |
| Maehara, Y | 1 |
| Lin, F | 1 |
| Lin, C | 1 |
| Hong, D | 1 |
| Lin, K | 1 |
| Chen, H | 1 |
| Cakir, E | 1 |
| Unal, HU | 1 |
| Arslan, E | 1 |
| Verim, S | 1 |
| McFann, K | 1 |
| Nashar, K | 1 |
| Fried, LF | 1 |
| Sebesta, I | 1 |
| Jeon, HG | 1 |
| Choo, SH | 1 |
| Jeong, BC | 1 |
| Seo, SI | 1 |
| Jeon, SS | 1 |
| Choi, HY | 1 |
| Lee, HM | 1 |
| Peng, Y | 1 |
| Xiao, P | 1 |
| Ryu, ES | 1 |
| Shin, HS | 1 |
| Jang, YH | 1 |
| Jo, I | 1 |
| Boelaert, J | 1 |
| Lynen, F | 1 |
| Van Landschoot, M | 1 |
| Waterloos, MA | 1 |
| Sandra, P | 1 |
| Ji, B | 1 |
| Zhang, S | 1 |
| Gong, L | 1 |
| Ren, W | 1 |
| Li, Q | 1 |
| Yeh, SM | 1 |
| Papavasiliou, E | 1 |
| Makedou, A | 1 |
| Ioannou, K | 1 |
| Katopodis, KP | 1 |
| Tselepis, A | 1 |
| Siamopoulos, KC | 1 |
| Tsakiris, D | 1 |
| García-López, E | 1 |
| Molinaei, H | 1 |
| Heimbürger, O | 1 |
| Bárány, P | 1 |
| Tighiouart, H | 1 |
| Elsayed, EF | 1 |
| Griffith, JL | 1 |
| Salem, DN | 1 |
| Levey, AS | 1 |
| Sarnak, MJ | 1 |
| Panomvana, D | 1 |
| Sripradit, S | 1 |
| Angthararak, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)[NCT00327860] | 1,100 participants (Actual) | Observational | 2003-10-31 | Active, not recruiting | |||
| Community-based Screening to Determine the Prevalence, Current Health and Nutritional Status of Individuals With Chronic Kidney Disease (CKD) and Measure the Outcome of Health Education to Enhance Knowledge, Awareness and Risk Reduction Strategies in Mirz[NCT04094831] | 126 participants (Anticipated) | Interventional | 2020-07-01 | Active, not recruiting | |||
| Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies: a Cross-over Randomized Clinical Trail[NCT05402397] | Phase 4 | 40 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| University of Alabama at Birmingham CORT Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure[NCT02038179] | Phase 2/Phase 3 | 99 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Chronobiology and Chronopharmacology to Prevent Sickle Cell Kidney Disease[NCT02373241] | Phase 2 | 1 participants (Actual) | Interventional | 2015-04-30 | Terminated (stopped due to Estimated GFR was determined not to be a reliable endpoint for this study. We identified significant variabilty in annual eGFR that it became inappropriate to randomize to a medication but use EGFR as the primary endpoint.) | ||
| The Metabolic and Anti-Inflammatory Effects of Combined Ezetimibe and Simvastin Therapy, as Compared to Simvastatin Alone, in Patients With Chronic Proteinuric Nephropathy[NCT00861731] | Phase 4 | 30 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
| African American Study of Kidney Disease and Hypertension ABPM Pilot Study[NCT00582777] | Phase 2/Phase 3 | 180 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
| Chinese Cohort Study of Chronic Kidney Disease[NCT03041987] | 5,000 participants (Anticipated) | Observational | 2012-01-01 | Active, not recruiting | |||
| Registro Campania Salute Network for the Treatment of Hypertension and Correlated Diseases[NCT02211365] | 10,000 participants (Anticipated) | Observational [Patient Registry] | 2014-02-28 | Recruiting | |||
| A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout[NCT02139046] | Phase 3 | 1,790 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| The Natural History, Physiology, Microbiome and Biochemistry Studies of Propionic Acidemia[NCT02890342] | 1,045 participants (Anticipated) | Observational | 2016-11-29 | Recruiting | |||
| Prospective Study of the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders[NCT06092346] | 999 participants (Anticipated) | Observational | 2024-01-03 | Recruiting | |||
| Study on the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention[NCT03425708] | Phase 4 | 400 participants (Anticipated) | Interventional | 2017-01-01 | Recruiting | ||
| Genetic-specific Effects of Fructose on Liver Lipogenesis[NCT03783195] | 15 participants (Actual) | Interventional | 2019-01-25 | Completed | |||
| A Population Based Cohort Study on Metabolic Syndrome Complications, and Mortality; (MetSCoM) Study[NCT02958579] | 10,000 participants (Anticipated) | Observational | 2005-01-31 | Recruiting | |||
| Randomized, Multicenter, Double-blind, Placebo-controlled Efficacy and Safety Study of 8 mg PEG-uricase in Two Dose Regimens in Hyperuricemic Subjects With Symptomatic Gout[NCT00325195] | Phase 3 | 225 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)[NCT03767322] | Phase 2 | 558 participants (Anticipated) | Interventional | 2018-12-05 | Not yet recruiting | ||
| Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 Diabetes[NCT03887416] | Phase 4 | 225 participants (Anticipated) | Interventional | 2019-04-12 | Recruiting | ||
| Assesment of Lactulose vs Lactobacillus Acidophilus Effect in CKD Patients[NCT05934552] | 150 participants (Anticipated) | Observational | 2023-12-31 | Not yet recruiting | |||
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| Study Protocol for a Prospective Observational Study Investigating the Role of Luminal Pressure on Arteriovenous Fistula Maturation[NCT04017806] | 60 participants (Anticipated) | Observational | 2018-09-19 | Recruiting | |||
| The Oral Fructose Load Test and Inflammation, Lipid Metabolism, Blood Pressure and Organ Damage in Patients With Obesity, Chronic Kidney Disease With Comparison With Healthy Controls.[NCT01332526] | 70 participants (Anticipated) | Observational | 2011-05-31 | Not yet recruiting | |||
| A Phase III, Multi-center, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia[NCT00772382] | Phase 3 | 116 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Observational Clinical Trials of Kibow Biotics (a Patented and Proprietary Probiotic Dietary Supplement) in Chronic Kidney Failure Patients, in Conjunction With Standardized Care of Treatment[NCT01450657] | 31 participants (Actual) | Observational | 2011-07-31 | Completed | |||
| Observational Clinical Trials of Kibow Biotics® (a Patented and Proprietary Probiotic Formulation) in Dialysis Patients, in Conjunction With Standardized Care of Treatment[NCT01450709] | 30 participants (Actual) | Observational | 2011-04-30 | Completed | |||
| Observational Clinical Trials of Kibow Biotics (a Patented and Proprietary Probiotic Dietary Supplement) in Dialysis Patients, in Conjunction With Standardized Care of Treatment[NCT01450670] | 30 participants (Actual) | Observational | 2011-05-31 | Completed | |||
| The Effect of Acute Fructose Load in Patients With Chronic Kidney Disease and Patients With Type 2 Diabetes Compared to Healthy Subjects[NCT03157960] | 20 participants (Actual) | Interventional | 2012-02-01 | Completed | |||
| Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial[NCT02502071] | Phase 4 | 45 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Compare endothelial function as indexed by flow-mediated arterial vasodilation (FMD) within each phase of treatment (allopurinol 300 mg/day PO or placebo). Percent (%) change in FMD is calculated by comparing FMD (%) at the end of each treatment phase to pre-treatment values. (NCT02038179)
Timeframe: 4 weeks (pre-treatment vs. post-treatment FMD Values (%))
| Intervention | percent change (Mean) |
|---|---|
| Allopurinol Phase | 2.5 |
| Placebo Phase | -0.1 |
Serum level of high sensitivity C-reactive protein will be reported as a change during treatment phase (allopurinol 300 mg/day PO or placebo). Change in serum level of C-reactive protein is calculated by comparing serum values at the end of each treatment phase to pre-treatment levels. (NCT02038179)
Timeframe: 4 weeks (pre-treatment vs. post-treatment serum levels)
| Intervention | mg/L (Mean) |
|---|---|
| Allopurinol Phase | 0.6 |
| Placebo Phase | 0.8 |
Compare systolic blood pressure (SBP) captured by wearing a 24 hour ambulatory blood pressure monitor during each phase of treatment (allopurinol 300 mg/day PO or placebo). Change in systolic blood pressure is calculated by comparing SBP at the end of each treatment phase to pre-treatment values. (NCT02038179)
Timeframe: 4 weeks (pre-treatment vs. post-treatment SBP)
| Intervention | mm Hg (Mean) |
|---|---|
| Allopurinol Phase | -1.39 |
| Placebo Phase | -1.06 |
"Outcome 1a. Document the rate of acceptance (quantitative) and reasons for acceptance/rejection (qualitative) in a randomized trial of trial of losartan for SCD patients with abnormal nocturnal blood pressures.~Outcome 1b. Identify the adherence rate to losartan during a randomized three year trial of losartan for SCD patients (n=40) with abnormal nocturnal blood pressure.~Outcome 1c. Determine the adherence rate to study procedures among participants enrolled in a three year trial of losartan for SCD patients (n=40) with abnormal nocturnal blood pressure." (NCT02373241)
Timeframe: 5 yrs
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Blood Pressure Management | 0 |
| Experimental Blood Pressure Management | 1 |
As a feasibility trial, the effect of losartan on lowering nocturnal hypertension will be monitored to identify the difference in nocturnal BP improvement between the two treatment arms, and within group standard deviation of BP (NCT02373241)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Blood Pressure Management | 1 |
We will prospectively evaluate the incidence of hypertension (Clinic BP in pts >5yrs and ABPM in pts >10 yrs) and role of blood and urine biomarkers (pts >5ys) among participants with HbSS or SB0 thalassemia (expected cohort n=200) over 5 yrs. We identified 20 participants (34%) with incident hypertension but randomized one to the study. The study was terminated as the eGFR was determined not to be a reliable endpoint in pediatric sickle cell. (NCT02373241)
Timeframe: 5 yrs
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Blood Pressure Management | 0 |
| Experimental Blood Pressure Management | 1 |
"A participant was considered to have a gout flare if the following criteria were met:~Participant-reported acute particular pain typical of a gout attack that was deemed by participant and/or investigator to require treatment and was treated with colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids, Participant experienced at least 3 or more of: 1) Joint swelling, 2) Redness, 3) Tenderness, 4) Pain, Participant experienced at least one or more of: 1) Rapid onset of pain, 2) Decreased range of motion, 3) Joint warmth, 4) Other symptoms similar to a prior gout flare." (NCT02139046)
Timeframe: Baseline to Month 3
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 20.7 |
| Febuxostat IR 40 mg | 21.0 |
| Febuxostat XR 40 mg | 22.8 |
| Febuxostat IR 80 mg | 27.2 |
| Febuxostat XR 80 mg | 26.6 |
(NCT02139046)
Timeframe: Month 3
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.3 |
| Febuxostat IR 40 mg | 15.7 |
| Febuxostat XR 40 mg | 25.9 |
| Febuxostat IR 80 mg | 42.6 |
| Febuxostat XR 80 mg | 50.1 |
(NCT02139046)
Timeframe: Month 3
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.6 |
| Febuxostat IR 40 mg | 40.3 |
| Febuxostat XR 40 mg | 48.2 |
| Febuxostat IR 80 mg | 57.7 |
| Febuxostat XR 80 mg | 61.1 |
Change from Baseline to Month 6 (or last observation carried forward)in number of swollen joints per subject. Values were inputed using last observation carried forward analysis for subjects who did not complete the studies. (NCT00325195)
Timeframe: Baseline and Final Visit (Month 6 or LOCF)
| Intervention | Swollen joints (Mean) |
|---|---|
| q2 Wks | -5.5 |
| q4 Wks | -5.1 |
| Placebo | -2.6 |
Change from Baseline to Month 6 (or last observation carried forward) in number of tender joints per participant (NCT00325195)
Timeframe: Baseline and Final Visit (Month 6 or LOCF)
| Intervention | Tender joints (Mean) |
|---|---|
| q2 Wks | -7.4 |
| q4 Wks | -6.1 |
| Placebo | -1.2 |
PUA Responder was defined as a participant who achieved and maintained plasma uric acid concentrations < 6 mg/dL for at least 80% of the time during months 3 and 6 combined. Participants who withdrew from the study before month 6 were considered non-responders. (NCT00325195)
Timeframe: Months 3 and 6
| Intervention | Participants (Number) |
|---|---|
| q2 Wks | 36 |
| q4 Wks | 29 |
| Placebo | 0 |
percentage of tophaceous subjects who demonstrated a complete resolution (100 % decrease in measured area or complete disappearance)of at least one tophus in the absence of other tophus progression or new tophi, as assessed by a blinded Central Reader using standardized digital photographs and image analysis software. (NCT00325195)
Timeframe: Baseline and Final Visit (6 months or LOCF)
| Intervention | Percent subjects with resolved tophus (Number) |
|---|---|
| q2 Wks | 40 |
| q4 Wks | 21 |
| Placebo | 7 |
Health Assessment Questionnaire(HAQ: VAS pain scale where 0 (no pain)-100 (severe pain); HAQ disability index (HAQ-DI) on a scale from 0(no disability) to 3 (completely disabled), and a unit change of > or =0.22 is considerd a mimimal clinically important difference(MCID). SF-36 Physical Component Summary Score (SF36-PCS), a composite score where 0 is the worst score and 100 the best possible, and where a change of > or =2.5 units in the PCS is considered a MCID. (NCT00325195)
Timeframe: Baseline to Final Visit (Month 6 or LOCF)
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| HAQ-VAS Pain | HAQ-DI | SF-36 PCS | |
| Placebo | 1.4 | 0.0 | -0.3 |
| q2 Wks | -11.4 | -0.22 | 4.4 |
| q4 Wks | -6.9 | -0.20 | 4.9 |
Percent of participants reporting a gout flare during Months 1-3 and Months 4-6. Denominator during the respective period was based upon number of participants during that period. (NCT00325195)
Timeframe: Months 1-3 and Months 4-6
| Intervention | Percent subjects reporting flares (Number) | |
|---|---|---|
| Months 1-3 | Months 4-6 | |
| Placebo | 54 | 67 |
| q2 Wks | 75 | 41 |
| q4 Wks | 81 | 56 |
(NCT00772382)
Timeframe: 52 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| MCI-196 | -1.18 |
(NCT00772382)
Timeframe: 52 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| At least 1 treatment-emergent AE | At least 1 drug-related treatment-emergent AE | At least 1 treatment-emergent serious AE | |
| MCI-196 | 109 | 50 | 63 |
Urine uric acid crystals were identified by polarized microscopy (Polarized light imaging Zeiss Axiovert 135; 0.3NA objective), and pictures were captured from each urine sample. UA crystals were defined dichotomously as being present or absent. (NCT02502071)
Timeframe: Day 1 (pre-therapy) and Day 2 (post-therapy)
| Intervention | participants (Number) | |
|---|---|---|
| Day 1 (pre-therapy) | Day 2 (post-therapy) | |
| Sodium Bicarbonate | 14 | 3 |
Urine uric acid were evaluated using a QuantiChrom UA kit assay (DIUA-250) with quantitative colorimetric UA determination at 590 nm (BioAssay System, California, USA). (NCT02502071)
Timeframe: Day 1 (pre-therapy) and Day 2 (post-therapy)
| Intervention | mg/dl (Geometric Mean) | |
|---|---|---|
| Day 1 (pre-therapy) | Day 2 (post-therapy) | |
| Sodium Bicarbonate | 23.81 | 22.30 |
84 reviews available for uric acid and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis.
Topics: Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney; Network Meta-Analysis; Renal Dialysis; | 2022 |
Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis.
Topics: Animals; Atherosclerosis; Comorbidity; Diabetes Mellitus, Type 2; Gout; Humans; Hypertension; Hyperu | 2021 |
Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease.
Topics: Atherosclerosis; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Male; Renal Insufficiency, | 2022 |
SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Renal Insuf | 2022 |
Serum uric acid level and all-cause and cardiovascular mortality in peritoneal dialysis patients: A systematic review and dose-response meta-analysis of cohort studies.
Topics: Cardiovascular Diseases; Humans; Mortality; Peritoneal Dialysis; Renal Insufficiency, Chronic; Uric | 2022 |
Uric Acid and Oxidative Stress-Relationship with Cardiovascular, Metabolic, and Renal Impairment.
Topics: Humans; Hyperuricemia; Oxidative Stress; Quality of Life; Renal Insufficiency, Chronic; Uric Acid | 2022 |
Research progress on related mechanisms of uric acid activating NLRP3 inflammasome in chronic kidney disease.
Topics: Humans; Hyperuricemia; Inflammasomes; Interleukin-1beta; NLR Family, Pyrin Domain-Containing 3 Prote | 2022 |
Update on Uric Acid and the Kidney.
Topics: Allopurinol; Female; Gout; Gout Suppressants; Humans; Kidney; Male; Parkinson Disease; Renal Insuffi | 2022 |
A systematic review and meta-analysis of the association between uric acid levels and chronic kidney disease.
Topics: Cohort Studies; Female; Humans; Incidence; Male; Renal Insufficiency, Chronic; Uric Acid | 2022 |
Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials.
Topics: Allopurinol; Bayes Theorem; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analy | 2022 |
Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights.
Topics: Endothelial Cells; Gout; Humans; Hyperuricemia; Inflammation; Renal Insufficiency, Chronic; Uric Aci | 2022 |
Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Hypertension; Hyperuricemia; Purines; Reactive O | 2022 |
Association of hyperuricemia with cardiovascular diseases: current evidence.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hyperuricemia; Mal | 2023 |
[Hyperuricemia and kidney damage in patients with cardiovascular disease: A review].
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney; | 2023 |
Serum uric acid levels in kidney transplant recipients: A cause for concern? A review of recent literature.
Topics: Humans; Hyperuricemia; Kidney Transplantation; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2023 |
Management of Patients with Gout and Kidney Disease: A Review of Available Therapies and Common Missteps.
Topics: Colchicine; Gout; Humans; Quality of Life; Renal Insufficiency, Chronic; Uric Acid | 2023 |
Dietary Antioxidant Supplements and Uric Acid in Chronic Kidney Disease: A Review.
Topics: Antioxidants; Biomarkers; Dietary Supplements; Humans; Hyperuricemia; Kidney; Oxidative Stress; Rena | 2019 |
Comorbidities in gout and hyperuricemia: causality or epiphenomena?
Topics: Cardiovascular Diseases; Comorbidity; Gout; Humans; Hyperuricemia; Prevalence; Renal Insufficiency, | 2020 |
Uric acid in CKD: has the jury come to the verdict?
Topics: Disease Progression; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Renal Insufficien | 2020 |
[Vascular dysfunction in Cardiorenal Syndrome type 4].
Topics: Aorta; Arginine; Autonomic Nervous System Diseases; Bone Diseases, Metabolic; Cardio-Renal Syndrome; | 2020 |
Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2020 |
The role of uric acid in inflammasome-mediated kidney injury.
Topics: Animals; Humans; Hyperuricemia; Inflammasomes; NLR Family, Pyrin Domain-Containing 3 Protein; Renal | 2020 |
Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease.
Topics: Humans; Hypertension; Hyperuricemia; Immunity; Renal Insufficiency, Chronic; Uric Acid | 2020 |
Uric acid and risk of diabetic kidney disease.
Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus; Diabetic Nephropathies; Humans; Renal Insufficienc | 2020 |
Renal effects of uric acid: hyperuricemia and hypouricemia.
Topics: Adolescent; Adult; Biomarkers; Child; Disease Progression; Female; Humans; Hyperuricemia; Kidney; Re | 2020 |
Hyperuricemia, the heart, and the kidneys - to treat or not to treat?
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Kidney; Myocardium; Renal Insufficiency, Chron | 2020 |
Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease.
Topics: Cardiovascular Diseases; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uri | 2021 |
Effect of Urate-Lowering Therapy on Cardiovascular and Kidney Outcomes: A Systematic Review and Meta-Analysis.
Topics: Blood Pressure; Cardiovascular Diseases; Disease Progression; Glomerular Filtration Rate; Gout Suppr | 2020 |
Role of comorbidities in heart failure prognosis Part 2: Chronic kidney disease, elevated serum uric acid.
Topics: Biomarkers; Comorbidity; Heart Disease Risk Factors; Heart Failure; Humans; Hyperuricemia; Prognosis | 2020 |
Managing hyperuricemia and gout in chronic kidney disease: a clinical conundrum.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2021 |
[Asymptomatic Hyperuricemia: Treatment Approaches According to the Risk of Cardiovascular and Renal Events].
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Uric Acid | 2021 |
Serum Uric Acid and Mortality in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Topics: Humans; Prognosis; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Factors; Uric Aci | 2021 |
Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease.
Topics: Disease Progression; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Tri | 2021 |
An update of genetics, co-morbidities and management of hyperuricaemia.
Topics: Cardiovascular Diseases; Comorbidity; Genome-Wide Association Study; Gout; Humans; Hyperuricemia; Re | 2021 |
Endogenous Fructose Metabolism Could Explain the Warburg Effect and the Protection of SGLT2 Inhibitors in Chronic Kidney Disease.
Topics: Animals; Cell Hypoxia; Diabetes Mellitus; Disease Progression; Fibrosis; Fructose; Glycolysis; Human | 2021 |
The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
Topics: Allopurinol; Blood Pressure; Enzyme Inhibitors; Febuxostat; Glomerular Filtration Rate; Gout Suppres | 2017 |
Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease.
Topics: Cardiovascular Diseases; Creatinine; Disease Progression; Glomerular Filtration Rate; Humans; Hyperu | 2017 |
[URATE AS A POTENTIAL RISK FACTOR OF CARDIOVASCULAR AND RENAL DISEASES].
Topics: Biomarkers; Cardiovascular Diseases; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Renal I | 2016 |
Cardiac and renal protective effects of urate-lowering therapy.
Topics: Cardiovascular Diseases; Gout; Gout Suppressants; Humans; Renal Insufficiency, Chronic; Uric Acid | 2018 |
Uric Acid: The Unknown Uremic Toxin.
Topics: Allopurinol; Febuxostat; Glomerular Filtration Rate; Gout Suppressants; Humans; Hypertension; Hyperu | 2018 |
Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
Topics: Allopurinol; Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily G, Membe | 2018 |
Does Altered Uric Acid Metabolism Contribute to Diabetic Kidney Disease Pathophysiology?
Topics: Diabetic Nephropathies; Disease Progression; Humans; Renal Insufficiency, Chronic; Uric Acid | 2018 |
Uric acid and progression of chronic kidney disease.
Topics: Age Factors; Allopurinol; Animals; Child; Diet Therapy; Disease Models, Animal; Disease Progression; | 2019 |
Serum uric acid levels and decreased estimated glomerular filtration rate in patients with type 2 diabetes: A cohort study and meta-analysis.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Down-Regulation; Female; Fo | 2018 |
Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways.
Topics: Benzhydryl Compounds; Blood Pressure; Canagliflozin; Disease Progression; Glomerular Filtration Rate | 2018 |
Effects of probiotic supplements on the progression of chronic kidney disease: A meta-analysis.
Topics: C-Reactive Protein; Creatinine; Dietary Supplements; Disease Progression; Gastrointestinal Microbiom | 2019 |
Uric acid and the cardio-renal effects of SGLT2 inhibitors.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gout; Heart; Humans; Hypoglycemic Agents; Kidney | 2019 |
Pharmacological urate-lowering approaches in chronic kidney disease.
Topics: Biological Products; Drug Discovery; Flavonoids; Humans; Renal Insufficiency, Chronic; Uric Acid | 2019 |
The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD.
Topics: Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2019 |
Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis.
Topics: Disease Progression; Febuxostat; Glomerular Filtration Rate; Gout Suppressants; Humans; Renal Insuff | 2019 |
Uric acid and chronic kidney disease: which is chasing which?
Topics: Animals; Humans; Rats; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2013 |
[Diabetes mellitus related common medical disorders: recent progress in diagnosis and treatment. Topics: I. Pathophysiology, diagnosis and treatment; 8. Asymptomatic hyperuricemia].
Topics: Cardiovascular Diseases; Diabetes Mellitus; Humans; Hyperuricemia; Metabolic Syndrome; Renal Insuffi | 2013 |
Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biom | 2013 |
[Hyperuricemia and the problem of chronic kidney disease].
Topics: Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2013 |
Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis.
Topics: Allopurinol; Disease Progression; Gout Suppressants; Humans; Renal Insufficiency, Chronic; Uric Acid | 2014 |
Sugar, uric acid, and the etiology of diabetes and obesity.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dietary Sucrose; Disease Models, Animal | 2013 |
Renoprotective strategies in lupus nephritis: beyond immunosuppression.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Disease Progression; Dyslipidemias; Humans; | 2013 |
Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
Topics: Animals; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ne | 2014 |
Serum uric acid and chronic kidney disease: the role of hypertension.
Topics: Aged; Aged, 80 and over; Cohort Studies; Female; Glomerular Filtration Rate; Humans; Hypertension; I | 2013 |
Serum uric acid and the risk of hypertension and chronic kidney disease.
Topics: Animals; Biomarkers; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hypertension; Hyperuricemi | 2014 |
The role of uric acid in kidney fibrosis: experimental evidences for the causal relationship.
Topics: Animals; Disease Models, Animal; Fibrosis; Humans; Inflammation; Renal Insufficiency, Chronic; Uric | 2014 |
Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies.
Topics: Biomarkers; Female; Humans; Incidence; Longitudinal Studies; Male; Middle Aged; Renal Insufficiency, | 2014 |
[Pleiotropic effects of sevelamer: a model of intestinal tract chelating agent].
Topics: Animals; Bone Remodeling; Cardiovascular Diseases; Chelating Agents; Chelation Therapy; Disease Mode | 2014 |
Hyperuricemia and chronic kidney disease: an enigma yet to be solved.
Topics: Humans; Hyperuricemia; Kidney; Kidney Transplantation; Renal Insufficiency, Chronic; Risk Factors; U | 2014 |
Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis.
Topics: Blood Pressure; Creatinine; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hyperur | 2014 |
Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis.
Topics: Cardiovascular Diseases; Creatinine; Disease Progression; Glomerular Filtration Rate; Gout Suppressa | 2015 |
[Uric acid, the kidney and cardiovascular mortality].
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Risk Factors; | 2015 |
Serum uric acid and the risk of cardiovascular and renal disease.
Topics: Cardiovascular Diseases; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Metabolic Syndrome; | 2015 |
Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy.
Topics: Blood Glucose; Diabetes Mellitus; Disease Progression; Glucose Transport Proteins, Facilitative; Hum | 2015 |
Uric acid in metabolic syndrome: From an innocent bystander to a central player.
Topics: Diabetes Mellitus; Humans; Hypertension; Hyperuricemia; Metabolic Syndrome; Non-alcoholic Fatty Live | 2016 |
Mesoamerican Nephropathy or Global Warming Nephropathy?
Topics: Adult; Agricultural Workers' Diseases; Aldehyde Reductase; Central America; Creatinine; Dehydration; | 2016 |
Time to target uric acid to retard CKD progression.
Topics: Animals; Biomarkers; Disease Progression; Genetic Predisposition to Disease; Gout Suppressants; Huma | 2017 |
Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis.
Topics: Adult; Aged; Female; Humans; Hyperuricemia; Male; Middle Aged; Renal Insufficiency, Chronic; Risk As | 2016 |
Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.
Topics: Disease Progression; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Renal Insufficiency, Ch | 2016 |
Major unanswered questions in the clinical gout field.
Topics: Allopurinol; Benzbromarone; Colchicine; Disease Progression; Febuxostat; Gout; Gout Suppressants; Hu | 2017 |
Uric Acid, Vascular Stiffness, and Chronic Kidney Disease: Is There a Link?
Topics: Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid; Vascular Stiffness | 2017 |
Allopurinol, an inhibitor of uric acid synthesis--can it be used for the treatment of metabolic syndrome and related disorders?
Topics: Allopurinol; Enzyme Inhibitors; Fatty Liver; Humans; Liver Diseases; Metabolic Syndrome; Mucositis; | 2009 |
Uric acid, CKD, and cardiovascular disease: confounders, culprits, and circles.
Topics: Animals; Cardiovascular Diseases; Confounding Factors, Epidemiologic; Glomerular Filtration Rate; Hu | 2010 |
Allopurinol, uric acid, and oxidative stress in cardiorenal disease.
Topics: Allopurinol; Animals; Cardiovascular Diseases; Enzyme Inhibitors; Humans; Hyperuricemia; Oxidative S | 2011 |
Uric acid: a starring role in the intricate scenario of metabolic syndrome with cardio-renal damage?
Topics: Biomarkers; Cardiovascular Diseases; Female; Humans; Hyperuricemia; Male; Metabolic Syndrome; Progno | 2012 |
Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations.
Topics: Asian People; Blood Urea Nitrogen; Cohort Studies; Creatinine; Genetic Predisposition to Disease; Ge | 2012 |
Uric acid as a target of therapy in CKD.
Topics: Disease Progression; Humans; Hyperuricemia; Predictive Value of Tests; Renal Insufficiency, Chronic; | 2013 |
Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor?
Topics: Animals; Biomarkers; Disease Progression; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Risk | 2012 |
Genetic disorders resulting in hyper- or hypouricemia.
Topics: Gout; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Renal Tubular Transport, Inborn Errors; U | 2012 |
51 trials available for uric acid and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study.
Topics: Creatinine; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Proteinuria; Renal I | 2022 |
Chronic Kidney Disease Awareness Campaign and Mobile Health Education to Improve Knowledge, Quality of Life, and Motivation for a Healthy Lifestyle Among Patients With Chronic Kidney Disease in Bangladesh: Randomized Controlled Trial.
Topics: Adult; Bangladesh; Health Education; Healthy Lifestyle; Humans; Motivation; Quality of Life; Renal I | 2022 |
Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus.
Topics: Diabetes Mellitus; Glomerular Filtration Rate; Humans; Renal Insufficiency, Chronic; Sodium-Glucose | 2023 |
Simiao pill inhibits epithelial mesenchymal transition in a mouse model of chronic hyperuricemic nephropathy by inhibiting NLRP3 inflammasome activation.
Topics: Actins; Animals; Cadherins; Caspases; Disease Models, Animal; Epithelial-Mesenchymal Transition; Feb | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2022 |
Cardiovascular and kidney outcomes of uric acid-lowering therapy in patients with different kidney functions: study protocol for a systematic review, pairwise and network meta-analysis.
Topics: Humans; Hyperuricemia; Kidney; Meta-Analysis as Topic; Network Meta-Analysis; Randomized Controlled | 2023 |
Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial.
Topics: Benzbromarone; Febuxostat; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Renal Insufficien | 2023 |
Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease.
Topics: C-Reactive Protein; Febuxostat; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Uric Ac | 2023 |
Plasma uric acid and renal haemodynamics in type 2 diabetes patients.
Topics: Aged; Biomarkers; Body Mass Index; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glome | 2020 |
Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Topics: Aged; Antioxidants; Biomarkers; Cross-Over Studies; Down-Regulation; Enzyme Inhibitors; Febuxostat; | 2020 |
α-lipoic acid in patients with autosomal dominant polycystic kidney disease.
Topics: Adult; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Blood Glucose; C-Reactive Protein; Caroti | 2020 |
The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Disease Progression; Female; Glomerular Filtration Rat | 2020 |
Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies | 2020 |
Effects of Allopurinol on the Progression of Chronic Kidney Disease.
Topics: Aged; Allopurinol; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Disease Progression; Double-Bl | 2020 |
A randomized, double-blind, positive-controlled, prospective, dose-response clinical study to evaluate the efficacy and tolerability of an aqueous extract of Terminalia bellerica in lowering uric acid and creatinine levels in chronic kidney disease subjec
Topics: Adult; Aged; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hype | 2020 |
Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial.
Topics: Adolescent; Adult; Allopurinol; Blood Pressure; C-Reactive Protein; Cross-Over Studies; Dilatation, | 2021 |
Cholesterol lowering treatment restores blood global DNA methylation in chronic kidney disease (CKD) patients.
Topics: 5-Methylcytosine; Aged; Allantoin; Biomarkers; Cholesterol; DNA Methylation; Down-Regulation; Ezetim | 2017 |
Allopurinol Against Progression of Chronic Kidney Disease.
Topics: Allopurinol; Biomarkers; Disease Progression; Female; Glomerular Filtration Rate; Gout Suppressants; | 2017 |
Metoprolol Increases Uric Acid and Risk of Gout in African Americans With Chronic Kidney Disease Attributed to Hypertension.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Antihypertensive Agents; Biomarkers; Black or African | 2017 |
The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial.
Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Female; Gout; Gout Suppressa | 2017 |
Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease.
Topics: Adolescent; Allopurinol; Child; Child, Preschool; Disease Progression; Female; Glomerular Filtration | 2018 |
Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
Topics: Aged; Alpha-Globulins; Benzbromarone; Febuxostat; Female; Glomerular Filtration Rate; Hemoglobins; H | 2018 |
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Colchicine; Cough; Creatinine; Delay | 2019 |
Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Allopurinol; Carotid Intima-Media Thickness; Chronic Kidney Disease-Mineral | 2018 |
Effects of acute fructose loading on levels of serum uric acid-a pilot study.
Topics: Aged; Analysis of Variance; Beverages; Diabetes Mellitus, Type 2; Female; Fructose; Humans; Hyperuri | 2019 |
Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients?
Topics: Aged; Endotoxemia; Endotoxins; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Human | 2019 |
[Effect of Different Walking Number on Inflammation and Nutrition in Patients with Chronic Kidney Disease].
Topics: C-Reactive Protein; Humans; Inflammation; Interleukin-6; Lipids; Nutritional Status; Parathyroid Hor | 2019 |
Chronic kidney disease in propionic acidemia.
Topics: Adolescent; Adult; Biomarkers; Child; Child, Preschool; Creatinine; Cross-Sectional Studies; Cystati | 2019 |
Chronic kidney disease in propionic acidemia.
Topics: Adolescent; Adult; Biomarkers; Child; Child, Preschool; Creatinine; Cross-Sectional Studies; Cystati | 2019 |
Chronic kidney disease in propionic acidemia.
Topics: Adolescent; Adult; Biomarkers; Child; Child, Preschool; Creatinine; Cross-Sectional Studies; Cystati | 2019 |
Chronic kidney disease in propionic acidemia.
Topics: Adolescent; Adult; Biomarkers; Child; Child, Preschool; Creatinine; Cross-Sectional Studies; Cystati | 2019 |
Which is a better treatment for hypertensive patients with diabetes: a combination of losartan and hydrochlorothiazide or a maximum dose of losartan?
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2013 |
Spironolactone increases serum uric acid levels in patients with chronic kidney disease.
Topics: Diuretics; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Renal | 2014 |
The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study.
Topics: Administration, Oral; Biomarkers; Clinical Protocols; Double-Blind Method; Drug Administration Sched | 2014 |
Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials.
Topics: Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Male; | 2014 |
Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.
Topics: Adiponectin; Aged; Albuminuria; Blood Pressure; Comorbidity; Creatinine; Double-Blind Method; Enzyme | 2014 |
Uric acid: association with rate of renal function decline and time until start of dialysis in incident pre-dialysis patients.
Topics: Biomarkers; Female; Humans; Hyperuricemia; Longitudinal Studies; Male; Middle Aged; Netherlands; Ren | 2014 |
Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension.
Topics: Adult; Aged; Creatinine; Diuretics; Drug Combinations; Drug Therapy, Combination; Female; Glomerular | 2014 |
The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients.
Topics: Acidosis; Adult; Aged; Allopurinol; Bicarbonates; Creatinine; Endothelium; Female; Gout Suppressants | 2015 |
Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement.
Topics: Aged; Allantoin; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Res | 2015 |
Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Creatinine; Disease Progression; Fema | 2015 |
Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
Topics: Aged; Albuminuria; Allopurinol; C-Reactive Protein; Cardiac Surgical Procedures; Cholesterol; Creati | 2015 |
Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Topics: Aged; Aged, 80 and over; Albuminuria; beta 2-Microglobulin; Enzyme Inhibitors; Fatty Acid-Binding Pr | 2015 |
The fructose tolerance test in patients with chronic kidney disease and metabolic syndrome in comparison to healthy controls.
Topics: Adult; Aged; Body Mass Index; Disease Progression; Female; Fructose; Glomerular Filtration Rate; Hum | 2015 |
Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Press | 2015 |
Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: A randomized controlled study.
Topics: Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Renal Insufficiency, Chron | 2015 |
[Effect of Individualized Low-protein Diet Intervention on Renal Function of Patients with Chronic Kidney Disease].
Topics: Blood Pressure; Calcium; Diet, Protein-Restricted; Humans; Renal Insufficiency, Chronic; Sodium; Uri | 2015 |
Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Dysl | 2015 |
Long-Term Evaluation of Colestilan in Chronic Kidney Disease Stage 5 Dialysis Patients with Hyperphosphataemia.
Topics: Adult; Aged; Bile Acids and Salts; Cholesterol, LDL; Diarrhea; Female; Glycated Hemoglobin; Hemodial | 2016 |
Benefits of Allopurinol Treatment on Blood Pressure and Renal Function in Patients with Early Stage of Chronic Kidney Disease.
Topics: Aged; Allopurinol; Biological Availability; Blood Pressure; Cardiovascular Diseases; Enzyme Inhibito | 2015 |
Synbiotic Supplementations for Azotemia in Patients With Chronic Kidney Disease: a Randomized Controlled Trial.
Topics: Aged; Azotemia; Blood Urea Nitrogen; Creatinine; Dietary Supplements; Double-Blind Method; Female; G | 2016 |
Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease.
Topics: Adult; Aged; Argentina; Canada; Creatinine; Dietary Supplements; Disease Progression; Double-Blind M | 2010 |
Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease.
Topics: Adult; Aged; Argentina; Canada; Creatinine; Dietary Supplements; Disease Progression; Double-Blind M | 2010 |
Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease.
Topics: Adult; Aged; Argentina; Canada; Creatinine; Dietary Supplements; Disease Progression; Double-Blind M | 2010 |
Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease.
Topics: Adult; Aged; Argentina; Canada; Creatinine; Dietary Supplements; Disease Progression; Double-Blind M | 2010 |
Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease.
Topics: Adult; Aged; Argentina; Canada; Creatinine; Dietary Supplements; Disease Progression; Double-Blind M | 2010 |
Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease.
Topics: Adult; Aged; Argentina; Canada; Creatinine; Dietary Supplements; Disease Progression; Double-Blind M | 2010 |
Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease.
Topics: Adult; Aged; Argentina; Canada; Creatinine; Dietary Supplements; Disease Progression; Double-Blind M | 2010 |
Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease.
Topics: Adult; Aged; Argentina; Canada; Creatinine; Dietary Supplements; Disease Progression; Double-Blind M | 2010 |
Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease.
Topics: Adult; Aged; Argentina; Canada; Creatinine; Dietary Supplements; Disease Progression; Double-Blind M | 2010 |
LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy.
Topics: Allantoin; Apolipoproteins B; Azetidines; Cholesterol, LDL; Drug Combinations; Dyslipidemias; Ezetim | 2012 |
Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
Topics: Adult; Aged; Allopurinol; Dose-Response Relationship, Drug; Drug Monitoring; Female; Glomerular Filt | 2008 |
348 other studies available for uric acid and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Pharmacologic inhibiting STAT3 delays the progression of kidney fibrosis in hyperuricemia-induced chronic kidney disease.
Topics: Aminosalicylic Acids; Animals; Benzenesulfonates; Disease Models, Animal; Fibrosis; Hyperuricemia; K | 2021 |
Association of uric acid and uric acid to creatinine ratio with chronic kidney disease in hypertensive patients.
Topics: Aged; Biomarkers; Creatinine; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Humans; H | 2021 |
Changes in serum uric acid levels as a predictor of future decline in renal function in older adults with type 2 diabetes.
Topics: Aged; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Gl | 2021 |
Effect of chronic kidney disease on the association between hyperuricemia and new-onset hypertension in the general Japanese population: ISSA-CKD study.
Topics: Glomerular Filtration Rate; Humans; Hypertension; Hyperuricemia; Japan; Renal Insufficiency, Chronic | 2021 |
Effects of Renal Function on Urinary Excretion and Serum Concentration of Uric Acid in Patients Treated with Febuxostat for Chronic Kidney Disease.
Topics: Febuxostat; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; | 2022 |
Untreated Chronic Gout.
Topics: Aged; Arthrocentesis; Chronic Disease; Gout; Gout Suppressants; Hand; Humans; Male; Metatarsophalang | 2021 |
Clinical Predictors and Long-term Impact of Acute Kidney Injury on Progression of Diabetic Kidney Disease in Chinese Patients With Type 2 Diabetes.
Topics: Acute Kidney Injury; Aged; Asian People; China; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic | 2022 |
Hyperuricemia is associated with secondary hyperparathyroidism in patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Calcium; Cholecalciferol; Female; Furosemide; Humans; H | 2022 |
Development of chronic kidney disease influenced by serum urate and body mass index based on young-to-middle-aged Japanese men: a propensity score-matched cohort study.
Topics: Adult; Body Mass Index; Cohort Studies; Glomerular Filtration Rate; Humans; Japan; Male; Middle Aged | 2022 |
Colchicine use and the risk of CKD progression: a multicentre nested case-control study.
Topics: Case-Control Studies; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal | 2022 |
Chronic Kidney Disease and Left Ventricular Hypertrophy. Potent Modifiers of the Prognostic Impact of Circadian Blood Pressure Changes.
Topics: Bayes Theorem; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Female; Huma | 2022 |
[Management of hyperuricemia in chronic kidney disease].
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2022 |
Genetic Risk Score for Plasma Uric Acid Levels Is Associated With Early Rapid Kidney Function Decline in Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Disease Progression; Genome-Wide Association Study; Glomerular Filtration | 2022 |
The Negative Association Between NAFLD Severity and CKD in a Non-Diabetic Gouty Population.
Topics: Cross-Sectional Studies; Female; Gout; Humans; Male; Non-alcoholic Fatty Liver Disease; Renal Insuff | 2022 |
Association and mediation analyses among multiple metals exposure, plasma folate, and community-based impaired estimated glomerular filtration rate in central Taiwan.
Topics: Adult; Arsenic; Cadmium; Cross-Sectional Studies; Female; Folic Acid; Glomerular Filtration Rate; Hu | 2022 |
Pararenal Fat and Renal Dysfunction in Patients without Significant Cardiovascular Disease.
Topics: Aged; Cardiovascular Diseases; Glomerular Filtration Rate; Humans; Middle Aged; Obesity; Overweight; | 2022 |
Association of neutrophil-to-lymphocyte ratio with renal impairment among patients with acute gouty arthritis.
Topics: Adult; Arthritis, Gouty; Biomarkers; C-Reactive Protein; Creatinine; Female; Humans; Lipoproteins, H | 2022 |
Developing and validating a prognostic prediction model for patients with chronic kidney disease stages 3-5 based on disease conditions and intervention methods: a retrospective cohort study in China.
Topics: Cohort Studies; Humans; Prognosis; Renal Insufficiency, Chronic; Retrospective Studies; Uric Acid | 2022 |
Evaluation of renal microperfusion in hyperuricemic nephropathy by contrast-enhanced ultrasound imaging.
Topics: Animals; Contrast Media; Hyperuricemia; Kidney; Rats; Renal Insufficiency, Chronic; Ultrasonography; | 2022 |
Electrochemical sensing of the secretion of indoxyl sulfate in a rat intestinal loop using a self-assembled monolayer-modified gold bead electrode.
Topics: Animals; Electrodes; Gold; Humans; Indican; Rats; Renal Insufficiency, Chronic; Uric Acid | 2022 |
Longitudinal changes in uric acid concentration and their relationship with chronic kidney disease progression in children and adolescents.
Topics: Adolescent; Child; Disease Progression; Glomerular Filtration Rate; Humans; Longitudinal Studies; Re | 2023 |
Association of Uric Acid-Lowering Therapy With Incident Chronic Kidney Disease.
Topics: Albuminuria; Cohort Studies; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Insuf | 2022 |
POSSIBILITIES OF RENOPROTECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERURICEMIA.
Topics: Allopurinol; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Tre | 2022 |
Association between Dietary Fat Intake and Hyperuricemia in Men with Chronic Kidney Disease.
Topics: Dietary Fats; Fatty Acids; Glomerular Filtration Rate; Humans; Hyperuricemia; Male; Middle Aged; Ren | 2022 |
A geniposide-phospholipid complex ameliorates posthyperuricemia chronic kidney disease induced by inflammatory reactions and oxidative stress.
Topics: Animals; Inflammation; Iridoids; Kelch-Like ECH-Associated Protein 1; Mice; NF-E2-Related Factor 2; | 2022 |
Local genetic covariance between serum urate and kidney function estimated with Bayesian multitrait models.
Topics: Bayes Theorem; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Hyperuricem | 2022 |
The effect of trajectory of serum uric acid on survival and renal outcomes in patients with stage 3 chronic kidney disease.
Topics: Humans; Kidney; Proportional Hazards Models; Renal Dialysis; Renal Insufficiency, Chronic; Risk Fact | 2022 |
Chlorogenic Acid Prevents Hyperuricemia Nephropathy via Regulating TMAO-Related Gut Microbes and Inhibiting the PI3K/AKT/mTOR Pathway.
Topics: Animals; Chlorogenic Acid; Fibrosis; Gastrointestinal Microbiome; Hyperuricemia; Mammals; Methylamin | 2022 |
A follow-up study to explore factors associated with rapid kidney function decline and new-onset kidney disease among Chinese elderly population.
Topics: Aged; China; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney; Male; Renal Insu | 2022 |
Demographic and clinical profile of black patients with chronic kidney disease attending a tertiary hospital in Johannesburg, South Africa.
Topics: Acidosis; Aged; Allopurinol; Anemia; Bicarbonates; Cross-Sectional Studies; Diabetes Mellitus; Doxaz | 2022 |
Sex Difference in the Associations among Hyperuricemia with New-Onset Chronic Kidney Disease in a Large Taiwanese Population Follow-Up Study.
Topics: Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hyperuricemia; Longitudinal Studies; | 2022 |
Intestinal Hyperuricemia as a Driving Mechanism for CKD.
Topics: Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2023 |
Association between Plasma Xanthine Oxidoreductase Activity and the Renal Function in a General Japanese Population: The Tohoku Medical Megabank Community-Based Cohort Study.
Topics: Aged; Cholesterol; Cohort Studies; East Asian People; Female; Glycated Hemoglobin; Humans; Kidney; L | 2022 |
Relation between obesity-related comorbidities and kidney function estimation in children.
Topics: Adolescent; Biomarkers; Child; Creatinine; Cross-Sectional Studies; Female; Glomerular Filtration Ra | 2023 |
Relation between obesity-related comorbidities and kidney function estimation in children.
Topics: Adolescent; Biomarkers; Child; Creatinine; Cross-Sectional Studies; Female; Glomerular Filtration Ra | 2023 |
Relation between obesity-related comorbidities and kidney function estimation in children.
Topics: Adolescent; Biomarkers; Child; Creatinine; Cross-Sectional Studies; Female; Glomerular Filtration Ra | 2023 |
Relation between obesity-related comorbidities and kidney function estimation in children.
Topics: Adolescent; Biomarkers; Child; Creatinine; Cross-Sectional Studies; Female; Glomerular Filtration Ra | 2023 |
Relation between obesity-related comorbidities and kidney function estimation in children.
Topics: Adolescent; Biomarkers; Child; Creatinine; Cross-Sectional Studies; Female; Glomerular Filtration Ra | 2023 |
Relation between obesity-related comorbidities and kidney function estimation in children.
Topics: Adolescent; Biomarkers; Child; Creatinine; Cross-Sectional Studies; Female; Glomerular Filtration Ra | 2023 |
Relation between obesity-related comorbidities and kidney function estimation in children.
Topics: Adolescent; Biomarkers; Child; Creatinine; Cross-Sectional Studies; Female; Glomerular Filtration Ra | 2023 |
Relation between obesity-related comorbidities and kidney function estimation in children.
Topics: Adolescent; Biomarkers; Child; Creatinine; Cross-Sectional Studies; Female; Glomerular Filtration Ra | 2023 |
Relation between obesity-related comorbidities and kidney function estimation in children.
Topics: Adolescent; Biomarkers; Child; Creatinine; Cross-Sectional Studies; Female; Glomerular Filtration Ra | 2023 |
A Retrospective Study of the Perioperative Period Management of Joint Arthroplasty in Patients with Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Creatinine; Hemoglobins; Humans; Middle Age | 2023 |
A Retrospective Study of the Perioperative Period Management of Joint Arthroplasty in Patients with Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Creatinine; Hemoglobins; Humans; Middle Age | 2023 |
A Retrospective Study of the Perioperative Period Management of Joint Arthroplasty in Patients with Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Creatinine; Hemoglobins; Humans; Middle Age | 2023 |
A Retrospective Study of the Perioperative Period Management of Joint Arthroplasty in Patients with Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Creatinine; Hemoglobins; Humans; Middle Age | 2023 |
Retrospective case-control study on screening risk factors of antibiotic-associated encephalopathy in patients with chronic kidney disease.
Topics: Albumins; Anti-Bacterial Agents; Brain Diseases; Case-Control Studies; Humans; Phosphorus; Renal Ins | 2022 |
Retrospective case-control study on screening risk factors of antibiotic-associated encephalopathy in patients with chronic kidney disease.
Topics: Albumins; Anti-Bacterial Agents; Brain Diseases; Case-Control Studies; Humans; Phosphorus; Renal Ins | 2022 |
Retrospective case-control study on screening risk factors of antibiotic-associated encephalopathy in patients with chronic kidney disease.
Topics: Albumins; Anti-Bacterial Agents; Brain Diseases; Case-Control Studies; Humans; Phosphorus; Renal Ins | 2022 |
Retrospective case-control study on screening risk factors of antibiotic-associated encephalopathy in patients with chronic kidney disease.
Topics: Albumins; Anti-Bacterial Agents; Brain Diseases; Case-Control Studies; Humans; Phosphorus; Renal Ins | 2022 |
Nontraditional Risk Factors for Progression Through Chronic Kidney Disease Risk Categories: The Coronary Artery Risk Development in Young Adults Study.
Topics: Adult; Albuminuria; Biomarkers; Coronary Vessels; Disease Progression; Glomerular Filtration Rate; H | 2023 |
Impact of Pulmonary Hypertension on Renal Functions in Obstructive Sleep Apnea Syndrome.
Topics: Female; Glomerular Filtration Rate; Humans; Hypertension, Pulmonary; Kidney; Male; Renal Insufficien | 2023 |
Association between serum uric acid/HDL-cholesterol ratio and chronic kidney disease: a cross-sectional study based on a health check-up population.
Topics: Cholesterol, HDL; Cross-Sectional Studies; Glomerular Filtration Rate; Humans; Renal Insufficiency, | 2022 |
Elevated serum leptin levels are associated with lower renal function among middle-aged and elderly adults in Taiwan, a community-based, cross-sectional study.
Topics: Adult; Aged; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Kidney; Lepti | 2022 |
Reduced type 3 innate lymphoid cells related to worsening kidney function in renal dysfunction.
Topics: Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunity, Innate; Kidney; Lymphocytes; Ren | 2023 |
Synergetic Association between Anemia and Hyperuricemia on New-Onset Chronic Kidney Disease in a Large Taiwanese Population Follow-Up Study.
Topics: Anemia; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hyperuricemia; Longitudinal S | 2023 |
The Bidirectional Relationship between Chronic Kidney Disease and Hyperuricemia: Evidence from a Population-Based Prospective Cohort Study.
Topics: Follow-Up Studies; Glomerular Filtration Rate; Humans; Hyperuricemia; Prospective Studies; Renal Ins | 2023 |
Lower range of serum uric acid level increases risk of rapid decline of kidney function in young and middle-aged adults: the Yuport Medical Checkup Center Study.
Topics: Aged; Glomerular Filtration Rate; Humans; Kidney; Kidney Function Tests; Middle Aged; Renal Insuffic | 2023 |
Association of MPPED2 gene variant rs10767873 with kidney function and risk of cardiovascular disease in patients with hypertension.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Glomerular Filtration Rate; Humans; Hypertension; | 2023 |
Serum Urate and Risk of Chronic Kidney Disease: A Mendelian Randomization Study Using Taiwan Biobank.
Topics: Biological Specimen Banks; Cohort Studies; Humans; Mendelian Randomization Analysis; Prospective Stu | 2023 |
Longitudinal uric acid has nonlinear association with kidney failure and mortality in chronic kidney disease.
Topics: Aged; Female; Humans; Kidney Failure, Chronic; Male; Proportional Hazards Models; Renal Insufficienc | 2023 |
Pattern of gout and its association with chronic kidney disease in Maiduguri, northeastern Nigeria.
Topics: Creatinine; Female; Glomerular Filtration Rate; Gout; Humans; Male; Nigeria; Renal Insufficiency, Ch | 2023 |
Golden mean of serum uric acid level on the risk of kidney function decline.
Topics: Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Risk Factor | 2023 |
The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD.
Topics: Aged; Benzhydryl Compounds; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Renal Insu | 2023 |
Prevalence and clinical association of hyperechoic crystal deposits on ultrasonography in patients with chronic kidney disease: a cross-sectional study from a single center.
Topics: Cross-Sectional Studies; Female; Glomerular Filtration Rate; Gout; Humans; Hyperuricemia; Male; Prev | 2023 |
Roflumilast alleviates adenine-induced chronic kidney disease by regulating inflammatory biomarkers.
Topics: Adenine; Animals; Antioxidants; Biomarkers; Calcium; Creatinine; Kidney; Magnesium Chloride; Male; R | 2023 |
Sex differences in the association between urate metabolism and kidney outcomes in patients with chronic kidney disease.
Topics: Female; Humans; Kidney; Kidney Failure, Chronic; Male; Prospective Studies; Renal Insufficiency, Chr | 2023 |
Comparison of benzbromarone and allopurinol on the risk of chronic kidney disease in people with asymptomatic hyperuricemia.
Topics: Allopurinol; Benzbromarone; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Ren | 2023 |
Association of uric acid with the decline in estimated glomerular filtration rate in middle-aged and elderly populations: evidence based on the China Health and Retirement Longitudinal Study.
Topics: Aged; China; Glomerular Filtration Rate; Humans; Longitudinal Studies; Middle Aged; Renal Insufficie | 2023 |
GLUT9 as a potential drug target for chronic kidney disease: Drug target validation by a Mendelian randomization study.
Topics: Glucose Transport Proteins, Facilitative; Gout; Humans; Mendelian Randomization Analysis; Organic An | 2023 |
Sudden Rise of Uric Acid Levels in a Patient with Chronic Kidney Disease: Is a Common Food to Blame?
Topics: Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2022 |
Fucoidan from
Topics: Animals; Fibrosis; Hyperuricemia; Janus Kinase 2; Kidney; Laminaria; Mice; Polysaccharides; Renal In | 2023 |
Serum uric acid is associated with chronic kidney disease in elderly Chinese patients with diabetes.
Topics: Aged; Cholesterol, HDL; Diabetes Mellitus; East Asian People; Female; Humans; Hyperuricemia; Male; R | 2023 |
Increased risk of chronic kidney disease in uric acid stone formers with high neutrophil-to-lymphocyte ratio.
Topics: Calcium; Humans; Inflammation; Kidney Calculi; Lymphocytes; Neutrophils; Renal Insufficiency, Chroni | 2023 |
Serum uric acid is related to liver and kidney disease and 12-year mortality risk after myocardial infarction.
Topics: Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Myocardial Infarction; Non-alcoholic Fat | 2023 |
Remote effects of kidney drug transporter OAT1 on gut microbiome composition and urate homeostasis.
Topics: Animals; Gastrointestinal Microbiome; Homeostasis; Kidney; Membrane Transport Proteins; Mice; Renal | 2023 |
Chronic Kidney Disease and Its Clinical Correlates in a Rural Community in Southwestern Nigeria.
Topics: Adult; Female; Glomerular Filtration Rate; Humans; Male; Nigeria; Prevalence; Renal Insufficiency; R | 2022 |
Uric acid regulates NLRP3/IL-1β signaling pathway and further induces vascular endothelial cells injury in early CKD through ROS activation and K
Topics: Animals; Creatinine; Disease Models, Animal; Endothelium, Vascular; Human Umbilical Vein Endothelial | 2019 |
The challenges of managing gout in primary care: Results of a best-practice audit.
Topics: Aged; Allopurinol; Clinical Audit; Clinical Chemistry Tests; Clinical Protocols; Colchicine; Comorbi | 2019 |
Association between serum uric acid and chronic kidney disease in patients with hypertension: A multicenter nationwide cross-sectional study.
Topics: Aged; Arthritis, Gouty; Cross-Sectional Studies; Female; Humans; Hypertension; Male; Middle Aged; Pr | 2019 |
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Topics: Allopurinol; Benzbromarone; Disease Progression; Febuxostat; Female; Glomerular Filtration Rate; Gou | 2019 |
Threshold Effects of Serum Uric Acid on Chronic Kidney Disease in US Women without Hypertension and Diabetes: A Cross-Sectional Study.
Topics: Adult; Cross-Sectional Studies; Female; Humans; Middle Aged; Renal Insufficiency, Chronic; United St | 2019 |
Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
Topics: Adult; Allopurinol; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chron | 2020 |
Genetically Elevated Serum Uric Acid and Renal Function in an Apparently Healthy Population.
Topics: Adult; Aged; Female; Genotype; Glomerular Filtration Rate; Humans; Kidney; Male; Mendelian Randomiza | 2020 |
Association of uric acid in serum and urine with subclinical renal damage: Hanzhong Adolescent Hypertension Study.
Topics: Adolescent; Adult; Biomarkers; Child; China; Cohort Studies; Creatinine; Cross-Sectional Studies; Di | 2019 |
Burden and management of gout in a multi-ethnic Asian cohort.
Topics: Adult; Aged; Allopurinol; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus; Dyslipidemias; Em | 2020 |
Effect of Low-Protein Diet and Inulin on Microbiota and Clinical Parameters in Patients with Chronic Kidney Disease.
Topics: C-Reactive Protein; Controlled Before-After Studies; Diet, Protein-Restricted; Feces; Gastrointestin | 2019 |
Interactive association of baseline and changes in serum uric acid on renal dysfunction among community-dwelling persons.
Topics: Aged; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Independent Living; Kidney; Male; M | 2020 |
Prognostic Value of Serum Uric Acid in Hospitalized Heart Failure Patients With Preserved Ejection Fraction (from the Japanese Nationwide Multicenter Registry).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin- | 2020 |
Unfavorable Reduction in the Ratio of Endothelin B to A Receptors in Experimental 5/6 Nephrectomy and Adenine Models of Chronic Renal Insufficiency.
Topics: Adenine; Animals; Calcium; Disease Models, Animal; Gene Expression Regulation; Kidney Cortex; Male; | 2020 |
The association of renal tubular inflammatory and injury markers with uric acid excretion in chronic kidney disease patients.
Topics: Acute Kidney Injury; Adult; Aged; Biomarkers; Correlation of Data; Cross-Sectional Studies; Female; | 2020 |
Impact of Uric Acid on Hypertension Occurrence and Target Organ Damage: Insights From the STANISLAS Cohort With a 20-Year Follow-up.
Topics: Adult; Aged; Albuminuria; Blood Pressure; Cohort Studies; Creatinine; Female; France; Glomerular Fil | 2020 |
Association of Impaired Renal Function With Changes in Urinary Mineral Excretion and Stone Composition.
Topics: Adult; Calcium; Calcium Oxalate; Calcium Phosphates; Citric Acid; Creatinine; Diabetes Mellitus; Dis | 2020 |
The case for evidence-based medicine for the association between hyperuricaemia and CKD.
Topics: Evidence-Based Medicine; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2020 |
Reply to 'The case for evidence-based medicine for the association between hyperuricaemia and CKD'.
Topics: Evidence-Based Medicine; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2020 |
Urate-Lowering Therapy and Chronic Kidney Disease Progression.
Topics: Allopurinol; Diabetes Mellitus, Type 1; Disease Progression; Gout Suppressants; Humans; Renal Insuff | 2020 |
A formula predicting the effective dose of febuxostat in chronic kidney disease patients with asymptomatic hyperuricemia based on a retrospective study and a validation cohort
.
Topics: Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Insuffi | 2020 |
Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Febuxostat; Female; Follow-Up Studies; Glomeru | 2020 |
Higher baseline uric acid concentration is associated with non-attainment of optimal blood pressure.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus; Female; Humans; Hypertension; Logi | 2020 |
Association between relative fat mass, uric acid, and insulin resistance in children with chronic kidney disease.
Topics: Adolescent; Body Mass Index; Cross-Sectional Studies; Humans; Hyperuricemia; Insulin Resistance; Obe | 2021 |
Whole genome sequence analysis identifies a PAX2 mutation to establish a correct diagnosis for a syndromic form of hyperuricemia.
Topics: Adult; Creatinine; DNA Mutational Analysis; Female; Heterozygote; Humans; Hyperparathyroidism, Secon | 2020 |
U-shaped relationship between serum uric acid level and decline in renal function during a 10-year period in female subjects: BOREAS-CKD2.
Topics: Adult; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Renal I | 2021 |
Kinetics of Serum Carnitine Fractions in Patients with Chronic Kidney Disease Not on Dialysis.
Topics: Adult; Aged; Amino Acids; Carnitine; Female; Glomerular Filtration Rate; Humans; Kidney; Kidney Fail | 2021 |
Research in brief: Serum urate reduction and its effect on the progression of chronic kidney disease.
Topics: Allopurinol; Diabetes Mellitus, Type 1; Disease Progression; Gout; Humans; Kidney; Renal Insufficien | 2020 |
Effects of repeated increasing doses of cisplatin as models of acute kidney injury and chronic kidney disease in rats.
Topics: Acute Kidney Injury; Albuminuria; Animals; Antineoplastic Agents; Caspase 3; Cisplatin; Creatinine; | 2021 |
Hyperuricemia in renal disease patients.
Topics: Disease Progression; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2020 |
Association Between Serum Uric Acid and Depression in Patients with Chronic Kidney Disease not Requiring Kidney Dialysis: Cross-Sectional and Longitudinal Analyses.
Topics: Adult; Aged; Cross-Sectional Studies; Depression; Female; Follow-Up Studies; Humans; Longitudinal St | 2020 |
Risk factors for subclinical renal damage and its progression: Hanzhong Adolescent Hypertension Study.
Topics: Adolescent; China; Cross-Sectional Studies; Disease Progression; Glomerular Filtration Rate; Humans; | 2021 |
Uric Acid and CKD Progression Matures with Lessons for CKD Risk Factor Discovery.
Topics: Disease Progression; Humans; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2021 |
Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Databases, Factual; Electrolyte | 2020 |
Allopurinol and Chronic Kidney Disease.
Topics: Allopurinol; Diabetes Mellitus, Type 1; Gout Suppressants; Humans; Renal Insufficiency, Chronic; Uri | 2020 |
Allopurinol and Chronic Kidney Disease.
Topics: Allopurinol; Diabetes Mellitus, Type 1; Gout Suppressants; Humans; Renal Insufficiency, Chronic; Uri | 2020 |
Allopurinol and Chronic Kidney Disease.
Topics: Allopurinol; Diabetes Mellitus, Type 1; Gout Suppressants; Humans; Renal Insufficiency, Chronic; Uri | 2020 |
Allopurinol and Chronic Kidney Disease.
Topics: Allopurinol; Diabetes Mellitus, Type 1; Gout Suppressants; Humans; Renal Insufficiency, Chronic; Uri | 2020 |
Allopurinol and Chronic Kidney Disease.
Topics: Allopurinol; Diabetes Mellitus, Type 1; Gout Suppressants; Humans; Renal Insufficiency, Chronic; Uri | 2020 |
Risk Factors for Chronic Kidney Disease in Newly Diagnosed Hypertensive Subjects in Southeast Nigeria.
Topics: Cross-Sectional Studies; Humans; Hypertension; Nigeria; Prevalence; Renal Insufficiency, Chronic; Ri | 2020 |
Association between serum urate, gout and comorbidities: a case-control study using data from the UK Biobank.
Topics: Adult; Aged; Cardiovascular Diseases; Case-Control Studies; Comorbidity; Diabetes Mellitus; Female; | 2021 |
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
Topics: Allopurinol; Cardiovascular Diseases; Endothelial Cells; Febuxostat; Gout; Gout Suppressants; Humans | 2021 |
Hyperuricemia and progression of chronic kidney disease: to treat or not to treat?
Topics: Allopurinol; Diabetes Mellitus, Type 1; Gout Suppressants; Humans; Hyperuricemia; Kidney; Renal Insu | 2021 |
The additive effects of kidney dysfunction on left ventricular function and strain in type 2 diabetes mellitus patients verified by cardiac magnetic resonance imaging.
Topics: Adult; Aged; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Disease Progression; Femal | 2021 |
Inter-relationship of risk factors and pathways associated with chronic kidney disease in patients with type 2 diabetes mellitus: a structural equation modelling analysis.
Topics: Adult; Aged; Biomarkers; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Ra | 2021 |
The effect of baseline serum uric acid on chronic kidney disease in normotensive, normoglycemic, and non-obese individuals: A health checkup cohort study.
Topics: Adult; Aged; Blood Pressure; Body Mass Index; Cohort Studies; Diabetes Mellitus; Female; Glomerular | 2021 |
Urate Lowering With Combination Therapy in CKD: Reason for Optimism or Einstein's Definition of Insanity?
Topics: Albuminuria; Diabetes Mellitus, Type 2; Febuxostat; Humans; Naphthalenes; Propionates; Pyridines; Re | 2021 |
Usefulness of Extra Virgin Olive Oil Minor Polar Compounds in the Management of Chronic Kidney Disease Patients.
Topics: Aged; Aged, 80 and over; Albuminuria; Aldehydes; Antioxidants; Azotemia; Biomarkers; Body Compositio | 2021 |
Association between serum uric acid and new onset and progression of chronic kidney disease in a Japanese general population: Iki epidemiological study of atherosclerosis and chronic kidney disease.
Topics: Aged; Asian People; Disease Progression; Female; Humans; Male; Middle Aged; Proteinuria; Renal Insuf | 2021 |
Allopurinol and Renal Outcomes in Adults With and Without Type 2 Diabetes: A Retrospective, Population-Based Cohort Study and Propensity Score Analysis.
Topics: Aged; Aged, 80 and over; Allopurinol; Diabetes Mellitus, Type 2; Female; Humans; Male; Propensity Sc | 2021 |
Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project.
Topics: Adult; Aged; Albuminuria; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Male; M | 2022 |
Different clinical impact of hyperuricemia according to etiologies of chronic kidney disease: Gonryo Study.
Topics: Adult; Aged; Allopurinol; Antimetabolites; Female; Glomerular Filtration Rate; Humans; Hyperuricemia | 2021 |
Serum Myeloperoxidase, Uric Acid, and the Risk of Atrial Fibrillation in Chronic Kidney Disease.
Topics: Adult; Aged; Atrial Fibrillation; Female; Humans; Incidence; Male; Middle Aged; Peroxidase; Renal In | 2021 |
Association between serum uric acid and left ventricular hypertrophy/left ventricular diastolic dysfunction in patients with chronic kidney disease.
Topics: Biomarkers; Cross-Sectional Studies; Echocardiography; Female; Humans; Hypertrophy, Left Ventricular | 2021 |
Alcohol consumption and serum uric acid are synergistically associated with renal dysfunction among community-dwelling persons.
Topics: Aged; Alcohol Drinking; Cross-Sectional Studies; Female; Follow-Up Studies; Glomerular Filtration Ra | 2021 |
A retrospective study on sex difference in patients with urolithiasis: who is more vulnerable to chronic kidney disease?
Topics: Female; Humans; Hypertension; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies | 2021 |
The Effects of Cardiometabolic Factors on the Association Between Serum Uric Acid and Chronic Kidney Disease in Chinese Middle-Aged and Older Population: A Mediation Analysis.
Topics: Biomarkers; Blood Glucose; Body Mass Index; Dyslipidemias; Female; Follow-Up Studies; Glomerular Fil | 2021 |
Detailed association between serum uric acid levels and the incidence of chronic kidney disease stratified by sex in middle-aged adults.
Topics: Adult; Aged; Female; Glomerular Filtration Rate; Humans; Incidence; Male; Middle Aged; Renal Insuffi | 2021 |
Hyperuricemia after orthotopic liver transplantation: divergent associations with progression of renal disease, incident end-stage renal disease, and mortality.
Topics: Adult; Creatinine; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; I | 2017 |
Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Child | 2017 |
Identification of C21orf59 and ATG2A as novel determinants of renal function-related traits in Japanese by exome-wide association studies.
Topics: Aged; Autophagy-Related Proteins; Creatinine; Exome; Female; Genetic Predisposition to Disease; Geno | 2017 |
Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes.
Topics: Aged; Blood Glucose Self-Monitoring; Blood Pressure; Blood Pressure Determination; Databases, Factua | 2017 |
Management of Gout and Hyperuricemia in CKD.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Diet Therapy; Disease Management; Febuxostat; | 2017 |
Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Comorbidity; Febuxostat; Female; Follo | 2017 |
Interactive association of serum uric acid and total bilirubin with renal dysfunction among community-dwelling subjects.
Topics: Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Antihypertensive Agents; Bilirubin; Body Mas | 2017 |
Oral uricase eliminates blood uric acid in the hyperuricemic pig model.
Topics: Administration, Oral; Animals; Disease Models, Animal; Hyperuricemia; Intestinal Mucosa; Male; Nephr | 2017 |
Effects of topiroxostat in hyperuricemic patients with chronic kidney disease.
Topics: Aged; Biomarkers; Blood Pressure; Enzyme Inhibitors; Female; Humans; Hypertension; Hyperuricemia; In | 2018 |
Relationship between uric acid levels and risk of chronic kidney disease in a retrospective cohort of Brazilian workers.
Topics: Brazil; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Male; Middle | 2017 |
Cross-linked Polyelectrolyte and Its Function in Adsorption of Fluid and Excess Nitrogen Waste Products: an Experimental Study on Dialysate Effluent Fluid.
Topics: Adsorption; Adult; Aged; Aged, 80 and over; Creatinine; Female; Hemodialysis Solutions; Humans; Kidn | 2017 |
Augmented Association Between Blood Pressure and Proteinuria in Hyperuricemic Patients With Nonnephrotic Chronic Kidney Disease.
Topics: Adult; Antihypertensive Agents; Biomarkers; Blood Pressure; Cross-Sectional Studies; Female; Glomeru | 2018 |
Accumulation of uraemic toxins is reflected only partially by estimated GFR in paediatric patients with chronic kidney disease.
Topics: Adolescent; Arginine; Biomarkers; Child; Child, Preschool; Female; Glomerular Filtration Rate; Human | 2018 |
The problem of cardio-renal diseases in patients with gout.
Topics: Cardiovascular Diseases; Gout; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Risk Factors; Ur | 2017 |
Fasting sugar, blood pressure, and uric acid are factors related to positive proteinuria and an impaired eGFR.
Topics: Aged; Blood Glucose; Blood Pressure; Body Mass Index; Fasting; Female; Glomerular Filtration Rate; H | 2017 |
The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: A primary care cohort study.
Topics: Aged; Aged, 80 and over; Albuminuria; C-Reactive Protein; Cohort Studies; Cost Savings; Cost-Benefit | 2017 |
Spontaneous variability of pre-dialysis concentrations of uremic toxins over time in stable hemodialysis patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Arginine; beta 2-Microglobulin; Creatinine; Female; H | 2017 |
Clinical features and CKD-related quality of life in patients with CKD G3a and CKD G3b in China: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE).
Topics: Adult; Anemia; Bicarbonates; Blood Pressure; China; Cholesterol, HDL; Cost of Illness; Female; Glome | 2017 |
Impact of Uric Acid Levels on Kidney Disease Progression.
Topics: Aged; Aged, 80 and over; Disease Progression; Electronic Health Records; Female; Follow-Up Studies; | 2017 |
Adherence to gout management recommendations of Chinese patients.
Topics: Adult; Age Factors; China; Gout; Gout Suppressants; Humans; Logistic Models; Male; Medication Adhere | 2017 |
Uric acid predicts adverse outcomes in chronic kidney disease: a novel insight from trajectory analyses.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Disease Progression; Female; Humans; Male; Middle Aged; | 2018 |
Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
Topics: Aged; Allopurinol; Benzbromarone; Cohort Studies; Disease Progression; Drug Monitoring; Febuxostat; | 2018 |
Serum 1,5-Anhydroglucitol Concentrations Remain Valid as a Glycemic Control Marker In Diabetes with Earlier Chronic Kidney Disease Stages.
Topics: Adult; Aged; Biomarkers; Deoxyglucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabeti | 2019 |
Uric acid in chronic kidney disease: the quest for causality continues.
Topics: Glomerular Filtration Rate; Humans; Renal Insufficiency, Chronic; Uric Acid | 2018 |
Chronic kidney disease associated with decreased bone mineral density, uric acid and metabolic syndrome.
Topics: Bone Density; Cross-Sectional Studies; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Progno | 2018 |
Levels of serum uric acid at admission for hypoglycaemia predict 1-year mortality.
Topics: Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Diabet | 2018 |
Uric Acid in the Follow-Up Determines 30% Decline in Estimated GFR Over 2 Years: a Propensity Score Analysis.
Topics: Adult; Aged; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Mal | 2017 |
Effective uric acid reduction with probenecid and febuxostat in a patient with chronic kidney disease.
Topics: Adult; Chronic Disease; Drug Therapy, Combination; Febuxostat; Foot Deformities, Acquired; Gout; Gou | 2018 |
Renal Effects of Hyperuricemia.
Topics: Acute Kidney Injury; Animals; Disease Models, Animal; Glomerular Filtration Rate; Humans; Hypertensi | 2018 |
Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells.
Topics: Actins; Animals; Antioxidants; Capillaries; Disease Progression; Endothelial Cells; Epithelial-Mesen | 2018 |
Disturbed purine nucleotide metabolism in chronic kidney disease is a risk factor for cognitive impairment.
Topics: Acetylcholinesterase; Catalytic Domain; Cognition Disorders; Computational Biology; Disease Progress | 2018 |
Serum uric acid levels and outcome during admission in acute ischaemic stroke, depending on renal function.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Cross-Sectional Studies; Female; Humans; Hyperuricemia; Mal | 2018 |
Relation of uric acid level to rapid kidney function decline and development of kidney disease: The Jackson Heart Study.
Topics: Adult; Black or African American; Disease Progression; Female; Glomerular Filtration Rate; Humans; I | 2018 |
[Acid uric : key player in a recently recognized devastating nephropathy and in the development of chronic kidney disease.]
Topics: Central America; Disease Progression; Gout; Humans; Renal Insufficiency, Chronic; Uric Acid | 2018 |
Uric acid stones increase the risk of chronic kidney disease.
Topics: Adult; Age Factors; Aged; Calcium Oxalate; Female; Glomerular Filtration Rate; Humans; Kidney; Kidne | 2018 |
Genome-wide association analysis identifies multiple loci associated with kidney disease-related traits in Korean populations.
Topics: Adult; Blood Urea Nitrogen; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 4; Creatinine; Fema | 2018 |
LDL-oxidation, serum uric acid, kidney function and pulse-wave velocity: Data from the Brisighella Heart Study cohort.
Topics: Aged; Biomarkers; Cohort Studies; Databases, Factual; Female; Humans; Italy; Kidney; Lipoproteins, L | 2018 |
Fibroblast growth factor-23 is a strong predictor of insulin resistance among chronic kidney disease patients.
Topics: Adult; Blood Glucose; Body Mass Index; Calcium; Case-Control Studies; Creatinine; Fasting; Female; F | 2018 |
Ameliorative effect of ursolic acid on renal fibrosis in adenine-induced chronic kidney disease in rats.
Topics: Adenine; Animals; Blood Urea Nitrogen; Collagen Type I; Connective Tissue Growth Factor; Creatinine; | 2018 |
Circulating RBP4 Increase and Its Diagnosis of Chronic Kidney Disease.
Topics: Adult; Creatinine; Cystathionine gamma-Lyase; Enzyme-Linked Immunosorbent Assay; Female; Humans; Mal | 2018 |
Urinary excretion of uric acid is negatively associated with albuminuria in patients with chronic kidney disease: a cross-sectional study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; China; Cross-Sectional Studies; Female; Hum | 2018 |
The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
Topics: Adult; Aged; Allopurinol; Blood Pressure; Febuxostat; Female; Glomerular Filtration Rate; Humans; Hy | 2018 |
Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Biomarkers; Down-Regulation; Drug Resistance; Drug Subs | 2018 |
Effects of uric acid on kidney function decline differ depending on baseline kidney function in type 2 diabetic patients.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Hyperur | 2019 |
Is increased uric acid a risk factor or a defensive response? The Campania Salute Network.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Arterial Pressure; Biomarkers; | 2018 |
Quercetin Treatment Improves Renal Function and Protects the Kidney in a Rat Model of Adenine-Induced Chronic Kidney Disease.
Topics: Adenine; Animals; Antioxidants; Blood Urea Nitrogen; Creatinine; Disease Models, Animal; Fibroblast | 2018 |
The association between time-mean serum uric acid levels and the incidence of chronic kidney disease in the general population: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cohort Studies; Female; Follow-Up Studies; Glomerular Fi | 2018 |
Gender-related differences in serum uric acid in treated hypertensive patients from central and east European countries: findings from the Blood Pressure control rate and CArdiovascular Risk profilE study.
Topics: Aged; Blood Pressure; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus; Europe, Eastern; Fema | 2019 |
Relationship between serum bilirubin levels s and the progression of renal function in patients with chronic kidney disease and hyperuricemia.
Topics: Aged; Bilirubin; Cohort Studies; Disease Progression; Female; Humans; Hyperuricemia; Male; Middle Ag | 2018 |
The Association of Urinary Sodium and Potassium with Renal Uric Acid Excretion in Patients with Chronic Kidney Disease.
Topics: Adult; Aged; Cross-Sectional Studies; Epidermal Growth Factor; Female; Humans; Hypertension; Hyperur | 2018 |
Abdominal obesity and reduction of glomerular filtration.
Topics: Adult; Analysis of Variance; Anthropometry; Black People; Brazil; Cholesterol; Creatinine; Cross-Sec | 2018 |
Low-density Lipoprotein Subclasses are Associated with Serum Uric Acid Levels.
Topics: Adult; Aged; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Dyslipidemias; | 2018 |
Genetics of serum urate concentrations and gout in a high-risk population, patients with chronic kidney disease.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cohort Studies; Female; Genetic Predi | 2018 |
Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
Topics: Aged; Allopurinol; Cohort Studies; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants | 2018 |
Liver stiffness assessed by transient elastography as a potential indicator of chronic kidney disease in patients with nonalcoholic fatty liver disease.
Topics: Cohort Studies; Diabetes Complications; Elasticity Imaging Techniques; Female; Humans; Liver; Male; | 2019 |
Effect of Uric Acid on the Development of Chronic Kidney Disease: The Korean Multi-Rural Communities Cohort Study.
Topics: Adult; Age Factors; Aged; Female; Glomerular Filtration Rate; Health Behavior; Humans; Male; Middle | 2018 |
Serum and urinary SOD3 in patients with type 2 diabetes: comparison with early chronic kidney disease patients and association with development of diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic N | 2019 |
Usefulness of multidisciplinary care to prevent worsening renal function in chronic kidney disease.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Blood Pressure; Diabetes Complications; Disease Progressio | 2019 |
A higher ratio of refined grain to whole grain is associated with a greater likelihood of chronic kidney disease: a population-based study.
Topics: Adult; Aged; Albumins; Albuminuria; Creatinine; Cross-Sectional Studies; Diet; Edible Grain; Female; | 2019 |
Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study.
Topics: Adult; Aged; Cohort Studies; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Population | 2018 |
Kidney Injury from Recurrent Heat Stress and Rhabdomyolysis: Protective Role of Allopurinol and Sodium Bicarbonate.
Topics: Acute Kidney Injury; Allopurinol; Animals; Disease Models, Animal; Disease Progression; Glycerol; He | 2018 |
Urate-Lowering Therapy for Preventing Kidney Disease Progression: Are We There Yet?
Topics: Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency | 2018 |
Risk factors analysis for hyperuricemic nephropathy among CKD stages 3-4 patients: an epidemiological study of hyperuricemia in CKD stages 3-4 patients in Ningbo, China.
Topics: Adult; Aged; Blood Pressure; Body Mass Index; China; Epidemiologic Studies; Female; Humans; Hyperuri | 2018 |
A Case Report of Immunosuppressant Medication‒Associated Polyarticular Tophaceous Gout Successfully Treated Using the Polyethylene Glycol‒Conjugated Uricase Enzyme Pegloticase.
Topics: Adult; Female; Gout; Gout Suppressants; Heart Transplantation; Humans; Immunocompromised Host; Immun | 2018 |
Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Topics: Aged; Allopurinol; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperu | 2019 |
No causal effects of serum urate levels on the risk of chronic kidney disease: A Mendelian randomization study.
Topics: Adult; Age Factors; Female; Genome-Wide Association Study; Glomerular Filtration Rate; Humans; Male; | 2019 |
Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: A national study.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Gout; G | 2019 |
Analysis of chronic kidney disease staging with different estimated glomerular filtration rate equations in Chinese centenarians.
Topics: Aged, 80 and over; Asian People; Creatinine; Cystatin C; Female; Glomerular Filtration Rate; Humans; | 2019 |
Secretion of IL-1β From Monocytes in Gout Is Redox Independent.
Topics: Acetylcysteine; Antioxidants; Cell Survival; Furans; Gene Expression; Gout; Heterocyclic Compounds, | 2019 |
Cardiovascular disease risk among children with focal segmental glomerulosclerosis: a report from the chronic kidney disease in children study.
Topics: Adolescent; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Carotid Intima-Media Thi | 2019 |
Coexistence of hyper-uricaemia and low urinary uric acid excretion further increases risk of chronic kidney disease in type 2 diabetes.
Topics: Aged; Albuminuria; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Femal | 2019 |
Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Renal Insuf | 2020 |
Gender-specific association between uric acid level and chronic kidney disease in the elderly health checkup population in China.
Topics: Aged; Aged, 80 and over; China; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Humans; | 2019 |
Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study.
Topics: Adult; Aged; Biomarkers; Disease Progression; Febuxostat; Female; Humans; Hyperuricemia; Kaplan-Meie | 2019 |
The association between serum uric acid to creatinine ratio and renal disease progression in type 2 diabetic patients in Chinese communities.
Topics: Adult; Aged; Case-Control Studies; China; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropath | 2019 |
Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Compared with Normal Kidney Function.
Topics: Allopurinol; Dose-Response Relationship, Drug; Drug Monitoring; Female; Gout; Gout Suppressants; Hum | 2019 |
Habitual Alcohol Intake Modifies Relationship of Uric Acid to Incident Chronic Kidney Disease.
Topics: Adult; Alcohol Drinking; Glomerular Filtration Rate; Humans; Incidence; Male; Middle Aged; Prospecti | 2019 |
Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.
Topics: Aged; Asymptomatic Diseases; Biomarkers; Comorbidity; Female; Glomerular Filtration Rate; Humans; Hy | 2019 |
Urine albumin and serum uric acid are important determinants of serum 25 hydroxyvitamin D level in pre-dialysis chronic kidney disease patients.
Topics: Adolescent; Adult; Albumins; Albuminuria; Cross-Sectional Studies; Female; Glomerular Filtration Rat | 2019 |
Saliva for assessing creatinine, uric acid, and potassium in nephropathic patients.
Topics: Adult; Biomarkers; Creatinine; Female; Humans; Male; Potassium; Renal Insufficiency, Chronic; Saliva | 2019 |
Association of obesity with chronic kidney disease in elderly patients with nonalcoholic fatty liver disease.
Topics: Age Factors; Aged; Biomarkers; Body Mass Index; Cross-Sectional Studies; Female; Humans; Kidney Func | 2019 |
Novel plasma peptide markers involved in the pathology of CKD identified using mass spectrometric approach.
Topics: Aged; Biomarkers; C-Reactive Protein; Cohort Studies; Disease Progression; Female; Humans; Kidney Fa | 2019 |
Circulating angiopoietin-2 is a marker for early cardiovascular disease in children on chronic dialysis.
Topics: Adolescent; Angiopoietin-2; Arteries; Biomarkers; Cardiovascular Diseases; Cell Adhesion Molecules; | 2013 |
Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease.
Topics: Aged; Albuminuria; Biomarkers; Creatinine; Cystatin C; Diabetes Mellitus; Female; Glomerular Filtrat | 2013 |
Nutrition in CKD: Songgaar | Burungaar.
Topics: Dietary Proteins; Humans; Interdisciplinary Communication; Obesity; Renal Insufficiency, Chronic; Ur | 2013 |
Changes in serum uric acid have a reciprocal effect on eGFR change: a 10-year follow-up study of community-based screening in Okinawa, Japan.
Topics: Adult; Aged; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Male; Middle Aged; Renal | 2013 |
Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat model of chronic kidney disease.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; | 2014 |
[Relationship between glomerular filtration rate, uric acid, and parathyroid hormone in children].
Topics: Adolescent; Albuminuria; Blood Pressure; Body Mass Index; Calcium; Child; Child, Preschool; Creatini | 2013 |
Timing of intra-lesion shaving for surgical treatment of chronic tophus.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Gouty; C-Reactive Protein; Calculi; Chronic Disease; Fema | 2013 |
The association between uric acid and chronic kidney disease in Korean men: a 4-year follow-up study.
Topics: Adult; Age Factors; Alcohol Drinking; Asian People; Blood Pressure; Body Mass Index; Cohort Studies; | 2013 |
Hyperuricemia and cardiovascular disease: is this relationship independent of the etiology of hyperuricemia?
Topics: Angina, Unstable; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Renal Insufficie | 2013 |
Predictive value of serum uric acid levels on mortality in acute coronary syndrome patients with chronic kidney disease after drug-eluting stent implantation.
Topics: Aged; Angina, Unstable; Brain Diseases; China; Drug-Eluting Stents; Female; Glomerular Filtration Ra | 2013 |
Acute effects of fructose consumption on uric acid and plasma lipids in patients with impaired renal function.
Topics: Adult; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fructose; Humans; Im | 2013 |
Effects of uric acid on endothelial dysfunction in early chronic kidney disease and its mechanisms.
Topics: Animals; Disease Models, Animal; Endothelin-1; Endothelium, Vascular; Hyperuricemia; Lipoproteins, L | 2013 |
The effect of disease on the urinary purine metabolite concentrations in dogs.
Topics: Animals; Case-Control Studies; Chromatography, High Pressure Liquid; Creatinine; Dog Diseases; Dogs; | 2013 |
Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function.
Topics: Biomarkers; Confounding Factors, Epidemiologic; Creatinine; Enzyme Inhibitors; Female; Genetic Predi | 2014 |
Impaired L-arginine uptake but not arginase contributes to endothelial dysfunction in rats with chronic kidney disease.
Topics: Animals; Arginase; Arginine; Biological Transport, Active; Blood Pressure; Blood Urea Nitrogen; Blot | 2014 |
Sex differences in the association between serum uric acid levels and cardiac hypertrophy in patients with chronic kidney disease.
Topics: Adult; Aged; Aging; Cardiomegaly; Cross-Sectional Studies; Disease Progression; Echocardiography; Fe | 2014 |
Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Creatinine; Enzyme Inhibitors; Febuxostat; Glomerular F | 2014 |
Uric acid level in patients with kidney disease.
Topics: Angina, Unstable; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Renal Insufficie | 2014 |
Uric Acid level should be stratified in order to better evaluate inflammatory status.
Topics: Angina, Unstable; Drug-Eluting Stents; Female; Humans; Male; Myocardial Infarction; Renal Insufficie | 2014 |
Fathoming uric acid nephropathy.
Topics: Foot; Humans; Kidney; Male; Middle Aged; Radiography; Renal Insufficiency, Chronic; Tarsal Bones; Ul | 2013 |
Fructokinase activity mediates dehydration-induced renal injury.
Topics: Aldehyde Reductase; Animals; Blood Pressure; Dehydration; Disease Models, Animal; Fructokinases; Kid | 2014 |
[Evaluation of dialysis in patients with end-stage renal disease by salivary urea, creatinine and uric acid].
Topics: Creatinine; Humans; Kidney Failure, Chronic; Renal Dialysis; Renal Insufficiency, Chronic; Saliva; U | 2013 |
Serum uric acid and eGFR_CKDEPI differently predict long-term cardiovascular events and all causes of deaths in a residential cohort.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Cohort Studies; Female; Follow-Up | 2014 |
Hyperuricemia is a significant risk factor for the onset of chronic kidney disease.
Topics: Adult; Age Factors; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Humans; Hyperuricem | 2014 |
Serum uric acid, the metabolic syndrome, and the risk of chronic kidney disease in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephrop | 2014 |
Prooxidative-antioxidative balance of cells in different types of renal replacement therapy.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Catalase; Female; Glucosephosphate Dehydrogenase; Glut | 2014 |
Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Female; Fluorobenzenes; Glomerular Filtration Rate; He | 2014 |
Analgesic use, parents' clan, and coffee intake are three independent risk factors of chronic kidney disease in middle and elderly-aged population: a community-based study.
Topics: Adult; Analgesics; Blood Glucose; Coffee; Educational Status; Feeding Behavior; Female; Glomerular F | 2014 |
[Risk stratification of diabetic chronic kidney disease using eGFR equations].
Topics: Blood Urea Nitrogen; Creatinine; Cystatin C; Diabetes Mellitus; Diabetic Nephropathies; Glomerular F | 2014 |
Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: insights from the I-DEMAND study.
Topics: Aged; Albuminuria; Biomarkers; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Cross-Secti | 2014 |
Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Databases | 2014 |
Validity of U-shaped risk of estimated glomerular filtration rate for all-cause mortality.
Topics: Cardiovascular Diseases; Female; Glomerular Filtration Rate; Humans; Male; Renal Insufficiency, Chro | 2014 |
Association of a polymorphism in a gene encoding a urate transporter with CKD progression.
Topics: Adult; Aged; Case-Control Studies; Disease Progression; Female; Gene Frequency; Glucose Transport Pr | 2014 |
The U-shaped risk of estimated glomerular filtration rate for all-cause mortality and the role of serum uric acid.
Topics: Adult; Aged; Biomarkers; Cohort Studies; Female; Glomerular Filtration Rate; Humans; Male; Middle Ag | 2014 |
Effects of insulin resistance on left ventricular hypertrophy in patients with CKD stage 1-3.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; C-Re | 2014 |
Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.
Topics: Adult; Allopurinol; Antimetabolites; Benzbromarone; Cardiovascular Diseases; Comorbidity; Diabetes M | 2014 |
A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients.
Topics: Enzyme Inhibitors; Febuxostat; Humans; Hyperuricemia; Nitriles; Pyridines; Renal Insufficiency, Chro | 2014 |
Serum uric acid and arterial stiffness in hypertensive chronic kidney disease patients: sex-specific variations.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Comorbidity; C | 2014 |
Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002.
Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Confounding Factors, Epidemiologic; Creatinine | 2014 |
Elevated serum homocysteine levels were not correlated with serum uric acid levels, but with decreased renal function in gouty patients.
Topics: Glomerular Filtration Rate; Gout; Homocysteine; Humans; Hyperhomocysteinemia; Male; Middle Aged; Ren | 2014 |
Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction.
Topics: Aged; Blood Pressure; Dose-Response Relationship, Drug; Endpoint Determination; Febuxostat; Female; | 2014 |
Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression.
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bioma | 2014 |
Simultaneous determination of plasma creatinine, uric acid, kynurenine and tryptophan by high-performance liquid chromatography: method validation and in application to the assessment of renal function.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Creatinine; Female; Humans; Hypertension; Kidney | 2015 |
Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Disease Progression; Drug Substitution; Febuxostat; Female; Go | 2014 |
Attenuating the mortality risk of high serum uric acid: the role of physical activity underused.
Topics: Adult; Aged; Asymptomatic Diseases; Cause of Death; Cohort Studies; Diabetes Mellitus; Exercise; Fem | 2015 |
A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population.
Topics: Aged; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hyperuricemia; Japan; Male; Mid | 2014 |
Mortality predictive role of serum uric acid in diabetic hemodialysis patients.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Female; Follow-Up Studies | 2014 |
[Proaterogenic metabolic disorders in patients with chronic kidney disease nondiabetic origin: possibility of statin therapy].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Cardiotonic Agents; Disease | 2014 |
Lactulose for reduction of nitrogen products in patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; beta 2-Microglobulin; Biomarkers; Blood Urea Nitrogen; Creatinine; F | 2014 |
Self-rated health and adverse events in CKD.
Topics: Acid-Base Equilibrium; Aged; Albuminuria; Area Under Curve; Biomarkers; C-Reactive Protein; Cause of | 2014 |
Effects of uric acid on hearts of rats with chronic kidney disease.
Topics: Allopurinol; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Gout Suppressants; Heart | 2014 |
High uric acid level is a risk factor for progression of IgA nephropathy with chronic kidney disease stage G3a.
Topics: Biomarkers; Biopsy; Chi-Square Distribution; Disease Progression; Female; Glomerulonephritis, IGA; H | 2015 |
Correlation between renal function and common risk factors for chronic kidney disease in a healthy middle-aged population: a prospective observational 2-year study.
Topics: Adult; Age Factors; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Cholesterol, LDL; F | 2014 |
Elevated uric acid level as a significant predictor of chronic kidney disease: a cohort study with repeated measurements.
Topics: Adult; Biomarkers; Disease Progression; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; L | 2015 |
Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression.
Topics: Aged; Alleles; Arginine; C-Reactive Protein; Calcium; Case-Control Studies; Cohort Studies; Creatini | 2015 |
Association between serum bilirubin and estimated glomerular filtration rate among elderly persons.
Topics: Age Factors; Aged; Aged, 80 and over; Bilirubin; Female; Glomerular Filtration Rate; Humans; Japan; | 2014 |
In-vitro evidence of enhanced breast cancer resistance protein-mediated intestinal urate secretion by uremic toxins in Caco-2 cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biologic | 2015 |
[Effect of concomitant chronic kidney disease on the xanthine metabolism in patients with chronic heart failure].
Topics: Aged; Chronic Disease; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Prognosis; R | 2014 |
Plasma aldosterone and its relationship with left ventricular mass in hypertensive patients with early-stage chronic kidney disease.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Creatinine; Female; Humans; Hypertension; Hypertrophy, Lef | 2015 |
Fructose intake: is there an association with uric acid levels in nondialysis-dependent chronic kidney disease patients?
Topics: Adolescent; Adult; Aged; Cross-Sectional Studies; Cytokines; Diet; Female; Fructose; Humans; Kidney | 2014 |
Uric acid level has a U-shaped association with loss of kidney function in healthy people: a prospective cohort study.
Topics: Adult; Exercise; Female; Glomerular Filtration Rate; Healthy Volunteers; Humans; Hyperuricemia; Kidn | 2015 |
Plasma Urate and Risk of a Hospital Stay with AKI: The Atherosclerosis Risk in Communities Study.
Topics: Acute Kidney Injury; Aged; Female; Follow-Up Studies; Glomerular Filtration Rate; Gout; Hospitalizat | 2015 |
Effects of uremic solutes on reactive oxygen species in vitro model systems as a possibility of support the renal function management.
Topics: Arginine; Biomarkers; Creatinine; Cresols; Hippurates; Humans; In Vitro Techniques; Kidney Function | 2015 |
Effects of oxonic acid-induced hyperuricemia on mesenteric artery tone and cardiac load in experimental renal insufficiency.
Topics: Analysis of Variance; Animals; Cardiac Output; Disease Models, Animal; Hyperuricemia; Male; Mesenter | 2015 |
Decreased urine uric acid excretion is an independent risk factor for chronic kidney disease but not for carotid atherosclerosis in hospital-based patients with type 2 diabetes: a cross-sectional study.
Topics: Adult; Aged; Biomarkers; Carotid Artery Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 2 | 2015 |
Serum uric acid and the incidence of CKD and hypertension.
Topics: Adult; Body Mass Index; Cholesterol, HDL; Cohort Studies; Female; Glomerular Filtration Rate; Humans | 2015 |
[Hyperuricemia and renal risk].
Topics: Humans; Hyperuricemia; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2015 |
The Removal of β2-Microglobulin in Spent Dialysate Cannot Be Monitored by Spectrophotometric Analysis.
Topics: Artifacts; beta 2-Microglobulin; Creatinine; Dialysis Solutions; Humans; Kidneys, Artificial; Membra | 2015 |
Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease.
Topics: Aged; Biomarkers; Cohort Studies; Disease Progression; Female; Glomerular Filtration Rate; Humans; H | 2015 |
Uric acid, indoxyl sulfate, and methylguanidine activate bulbospinal neurons in the RVLM via their specific transporters and by producing oxidative stress.
Topics: Animals; Anion Transport Proteins; Benzoxazoles; Enzyme Inhibitors; Indican; Medulla Oblongata; Memb | 2015 |
Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.
Topics: Adolescent; Child; Cohort Studies; Cross-Sectional Studies; Disease Progression; Female; Humans; Hyp | 2015 |
Serum Uric Acid and Risk of CKD in Type 2 Diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Humans; Longitudinal Studies; Male; Middle Aged; Renal Insu | 2015 |
Nephrolithiasis as a Risk Factor for CKD: The Atherosclerosis Risk in Communities Study.
Topics: Atherosclerosis; Female; Humans; Male; Middle Aged; Nephrolithiasis; Prospective Studies; Renal Insu | 2015 |
Relationship between Serum Uric Acid Levels and Chronic Kidney Disease in a Japanese Cohort with Normal or Mildly Reduced Kidney Function.
Topics: Asian People; Cohort Studies; Glomerular Filtration Rate; Humans; Kidney; Kidney Function Tests; Mid | 2015 |
Plasma Xanthine Oxidase Activity Is Predictive of Cardiovascular Disease in Patients with Chronic Kidney Disease, Independently of Uric Acid Levels.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Follow-Up Studies; Humans; Kaplan-M | 2015 |
Heat Stress Nephropathy From Exercise-Induced Uric Acid Crystalluria: A Perspective on Mesoamerican Nephropathy.
Topics: Adult; Central America; Crystallization; Exercise; Heat Stress Disorders; Humans; Male; Renal Insuff | 2016 |
Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus-a 4.6-year cohort study.
Topics: Biomarkers; Cohort Studies; Diabetes Mellitus, Type 2; Disease Progression; Female; Glomerular Filtr | 2016 |
The role of uric acid in chronic kidney disease patients.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Female; Glomerular Filtration Rate; Hospitalization; | 2017 |
Revisiting medullary tophi: a link between uric acid and progressive chronic kidney disease?
Topics: Adult; Aged; Biopsy; Cohort Studies; Creatinine; Cross-Sectional Studies; Disease Progression; Femal | 2016 |
Serum uric acid as a marker of microvascular damage in systemic sclerosis patients.
Topics: Adult; Arterial Pressure; Biomarkers; Creatinine; Echocardiography; Female; Humans; Male; Microcircu | 2016 |
Prevalence and associating factors of atrial fibrillation in patients with hypertension: a nation-wide study.
Topics: Age Factors; Aged; Atrial Fibrillation; Biomarkers; Chi-Square Distribution; Cholesterol, LDL; Comor | 2016 |
Association Between Uric Acid and Renal Hemodynamics: Pathophysiological Implications for Renal Damage in Hypertensive Patients.
Topics: Adult; Aged; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Hypertension; Male; Middle Ag | 2016 |
Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Cost-Benefit Analysis; Febuxostat; Female; Gou | 2016 |
Febuxostat for Asymptomatic Hyperuricemia in CKD.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; | 2016 |
Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; | 2016 |
In Reply to 'Febuxostat for Asymptomatic Hyperuricemia in CKD' and 'Febuxostat Renoprotection in CKD Patients With Asymptomatic Hyperuricemia'.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; | 2016 |
The association between serum uric acid and 1-year mortality in patients with ST-segment elevation myocardial infarction and chronic kidney disease: contrast-induced acute kidney injury and bleeding complications should be adjusted.
Topics: Acute Kidney Injury; Electrocardiography; Humans; Myocardial Infarction; Percutaneous Coronary Inter | 2016 |
Serum bilirubin: a simple routine surrogate marker of the progression of chronic kidney disease.
Topics: Adult; Bilirubin; Biomarkers; Blood Glucose; Creatinine; Cross-Sectional Studies; Disease Progressio | 2016 |
Association between uric acid and renal function in hypertensive patients: which role for systemic vascular involvement?
Topics: Adult; Aged; Aorta; Body Mass Index; Carotid Intima-Media Thickness; Cross-Sectional Studies; Female | 2016 |
Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid.
Topics: Computer Simulation; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Models, Biological; Renal | 2016 |
The prognostic impact of uric acid in patients with severely decompensated acute heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Female; Heart Failure; Humans; Hyperuricemia; Japan; Male; M | 2016 |
The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
Topics: Adult; Aged; Allopurinol; Budgets; Chronic Disease; Febuxostat; Female; Gout; Gout Suppressants; Hea | 2016 |
Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chroni | 2016 |
Serum Uric Acid as a Risk Factor for Chronic Kidney Disease in a Japanese Community - The Hisayama Study.
Topics: Albuminuria; Female; Follow-Up Studies; Humans; Incidence; Japan; Male; Middle Aged; Renal Insuffici | 2016 |
Genetic and environmental influences on the associations between change in kidney function and changes in cardiometabolic factors in Koreans.
Topics: Adult; Asian People; Biomarkers; Blood Glucose; Chi-Square Distribution; Female; Gene-Environment In | 2017 |
Combined Association of Serum Uric Acid and Metabolic Syndrome with Chronic Kidney Disease in Hypertensive Patients.
Topics: Cross-Sectional Studies; Female; Humans; Hypertension; Male; Metabolic Syndrome; Middle Aged; Preval | 2016 |
Prevalence of Homocysteine-Related Hypertension in Patients With Chronic Kidney Disease.
Topics: Adolescent; Adult; Aged; Female; Glomerular Filtration Rate; Homocysteine; Humans; Hyperhomocysteine | 2017 |
Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease.
Topics: Allantoin; Anticholesteremic Agents; Arginine; Biomarkers; Cholesterol; Endothelium; Ezetimibe; Fema | 2016 |
Associations of fibroblast growth factor 23 with urate metabolism in patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Calcitriol; Cross-Sectional Studies; Diabetes Mellitus; Diuretics; D | 2016 |
Familial juvenile hyperuricemic nephropathy as rare cause of dialysis-dependent chronic kidney disease-a series of cases in two families.
Topics: Adolescent; Adult; Child; Child, Preschool; DNA Mutational Analysis; Female; Gout; Humans; Hyperuric | 2016 |
High Prevalence of Hyperhomocysteinemia and Its Association with Target Organ Damage in Chinese Patients with Chronic Kidney Disease.
Topics: Adult; Calcium Phosphates; Carotid Arteries; Carotid Intima-Media Thickness; Cross-Sectional Studies | 2016 |
Hyperuricemia as a Predictive Marker for Progression of Nephrosclerosis: Clinical Assessment of Prognostic Factors in Biopsy-Proven Arterial/Arteriolar Nephrosclerosis.
Topics: Adolescent; Adult; Aged; Biomarkers; Biopsy; Cohort Studies; Comorbidity; Disease Progression; Femal | 2017 |
Uric acid metabolism of kidney and intestine in a rat model of chronic kidney disease.
Topics: Animals; Colon; Creatinine; Duodenum; Gene Expression; Ileum; Kidney; Male; Organic Anion Transporte | 2016 |
The Association of Vitamin D Status and Vitamin D Replacement Therapy with Glycemic Control, Serum Uric Acid Levels, and Microalbuminuria in Patients with Type 2 Diabetes and Chronic Kidney Disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Blood Glucose; Creatinine; Diabetes Mellitu | 2017 |
Serum uric acid and its association with hypertension, early nephropathy and chronic kidney disease in type 2 diabetic patients.
Topics: Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female | 2016 |
The Effect of Allopurinol on Renal Function.
Topics: Aged; Allopurinol; Antimetabolites; Creatinine; Glomerular Filtration Rate; Humans; Hyperuricemia; M | 2017 |
Glycosuria and Renal Outcomes in Patients with Nondiabetic Advanced Chronic Kidney Disease.
Topics: Creatinine; Cross-Sectional Studies; Electrolytes; Female; Glomerular Filtration Rate; Glycosuria; H | 2016 |
Serum uric acid to creatinine ratio: A predictor of incident chronic kidney disease in type 2 diabetes mellitus patients with preserved kidney function.
Topics: Aged; Biomarkers; Chi-Square Distribution; China; Creatinine; Diabetes Mellitus, Type 2; Diabetic Ne | 2017 |
Elevated Serum Uric Acid Level Predicts Rapid Decline in Kidney Function.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Female; Glomerular Filtration Rate; Humans; Japan; Kidne | 2017 |
Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency.
Topics: Aldosterone; Animal Feed; Animals; Autoradiography; Blood Pressure; Disease Models, Animal; Hyperten | 2008 |
Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease.
Topics: Cardiovascular Diseases; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Proportional Hazards | 2009 |
Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells.
Topics: Adenosine Triphosphate; Animals; Base Sequence; Cell Line; Chemokine CCL2; DNA Primers; Fructokinase | 2009 |
Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate.
Topics: Adult; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Male; Metabolic Syndrome; Middle A | 2009 |
Posing the question again: does chronic uric acid nephropathy exist?
Topics: Animals; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Uric Acid | 2010 |
Predictors of carotid artery intima-media thickness in chronic kidney disease and kidney transplant patients without overt cardiovascular disease.
Topics: Adult; Biomarkers; Blood Pressure; Carotid Artery Diseases; Carotid Artery, Common; Cross-Sectional | 2010 |
Association of uric acid with change in kidney function in healthy normotensive individuals.
Topics: Adult; Aged; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Prop | 2010 |
Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population.
Topics: Aged; Confounding Factors, Epidemiologic; Female; Glomerular Filtration Rate; Health Surveys; Humans | 2010 |
Prevalence and risk factors for renal artery stenosis and chronic kidney disease in Japanese patients with peripheral arterial disease.
Topics: Age Factors; Aged; Aged, 80 and over; Albuminuria; Angiography; Asian People; Cholesterol, LDL; Como | 2010 |
Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases.
Topics: Age Factors; Case-Control Studies; Comorbidity; Creatinine; Genetic Variation; Genome-Wide Associati | 2010 |
Acute kidney injury network classification predicts in-hospital and long-term mortality in patients undergoing elective coronary artery bypass grafting surgery.
Topics: Acute Kidney Injury; Age Factors; Aged; Biomarkers; Coronary Artery Bypass; Epidemiologic Methods; E | 2011 |
The relationship between serum uric acid and chronic kidney disease among Appalachian adults.
Topics: Adult; Appalachian Region; Causality; Confounding Factors, Epidemiologic; Humans; Renal Insufficienc | 2011 |
Hemodialysis duration impairs food intake and nutritional parameters in chronic kidney disease patients.
Topics: Adult; Body Height; Body Mass Index; Body Weight; Cholesterol; Creatinine; Diet Surveys; Dietary Car | 2012 |
Uric acid levels predict future development of chronic kidney disease.
Topics: Aged; Body Mass Index; Dyslipidemias; Female; Glomerular Filtration Rate; Humans; Kidney Failure, Ch | 2011 |
Low-fructose diet lowers blood pressure and inflammation in patients with chronic kidney disease.
Topics: Aged; Analysis of Variance; Blood Pressure Determination; Cohort Studies; Diet, Carbohydrate-Restric | 2012 |
Relationship between uric acid and subtle cognitive dysfunction in chronic kidney disease.
Topics: Age Factors; Aged; Cerebrovascular Disorders; Cognition Disorders; Educational Status; Female; Human | 2011 |
Elevated serum uric acid predicts chronic kidney disease.
Topics: Adult; Aged; Blood Pressure; Body Mass Index; Female; Glomerular Filtration Rate; Humans; Japan; Log | 2011 |
Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider.
Topics: Adult; Aged; Cardiovascular Diseases; Cohort Studies; Comorbidity; Creatinine; Databases, Factual; F | 2011 |
Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan.
Topics: Adult; Aged; Cohort Studies; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hyperuri | 2011 |
Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hype | 2012 |
Uric acid, hypertension, and chronic kidney disease among Alaska Eskimos: the Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study.
Topics: Adult; Alaska; Coronary Artery Disease; Female; Glomerular Filtration Rate; Humans; Hypertension; In | 2012 |
Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function.
Topics: Child; Cross-Sectional Studies; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Huma | 2012 |
Clinical study of ammonium acid urate urolithiasis.
Topics: Adult; Aged; Comorbidity; Female; Gout; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Renal I | 2012 |
Renal calcium, phosphorus, magnesium and uric acid handling: comparison between stage III chronic kidney disease patients and healthy oldest old.
Topics: Adult; Aged; Aged, 80 and over; Aging; Calcium; Case-Control Studies; Creatinine; Female; Glomerular | 2012 |
Selected nutraceutic screening by therapeutic effects on doxorubicin-induced chronic kidney disease.
Topics: Albuminuria; Animals; bcl-2-Associated X Protein; bcl-Associated Death Protein; Blood Urea Nitrogen; | 2012 |
An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study.
Topics: Adult; Arterioles; Biopsy; Cross-Sectional Studies; Female; Glomerulosclerosis, Focal Segmental; Hum | 2013 |
Effect of hyperuricemia on the blood pressure response to antihypertensive agents in hospitalized elderly patients.
Topics: Aged; Antihypertensive Agents; Biomarkers; Blood Pressure; Chi-Square Distribution; Diabetes Mellitu | 2012 |
Serum uric acid independently predicts cardiovascular events in advanced nephropathy.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus; Endothelium, Vascular; Female; | 2012 |
Uric acid levels correlate with baseline renal function and high levels are a potent risk factor for postoperative chronic kidney disease in patients with renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Glomerular Filtration Rate; Humans; K | 2013 |
[Clinical significance of saliva urea, creatinine, and uric acid levels in patients with chronic kidney disease].
Topics: Adolescent; Adult; Aged; Case-Control Studies; Creatinine; Female; Humans; Male; Middle Aged; Renal | 2012 |
Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease.
Topics: Actins; Animals; Cadherins; Creatinine; Disease Models, Animal; Epithelial Cells; Hyperuricemia; Kid | 2013 |
A novel UPLC-MS-MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients.
Topics: Cardiovascular Diseases; Case-Control Studies; Chromatography, High Pressure Liquid; Cresols; Female | 2013 |
The risk factors of mild decline in estimated glomerular filtration rate in a community-based population.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cross-Sectional Studies; Female; Glomerular Filtration R | 2013 |
Association of uric acid and left ventricular mass index with renal outcomes in chronic kidney disease.
Topics: Aged; Comorbidity; Creatinine; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration | 2013 |
Oxidative stress is progressively enhanced with advancing stages of CKD.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Dinoprost; Disease Progression; Female; Glo | 2006 |
J-shaped mortality relationship for uric acid in CKD.
Topics: Adult; Aged; Allopurinol; Antimetabolites; Cause of Death; Comorbidity; Confounding Factors, Epidemi | 2006 |
The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Biomarkers; Blood Pressure; Body Mass Index; C-Reacti | 2008 |